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ABSTRACT
Compaction of DNA into chromatin is an important feature of every living
cell. This compaction phenomenon is brought about and maintained by a variety of
DNA binding proteins, which have evolved to suit the specific needs of the different
cell types spanning the three kingdoms of life; the eukaryotes, prokaryotes and
archaea. Sulfolobus solfataricus, a member of the crenarchaeal subdivision of the
archaea, has two prominent DNA binding proteins known as Alba (1&2) and Sso7d.
Alba1 is acetylated in vivo at two positions and this modification lowers its’ affinity
for binding DNA. Acetylation levels impact many cellular processes and in higher
organisms play a critical role in the development of many cancers and other diseases.
This thesis documents the finding and characterisation of the N-terminal
acetyltransferase (ssArd1) of SsoAlba1, based on its’ sequence homology to the
catalytic subunits Ard1, Nat3 and Mak3 belonging to the larger eukaryal Nat
complexes NatA, NatB and NatC, respectively. Mutagenesis studies revealed that
ssArd1 preferentially acetylates N-termini bearing a serine or alanine residue at
position 1 (after methionine cleavage). It is also capable of acetylating other proteins
with very different physical structures. These findings allow classification of ssArd1
as a promiscuous acetyltransferase belonging to the Gcn5-N-acetyltransferase
(GNAT) superfamily. The active site of the enzyme was examined through
mutagenesis studies, revealing that the mechanism of acetylation is likely to proceed
through a direct acetyl transfer involving a tetrahedral intermediate. Structural
studies provided some insight into the molecular structure of ssArd1.
xvii
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Introduction
DNA compaction is vital for the cell. Eukaryotic cells can contain several
metres of DNA and this DNA must fit into the nucleus in an orderly way so that it
can be easily accessed for repair, transcription and DNA replication when required.
In addition, the winding and coating of DNA by protein complexes affords protection
against many forms of damage and sustains the integrity of the DNA molecule.
1.1 Histones and Chromatin
In eukaryotes, DNA compaction is achieved through a variety of interactions
with histone proteins. There are five histones. Four of these histones, H2A, H2B, H3
and H4 combine to form a core octamer (two H2A/H2B dimers and one H3/H4
tetramer) consisting of two of each protein (Luger, 1997). Each core will coil 146
base pairs (bp) of DNA around itself 1.65 times in a left-handed super-helix. Short N-
and C-terminal tails of varying lengths protrude from the histones (figure 1.1b) and
the positive charges associated with residues such as lysine and arginine enable these
tails to bind and hold the DNA. This configuration is known as the nucleosome,
which is further stabilized by the binding of H1 (Zlatanova, 1998) to the outer surface
(figure 1.1a). There are eight species of H1 (or H5) and exactly which one is found
where depends on factors such as stage in the cell cycle, type of cell etc. A short
piece of linker DNA, of approximately 50 bp, joins one nucleosome to the next
giving the appearance of ‘beads on a string’ (figure 1.2a). Each piece of linker DNA
is bound by one molecule of H1. This structure is known as euchromatin and the
loose binding of the DNA means that transcription of genes is possible at this level.
Chapter 1: Introduction
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Figure 1.1: The Nucleosome.
A) Cartoon version of the nucleosome showing DNA wound around the core octamer of histone
proteins. H1 is associated with the linker DNA between nucleosomes, serving to stabilise them.  B)
Protein Data Bank (PDB) structure of the nucleosome looking down through the superhelical axis
(Luger, 1997) shows the positions of histone N and C terminal tails relative to the DNA. H2A (orange)
and H2B (red) form two  heterodimers, whilst H3 (blue) and H4 (green) form a tetramer.
After this initial stage of packaging, the chromatin is further packaged in a second
stage (Figure 1.2b). This involves condensing of the nucleosomes into 30 nm thick
fibres (called the solenoid) by the action of charged histone N-termini from one
nucleosome binding to the DNA of a neighbouring nucleosome. Further recruitment
of H1 aids stability of the solenoid structure. At this point, gene transcription is
completely unfeasible and this silent form of chromatin is known as heterochromatin,
which is easily distinguished from the euchromatin in a cell because it stains much
darker with Giemsa (also known as G-banding), Feulgen and DAPI/Hoechst dyes.
Heterochromatin only exists in eukaryotes, having probably evolved with the
development of the nucleus in order to cope with the smaller volume to which it is
confined. Finally, this  solenoid structure is  joined by a number of other proteins and
compacted into the metaphase chromosome (figure 1.2c).
A Linker DNA
~ 50 bp
H1
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Figure 1.2: Electron micrographs of chromatin at different stages of
compaction. (A) Chromatin at stage 1 of packaging to give ‘beads on a string
conformation’. (Alberts, B., 2002).
(B) Chromatin at stage 2 of packaging: 30 nm thick chromatin fibres. Picture by
Barbara Hamkalo (Alberts, B., 2002).
(C) Metaphase chromosome (Bloom, W., 1994).
Chromatin has three main functions: (i) DNA compaction, allowing the vast
amount of DNA to be systematically arranged within the nucleus, (ii) DNA
protection against damaging agents and nucleases, and (iii) regulating the
accessibility of the genome to transcription, replication and repair machinery. These
processes are highly dependent on the precise organization of the chromatin fibres.
Histone proteins therefore play an important role as control elements which are
effectively switched on and off by modifications targeted at the internal globular
structure or, more commonly, the protein N-termini. Lysine rich tails protruding
from the nucleosome core are accessible to reversible covalent modifications (e.g.
methylation, phosphorylation, ubiquitination and acetylation) resulting in purposeful
remodelling of chromatin for the manipulation of processes such as transcription,
gene silencing, cell proliferation, senescence and apoptosis (Cheung, 2000; Han,
2006). These modifications constitute what is hypothesised as the ‘histone code’ and
in addition to other factors, including DNA methylation, they contribute to the
epigenetic code that determines the differentiation pattern of a particular cell. Figure
1.3 shows the known post-translational modifications that have been commonly
found at the N-terminal regions of the different histone proteins. H1/H5 is not shown
   50nm
A  B
C
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here because until recently, very little was known about its modification status
(except for phosphorylation). Although H1 is an important determinant in DNA
condensation, it was thought not to be regulated by acetylation. However, new
research has revealed that H1 variants also incur a range of modifications similar to
histones H2A, H2B, H3 and H4 (Wisniewski, 2006).
Figure 1.3: Common N-terminal Histone modifications.
Common modifications on the N-terminal tails of human histones H1 (Wisniewski, 2007), H2A, H2B,
H3 and H4 (Croce 2005). In Vitro experiments have demonstrated that several known HAT proteins
will preferentially target selected N-terminal lysines on histones H2A, H2B, H3 and H4 for
acetylation.
GCN-5, PCAF, Hpa2, TAF##230 (TAFII230 is the Drosophila homolog of human TAFII250 (Sterner &
Berger, 2000), SRC-1 and p300/CBP have all been demonstrated to acetylate H3 at position denoted
‘5’. SRC-1 has been shown to target position denoted ‘4’, p300/CBP targets multiple sites denoted ‘1’,
‘2’, ‘3’, ‘5’, ‘6’, ‘7’ and ‘8’ , Esa1 targets position denoted ‘7’, Hat1 acetylates at position denoted ‘9’
and  MOF acetylates at position denoted ‘10’. Gene identifications are as follows: H1
>gi|4885377|NP_005311.1| H1 histone family, member 3 [Homo sapiens], H2A
>gi|121986|sp|P04908|H2AM_HUMAN Histone H2A.m, H2B >gi|20336754|NP_066402.2| H2B
histone family, member R [Homo sapiens], H3 >gi|45768281|gb| AAH 67493.1| H3 histone family,
member F [Homo sapiens] and H4 >gi|55930957|gb|AAH50615.1|H4 histone family, member J
[Homo sapiens].
    SETAPLAPTIPAPAEKTPVKKKAKKAGATAGKRKASGP H1
  ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKKP H3
        4               5            6
  SGRGKGGKGLGKGGAKRHRKVLRDN H4
            7         8            9           10
SGRGKQGGKARAKAKTRSSRAGLQF H2A
1
PEPAKSAPAPKKGSKKAVTKAQKKD H2B
Methylation
Acetylation
Phosphorylation
2
3
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Histone methylation is typically associated with transcriptional repression
(Curradi, 2002) but in certain cases i.e. methylation of lysine 4 on histone H3 and/or
specific arginine residues of H3 and H4, it has been shown to activate transcription
(Bernstein, 2002; Wang, 2001).
Phosphorylation of histone tails neutralises the basic charge of the histone and
therefore reduces its affinity for DNA binding, again leading to transcriptional
activation. Phosphorylation of serine 10 on histone H3 and other substrates has been
shown to increase acetylation of these substrates by Gcn-5- acetyltransferase
enzymes (Lo, 2000).
Ubiquitination of histones represents the most bulky of modifications
considered so far. The function of this kind of histone modification is not well
understood but mono-ubiquitinated substrates can initiate cell signalling by allowing
other proteins with ubiquitin binding domains to interact with them. Many substrates
targeted for ubiquitination have a chain of ubiquitin molecules added onto a lysine
residue and this usually leads to degradation of the poly-ubiquitinated protein by the
26S proteasome (Fu, 1998).
Acetylation is among the most studied of the histone modifications. It appears
that acetylation may be responsible for a vast amount of subtle signalling processes
within the cell, however, no major immediate phenotypic defect can be seen in yeast
by altering the levels of the enzymes responsible for N-terminal acetylation. Defects
noted thus far include failure to enter G0 phase of growth and sensitivity to
temperature fluctuation (Polevoda & Norbeck, 1999). In the 1960’s, Allfrey and
colleagues first demonstrated that acetylation of core histone tails affected the level
of eukaryotic gene expression (Allfrey, 1964). Thus, the link to transcriptional
activation was discovered and since then, many examples of increased or decreased
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transcription of certain genes (or groups of genes) have been recorded in relation to
this modification (Eberharter, 2002).
1.2 Acetylation
Acetylation is a process that involves the transfer of an acetyl radical derived
from a molecule such as acetic anhydride (in the case of chemical acetylation) or an
acetyl group from a cofactor such as acetyl-CoA (in the case of biological
acetylation) to another molecule. This type of chemical reaction is known as a
nucleophilic acyl substitution and usually involves two steps: the nucleophilic
addition of a new group to form a tetrahedral intermediate and then the elimination of
a leaving group. Acetylation is assumed to be an SN1 reaction but there may be some
exceptions depending on the exact enzymes/substrates in question. The process is
catalyzed by a variety of enzymes, which have the ability to acetylate N-terminal !-
amino groups (non-reversible) on proteins or molecules and the $-amino groups
(reversible) of specific lysine residues found on the N-terminal regions of the histone
components of chromatin (figure 1.4). Acetylation of these histone tails, or indeed,
other DNA binding proteins, neutralises the positive charge that they carry and is
therefore thought to weaken interactions with the DNA. This gives rise to a relaxed
chromatin structural conformation (Hansen, 1998; Walia, 1998) and thus allows
RNA polymerase and other transcriptional machinery to gain access to the promoters
belonging to genes located at that site (Nightingale, 1998; Tse and Sera et al, 1998).
In contrast, genes that are located in a region of DNA that is wound tightly by histone
molecules, due to little or no acetylation, show transcriptional repression
(Marmorstein, 2001).
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Figure 1.4: Mechanism of Biological Acetylation. (A) A possible mechanism for acetylation of
protein N!-terminal amino groups via direct nucleophilic substitution/attack on acetyl-CoA (Dyda,
2000). (B) Direct acetyl transfer from cofactor to $-NH2 of lysine side chain (adapted from Walsh,
2007).
Histone acetyltransferases (HAT’s) are involved not only in transcriptional activation
but also DNA repair, gene silencing and cell cycle progression (Carrozza, 2003).
Therefore, a good understanding of the structure and function of N-acetyltransferase
enzymes will improve our understanding of the regulation of gene expression and
provide insight into the diseases in which anomalous HAT activity has been
implicated as a possible cause (Marmorstein, 2001).
1.2.1 The enzymes responsible
There are thousands of enzymes that have acetyltransferase activity, very few
of which have been structurally characterised to date. These enzymes fall into a
B
A
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number of different families, many of which belong to the large superfamily of
GNAT’s (Gcn5-related N-Acetyltransferases) of which it has been noted that
approximately 10,000 identified members exist (Vetting, 2004) across all the
kingdoms of life. Other families include the MYST superfamily, the CBP/p300
family and transcriptional co activators. Each of these families includes enzymes
with diverse functions and affinity for certain substrate types (Angus-Hill, 1999), e.g.
histones, aminoglycoside antibiotics, arylalkylamines (Dyda, 2000) as well as
puromycin and diamines. Histone acetyltransferase (HAT) enzymes, in particular,
are abundant throughout the GNAT/MYST superfamilies and others including global
co-activators such as p300/CBP and nuclear receptor co-activators (Table 1.1).
Acetylated proteins Residues Acetyltransferases
Majority of eukaryotic proteins. !-Ser, !-Ala, etc. NatA, NatB, and NatC
E. coli ribosomal proteins (S18, S5,
and L12).
! -Ser, !-Ala RimI, RimJ, and RimL
Regulatory peptides ("-endorphin,
!-MSH, enkephalin, GHRF).
!-Tyr, !-Ser, !-Ala Unknown
Histones (H2A, H2B, H3, H4).
Transcription factors: (p53, E2F1-3,
EKLF, TFIIE", TFIIF, c-Jun, TCF,
GATA1, MyoD, HMGI(Y), pRb,
NF-E2(MafG) and ACTR).
$-Lys
$ -Lys
GNAT ‘s: Gcn5, PCAF,Hat1, Elp3 &
Hpa2
MYST’s: Esa1, MOF, Sas2, Sas3,
Tip60 & MORF
p300/CBP group
Transcription factor’s: TAFII250 &
TFIIIC
Nuclear receptors cofactors: ACTR &
SRC-1
PCAF/GCN5, p300/CBP, TAFII250,
SRC-1?, MOZ, Tip60? & BRCA2?
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Table 1.1: Acetylated proteins and the corresponding acetyltransferase enzymes that act on
them. Abbreviations not mentioned in the text: BRCA2, breast cancer protein; Elp3, elongator
protein, a subunit of the RNA polymerase II holoenzyme complex; Esa1, essential SAS2-related
acetyltransferase; Gcn5, general control nonrepressible protein, a nucleosomal histone
acetyltransferase; GHRF, growth-hormone-releasing factor; GNAT, Gcn5p-related amino-
acetyltransferase superfamily; Hpa2, histone and other protein acetyltransferase; MOF, males absent
on the first, an X-linked dosage-compensation protein in Drosophila; MORF, monocytic leukaemia
zinc-finger protein related factor; MOZ, monocytic leukaemia zinc-finger protein; MYST group,
named for the founding members MOZ, YBF2/SAS3 and Tip60; p53, a tumour-suppressor protein;
pRb, retinoblastoma protein; Rch1, Rag1 cohort, human importin-!; Sas2, something about silencing
protein, involved in silencing at telomeres and mating-type loci; SRC1, steroid nuclear receptor co-
activator; Tip60, HIV Tat-interactive protein. A question mark indicates uncertainty. (Table adapted
from Polevoda & Sherman, 2002, Diversity of acetylated proteins).
1.2.1.1 The GNAT’s
The GNAT superfamily consists of a few distinct subfamilies (figure 1.5),
designated GCN5 (general control non-repressed), PCAF, AANAT, AAC, ELP3,
HAT1 and HPA2 (Pandey, 2002) among others (figure 1.5a). GNAT enzymes are
characterised by their N-acetyltransferase domain, which consists of four motifs A-
D. These motifs are ordered C, D, A and B from N- to C-terminus of the proteins
(figure 1.5b). These motifs were first discovered by Tercero et al (1992) and further
characterised by Neuwald & Landsman (1997). Motifs A and B are common to the
general histone acetyltransferase population, motif A being the most highly
conserved. It contains a consensus sequence (R/Q)XXGX(G/A) (where X is any
amino acid), which is partly responsible for the recognition and binding of acetyl-
CoA (Dutnall, 1998b; Wolf, 1998). Motif C is found only in the GNATs. It is not
highly conserved at the sequence level but structural homology is well preserved
HMG proteins (HMG1 and
HMG2).
$ -Lys2 & $-Lys11 p300/CBP & PCAF
Nuclear receptor HNF-4. $-Lys p300/CBP
Nuclear import factors (importin-
!7 and Rch1).
$-Lys22 p300/CBP
!-tubulin. $-Lys40 62-67 kDa protein
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throughout subsets of the superfamily. The hypothesised function of motif C is
substrate recognition/binding (Trievel, 1999). The typical secondary structure of a
GNAT member will contain four !-helices and six to eight "-sheets (figure 1.5c).
Figure 1.5: The GNAT family. (A) GNAT superfamily of enzymes showing a few well-
characterised members. ^ denotes enzymes with additional function/s related to transcription. (B)
Domains and motifs within the general GNAT protein. (C) Topology of the GNAT fold. Yellow and
red regions highlight the conserved CoA binding domain, whilst green and blue show the less
conserved N- and C-termini (Vetting, 2004).
GCN5 (also known as ADA4) is one of the founding members of the GNAT
superfamily and is a type A HAT, i.e. localised to the nucleus (Mizzen, 1998). GCN5
contains a high number of charged residues; the N-terminal region is quite acidic and
its mid section is more basic (Georgakopoulos, 1992). It includes the signature HAT
domain of the GNAT family (figure 1.5b) and has many closely related homologues
including T. thermophila P55 (the catalytic subunit of a previously identified HAT).
Brownell and colleagues were the first to prove that GCN5 displayed HAT activity
toward free histones in vitro (Brownell & Zhou et al, 1996), showing a marked
GNAT
superfamily
C D A B
HAT domain  Bromo
domain
 B
CA
Hat2
Hat1
Elp3^
Hpa2
Spt10^
Hpa3^
GCN5^/PCAF^
AANAT
AAC
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preference for Lys 14 of histone H3 and residues Lys 8 and Lys 16 in histone H4
(Kuo, 1996). Recombinant GCN5 cannot acetylate chromatin associated histones but
it exists in vivo as a subunit belonging to the multimeric complexes ADA and SAGA,
and as part of these complexes, GCN5 is able to acetylate nucleosomal histones
(Grant, 1997). GCN5 activity causes remodelling of promoter DNA (Gregory, 1998)
and assists in transcriptional initiation/activation through interaction with a variety of
transcriptional regulators e.g. the GCN4 homodimer and the CYCI (encoding iso-1-
cytochrome c) UAS2 element, as well as transcriptional activation through the
heterotrimer complex HAP2-HAP3-HAP4. GCN4 is needed to transcribe amino acid
biosynthetic genes in yeast cells when the supply of amino acids is lacking in the
environment (Georgakopoulos, 1992). The CYCI UAS2 element is involved in the
transcription of genes responsible for regulating the oxidative phosphorylation
process (Trueblood, 1998). Transcription of several genes involved in S. cerevisiae
respiratory function is brought about by the activity of the HAP2-HAP3-HAP4
complex.
PCAF (p300/CBP associated factor) is a close homologue to GCN5 which has
been found to associate with the transcriptional co activators p300/CBP in vivo
(Yang, 1996). As a HAT and a co activator, it has been implicated in growth factor-
signalled activation (Xu, 1998) and receptor-receptor mediated activation (Blanco,
1998). PCAF not only acetylates histones but also non-histone proteins such as the
activators p53, HIV Tat, MyoD and general transcription factors (TFIIE and TFIIF)
and chromatin associated proteins (HMG17 and HMGI) (Sterner & Berger, 2000).
During myogenesis, MyoD recruits PCAF and p300/CBP to the promoters of
myogenic genes, where they all combine to form a complex that initiates the
transcription of these genes. The HAT activity of PCAF is then essential for
differentiation of cells into specific muscle tissue types (Puri, 1997). PCAF and
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p300/CBP also form complexes with other proteins e.g. the multimeric activation
complex with a nuclear co-activator ACTR, which has also been discovered to be a
HAT (Chen, 1997).
The AANAT subfamily comprises arylalkylamine N-acetyltransferase and its
homologues. AANAT is a ~23 kDa globular cytosolic protein that is expressed
highly in both the pineal gland and the retinal photoreceptor of the eye (Klein &
Coon, 1997). It forms a reversible complex with 14-3-3 proteins and its main
function is to regulate the levels of melatonin that are produced during the circadian
rhythmic cycle in response to levels of daylight. Its role in the retina is less
understood but it may be involved in local signalling through N-acetyserotonin or
melatonin (Pozdeyev, 2006). AANAT preferentially acetylates arylethylamines such
as serotonin, dopamine and tryptamine. Diamines and monoamines are also
acetylated but to a far lesser degree (Klein 2007).
The AAC subfamily (aminoglycoside antibiotic N-acetyltransferases) is
another important group belonging to the GNAT superfamily. Aminoglycosides are
bactericidal antibiotics that target the A-site of the 16S ribosomal RNA (Moazed &
Noller, 1987). An increase in the amount of antibiotic resistance among pathogenic
bacteria such as Gram positive enterococci and staphylococci has resulted from N-
acetyltransferase activity on certain amino groups of aminoglycosides, which results
in reduced affinity of the antibiotic for its target (Dyda, 2000).
To briefly mention the other GNAT enzymes outlined in figure 1.5a and their
substrates:-
Hat1 is a B type HAT (responsible for predominant cytoplasmic HAT activity
in yeast) and is associated with a second subunit Hat2. It was one of the first yeast
HATs to be discovered (Kleff, 1995 and Parthun, 1996) but its function is thought
perhaps to be redundant since null mutation confers no phenotypic defect. Previous
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studies have shown its involvement in telomeric silencing and DNA-double strand
break repair (Duntall, 1998b, Ruiz-Garcia 1998, Parthun 1996, Kelly 2000, Kleff
1995 and Qin 2002).
Elp3 (elongator protein 3, also known as Hpa1 or Tot3) targets H3 and H4
(Wittschieben, 1999; Winkler, 2002). Elp3 is part of the RNA polymerase II
holoenzyme and plays a role in transcriptional elongation. S. cerevisiae elp3 null
mutants are temperature sensitive and show poor growth adaptation but are still
viable (Sterner & Berger, 2000).
Hpa2 is capable of forming a dimer or a tetramer in vitro and is only found in
fungi. Histones H3 and H4 are both substrates of Hpa2 as well as Elp3. Hpa2 also
exhibits autoacetylation activity (Angus-Hill, 1999).
Hpa3 is a close homologue of Hpa2 but although it too can autoacetylate, it
displays very poor HAT activity in vitro (Sterner and Berger, 2000).
Spt10 is a yeast transcriptional regulator that shares homology to GNAT
proteins but as yet, no acetyltransferase activity has been demonstrated for it
(Natsoulis, 1994).
1.2.1.2 The MYST’s
The founding members of the MYST family are Moz, Yfb2/Sas3, Sas2 and
Tip60. The MYST superfamily (figure1.6a) contains a HAT region identified by its
homology to motif A of the GNATs and an unusual C2HC zinc finger domain
(figure 1.6b). The other identifying properties of this group are the C-terminal
bromodomain and the occasional inclusion of one or more zinc finger motifs or
chromo-like domains near the N-terminus (Sterner and Berger, 2000). Moz was first
identified as a putative acetyltransferase, found fused to the CREB binding protein
(CBP) (Borrow, 1996), and is involved in oncogenic transformation (see section
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1.2.4). Sas2 and 3 (Something about silencing) are connected to transcriptional
silencing in yeast. Sas2 is involved in telomeric silencing, capable of either
suppressing it at the HMR loci or promoting it at the HML loci (Ehrenhofer-Murray,
1997). Sas3 has weaker HAT activity than Sas2 but is still active in the silencing of
mating type loci (Reifsnyder, 1996). Tip60, the first MYST protein to be discovered,
is a 60 kDa protein that interacts with the activation domain of Tat, the HIV-1
transactivator protein (Kamine, 1996). Tip60 cannot acetylate chromatin-associated
proteins very well but it is able to acetylate free histone proteins H2A, H3 and H4
(Kimura, 1998; Yamamoto, 1997). Tip60 allows positive regulation of the Tat-
repressed gene for Mn-dependent superoxide dismutase (Westendorp, 1995) but once
bound, Tat can cause inhibition of Tip60 acetyltransferase activity (Creaven, 1999).
Esa1, an essential sas family acetyltransferase required for cell cycle
progression (Smith, 1998), is also unable to act on nucleosomal histones but like
Tip60, it is able to modify free histones in vitro. It has a high specificity for Lys 5 of
histone H4. Yeast cells that are deficient in Esa1 are halted in growth between the
DNA replication and mitosis stage of the cell cycle (Clarke, 1999). MORF, a close
homologue of Moz (Moz related factor; Champagne, 1999), exists as MORF! and
MORF", each having slightly different insertions in the N-terminal repressed region
of the protein. This region contains two zinc fingers and deletion of it causes the
HAT activity of the enzyme to be enhanced, leading to increased in vivo
transcription. It acetylates nucleosomal histone H4 strongly and will also acetylate
free histones H3 and H4, but unlike its relative Moz, it has not yet been linked to any
kind of cancer. HBO1 is a HAT that interacts with a specific subunit (ORC1) of the
origin recognition complex, ORC (Iizuka, 1999), which is conserved throughout the
eukaryotic kingdom. The main function of ORC is the binding of DNA replication
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origins in order to initiate replication (Dutta, 1997). The subunits of the origin
recognition complex enhance the otherwise weak HAT activity of HBO1 and its
preferred substrates are free histones H3 and H4.
Figure 1.6: The MYST family. (A) The MYST family founding members and some others. (B) The
general MYST domains. Note that one or more zinc fingers (Z) may be present depending on the
actual enzyme. A chromo-like domain ‘C’ may exist near the N-terminus, again depending on the
actual enzyme (Sterner & Berger, 2000).
1.2.1.3 p300/CBP
p300 and CBP are two very closely related proteins with a high level of
sequence homology, both containing a transactivation domain at each terminus and
an acetyltransferase domain in the middle (figure 1.7). They were first identified as
belonging to a conserved family of transcriptional co-activators (Arany, 1994) and
found to interact with many cellular proteins, either as modifying agents in cellular
cascades or as subunits in a number of multi-subunit complexes. The adenovirus
oncoprotein E1A targets p300 and CBP and the interaction between these proteins
suggests involvement in DNA synthesis control and progression of yeast cells into
MYST
superfamily
A
ESA1
MORF
HBO1
Tip60
MOZ
Sas2
Ybf2/Sas3
B
HAT domain  Bromo domain
A  Z C
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the S-phase of the cell cycle (Stein, 1990; Moran, 1993). These co-activators play a
range of distinct roles in processes such as retinoic-acid-induced F9-cell
differentiation (Kawasaki, 1998) and the cellular response to hypoxic conditions
(Arany, 1996). Bannister and colleagues were among the first to notice that CBP and
p300 are histone acetyltransferases (Bannister, 1996; Ogryzko, 1996) and they also
demonstrated that p300/CBP acetylated a nuclear import factor called importin
(Bannister, 2000).
Figure 1.7: Organisation of p300/CBP proteins. (A) Comparison of p300 and CBP. The dark
regions indicate the areas of highest homology, with the percentage amino acid identity between the
two proteins indicated. The size of each protein, in number of amino acid residues, is indicated. (B)
The functional domains in p300 are also indicated (adapted from Chan, 2001).
It was also observed that P300/CBP were recruited in p53 dependent pathways
(Avantaggiati, 1997) and activation of p53 (Sakaguchi, 1998) has been demonstrated,
in vivo, with several sites on this major protein becoming targets for acetylation by
PCAF and p300 in response to DNA damage (Liu, 1999a). Among their many other
roles, acetylation by p300/CBP is also responsible for the control of the
retinoblastoma tumour suppressor protein (Chan, 2001). Therefore, p300/CBP are
essential as transcriptional co-activators and HATs within the cell. They have been
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described as ‘partners in life and death’ (Giordano, 1999) because they are major
players implicated in so many pathways and no doubt, new functions will continue to
come to light regarding this pair of ubiquitous enzymes.
1.2.2 Histone deacetyltransferase enzymes
Histone deacetyltransferases enzymes (HDACs) can generally be divided into
three different groups (de Ruijter, 2003). Each group possess highly differing
sequences, sharing no homology with each other. Class I members can be found
localised to the nucleus and they share a considerable degree of homology to yeast
RPD3 (reduced potassium dependency). Members of class I include HDACs 1, 2, 3
and 8. Class II affiliates are homologous to yeast Hda1 (histone deacetylase) and are
approximately twice the molecular weight of their class I relatives. HDACs 4, 5, 6, 7,
9 and 10 fall into the class II and they can be found in both the nucleus and the
cytoplasm of the cell. HDAC 11 shares in the properties of both class I and II
enzymes and is sometimes referred to as class IV. A third class of HDACs consists
of yeast Sir2 related proteins (sirtuins), Sirt1-Sirt7, and is based around their distinct
NAD-dependent mode of action. Class III enzymes are also found in the nucleus and
the cytoplasm. In the same way that some HATs have an additional role as co-
activators, many HDACs also double up as transcriptional co-repressors and can be
found as subunits belonging to large regulatory complexes. Histone deacetylation by
HDACs is generally considered one of the main mechanisms controlling
transcriptional repression in mammalian cells and one would guess that if HDACs
were inhibited by the action of a specific compound that gene induction would
rapidly increase. In fact, only about 2% of genes have been shown to be switched on
by treatment with HDAC inhibitors (Van Lint, 1996).
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1.2.2.1 Class I
HDAC1 interacts physically with the retinoblastoma tumor-suppressor protein
(Rb) via the LXCXE sequence motif to cooperatively enhance its activity. Rb inhibits
cell proliferation and progression from G1 to S phase of the cell cycle by repressing a
subset of genes that are controlled by the E2F1 transcription factor. This complex
plays a key role in the control of cell proliferation and differentiation (Magnaghi-
Jaulin, 1998). In addition to this role, HDAC1 also interacts with metastasis-
associated protein-2 in order to deacetylate the promiscuous p53 protein. HDAC1
and p53 are “antagonistic regulators of the cyclin-dependent kinase inhibitor gene,
p21” (Lagger, 2003) and thus adapt it to affect cell growth and apoptosis. The p21
gene has been found to be regularly induced in differing cell types by the action of
HDAC inhibitors (Marks, 2001). HDAC2 interacts with PELP1 (proline-, glutamic
acid-, and leucine-rich protein 1), a co-activator of estrogen receptor (ER), which
recruits p300/CREB-binding protein HAT to the target chromosome. HDAC2 acts to
repress this activity (Choi, 2004) and also functions to a similar level in conjunction
with numerous different factors. HDAC3, like HDAC1 can facilitate recruitment of
the histone binding protein RbAp48 to Rb and leads to the gathering of a repressive
complex  to the E2F-regulating promoters (Nicolas, 2001). HDAC8 is induced by
interleukin-2 and is important for the contractile ability of smooth muscle tissue by
association with !-actin. It is co-expressed with !-actin and heavy chain myosin
(Waltregny, 2005). HDAC8 regulates hEST1B protein stability and thus alters the
enzymatic activity of telomerase in humans, resulting in a contribution to
tumourigenesis (Lee, 2006).
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1.2.2.2 Class II
HDAC4 is able to shuttle between the cytoplasm and nucleus, its subcellular
localization being affected by phosphorylation at specific sites. It has been suggested
that HDAC4 has a positive role in the differentiation of muscle tissue (Zhao, 2001).
HDAC4 is also involved in cardiac cell signaling (leading to cardiac hypertrophy
and/or arrest) as a downstream substrate of nuclear calcium/calmodulin-dependent
protein kinase II% (Little, 2007). HDAC4 is also linked to caspase enzymes and
therefore plays a part in the control of cell differentiation and death (Liu, 2004). G"&,
a subunit of heterotrimeric G proteins,  binds and inhibits the transcriptional co-
repression activity of HDAC5 (Spiegelberg, 2005). HDAC5 can bind
Ca2+/calmodulin and this inhibits MEF2a (monocyte enhancer factor) binding, thus
impacting the differentiation of cardiac and skeletal cells (Berger, 2003). Over-
expression of HDAC5 has been found to inhibit tumour cell growth and lead to
apoptosis of such cells (Huang, 2002). HDAC6 deacetylation of tubulin plays a key
role in microtubule-dependent cell motility (Hubbert, 2002).
The activity of molecular chaperone heat shock protein 90 (Hsp90) “is
regulated by reversible acetylation and controlled by the deacetylase HDAC6”
(Kovacs, 2005). Hyperacetylation of Hsp90 by inhibition or deactivation of HDAC6
results in its dissociation from p23, an essential co-chaperone, and leads to a loss of
chaperone activity. Glucocorticoid receptor (GR) maturation is dependent on Hsp90
and is compromised in HDAC6-deficient cells, giving rise to GR defective ligand
binding, nuclear translocation, and transcriptional activation (Kovacs, 2005). HDAC7
is found mainly in the nucleus, as outlined for class II enzymes, but can also be found
to a degree in the cytoplasm, indicating the likelihood of nucleocytoplasmic
shuffling. It often associates with class I HDAC3 in vivo but cytoplasmic HDAC7 is
inactive when not bound to HDAC3 (Fischle, 2001). Along with other class II
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HDACs, HDAC7 contributes to the regulation of MEF-2 function in muscle and
heart tissue (Dressel, 2001). HDAC9, also known as HDAC7B, is also a repressor of
MEF-2 mediated transcription.
1.2.2.3 Class III
The Sirtuins (silent information regulator 2) family are composed of a core
domain of 250 amino acids and share 25-60 % sequence identity (reviewed in
Moazed, 2001). Sir2 is a unique deacetylase that removes acetyl groups from
acetylated lysine residues on histones and other proteins in an NAD dependent mode.
This makes it the first deacetylase of its kind since other members of the family
catalyze an NAD-nicotinamide exchange reaction that requires the presence of
acetylated lysine residues but they do not absolutely require NAD when it comes to
the catalysis of histone deacetylation (Landry, 2000). Conservation of the Sir2 family
throughout all domains of life, even in organisms that do not possess histones,
indicates that it is an enzyme with a broad range of substrates and little specificity. In
yeast and other eukaryotes, Sir2 has potential links to chromosome segregation,
transcriptional silencing, cell ageing  (Guarente, 2000),  cell  cycle progression and
DNA repair.  It interacts with the hypoacetylated H3 and H4 histone tails of the
nucleosome and therefore hinders access of the DNA to replication, transcription and
recombination machinery, hence it is known as a chromatin silencer.
1.2.3 Acetylation and disease
Abnormal levels of acetylation have been linked to several major diseases
including acute myeloid leukaemia, Non-Hodgkins lymphoma, Epithelial cancers,
Rheumatoid arthritis, Huntington’s disease, Fragile-X syndrome and Rubenstein-
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Taybi syndrome (see table 1.2 for specific acetylation defects in some of these
diseases). However, the underlying causes of such aberrant hypo/hyperacetylation
levels noticed in these diseases is not at all well understood. In most cases, it has
been observed that HDAC levels are more prevalent and given that there are several
known HDAC inhibitors already commercially available,  this lends an ideal
opportunity for potential therapeutic treatments tailored towards specific diseases. A
quick overview of some of the above mentioned diseases follows in table 1.2.
Disease Acetylation Defect
Leukaemia
Epithelial cancers*
RTS (Rubenstein-Taybi
syndrome)
Polysomy X
Fragile X syndrome
HAT fusions                   HDAC mediated
MOZ/CBP                      RAR/PML
MOZ/P300                      RAR/PLZF
MOZ/TIF-2                    AML1 fusions
MLL/CBP
MLL/p300
P300 mutations in colorectal, gastric, breast, pancreatic
carcinomas/cancer cell lines
CBP haploinsufficiency due to mono-allelic CBP mutations
Incomplete acetylation of all X chromosomes
FRM-1 mutations linked to deacetylation and hypermethylation
of X chromosome
Table 1.2: Acetylation defects in various human diseases. (Adapted from Timmermann, 2001).
*Epithelial cancers are too numerous and diverse to  cover in the above body of text. MOZ –
monocytic leukaemia zinc-finger protein, CBP – CREB binding protein, p300 - ??, TIF2 –
transcription factor, MLL – mixed lineage leukaemia, HDAC – histone deacetyltransferase, RAR –
retinoic acid receptor, promonocytic leukaemia, PLZF – promyelocytic leukaemia zinc-finger
protein, AML – Acute myeloid leukaemia, FRM-1 – fragile X gene.
Acute myeloid leukaemia (AML) is a disease affecting the myeloid/blast white
blood cells, where they do not mature but continually divide and cause congestion in
the bone marrow so that the production of red blood cells and platelets is also
hindered. This can cause anaemia, bruising, repeated infections and aching joints.
There are several classifications of AML, for which different chromosomal
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translocations have been pinpointed. This results in an array of mutant fusion
proteins that over-recruit co-repressor HDAC complexes. Inhibition of these HDAC
complexes by the HDAC inhibitor trichostatin A can relieve transcriptional
repression, arrest disease progression and induce remission (Collins, 1998; Zwiebel,
2000). Non-Hodgkin’s Lymphoma (NHL) is a cancer of the immune system that
primarily causes swelling of the lymph nodes. Again, there are many types of NHL
but the largest subgroup is diffuse large B-cell lymphoma (DLBCL). In 35 % of
DLBCL cases, a 95 kDa nuclear phosphoprotein protein and transcription factor,
Bcl-6, is expressed constitutively. This protein recruits HDAC complexes and thus
causes repression of genes important for the control of lymphocyte activation and
differentiation. Acetylation down regulates the activity of Bcl-6 by hindering its
interaction with HDACs (Pasqualucci, 2003).
Huntington’s disease (HD) is an autosomal (dominant) inherited neurodegenerative
disorder arising from an expansion of CAG trinucleotide (polyglutamine) repeats in
the huntingtin protein (Taylor, 2002). It is thought that a transcriptional dysregulation
is responsible for the disease. Mutant proteins with expanded polyglutamine are able
to bind to and restrain CBP and cause cellular toxicity (Jiang, 2006). This obviously
leads to problems with CBP co-factor dependent transcription and also results in
diminished HAT activity within the cell (McCampbell, 2000). Fragile X-syndrome
is a mental retardation disease occurring on a sliding scale from mild to severe
depending on the number of CGG trinucleotide repeats found at the 5’ end of FMR1
(fragile X mental retardation). The 5’ end of normal FMR1  associates with
acetylated histones H3 and H4 (Coffee, 1999), allowing transcription of the FMR1
RNA-binding protein, but in fragile X patients (>200 CGG repeats) the chromatin
structure at the 5’ end of F M R 1 is altered (Eberhart, 1996). In addition to
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methylation, this repetitive area of the gene attracts HDAC complexes which reduce
the acetylation levels of the histones and result in transcriptional silencing.
Rheumatoid arthritis shares many similarities with cancer e.g. hyper-proliferation
of synovial tissue surrounding the joints and a dependency on angiogenesis. Nuclear
acetylation levels are enhanced in rheumatoid synovial cells causing over activation
of several transcription factors (Nakawaza, 2002). N-acetyltransferase
polymorphisms (of NAT2) have been implicated in the disease. People with slow
NAT2 acetylation genotypes are up to 4.39 times more likely to develop Rheumatoid
arthritis (Pawlik, 2004; Astbury, 1995). High concentrations of tumour necrosis
factor alpha (TNF-!) in synovial cells cause them to undergo abnormal rates of
mitosis and become enlarged (hyperplasia). TNF! recruits (and therefore depletes)
CBP to its promoter to activate further transcription of the gene (Cvoro, 2006). P53
acts to suppress local inflammation (Yamashini, 2002) but depleted CBP levels mean
the p53 promoter cannot be activated, resulting in decreased transcriptional
activation and little/no p53 induced apoptosis of hyperplastic cells. It has been
reported that TNF! also causes increased acetylation of p53 (Nakazawa, 2002),
inducing accumulation of an inactive form of the protein (Drané, 2002). It should be
noted that p53 acetylation can also activate the protein e.g. by the HAT activity of
CBP , depending on the site of the modification. Needless to say, this disease
involves some extremely complex pathways, many of which are still poorly
understood but it is evident that acetylation plays a key role.
Rubinstein-Taybi syndrome is an inherited mental retardation syndrome
characterised by congenital malformations such as beaked nose, broad thumbs/big
toes and cardiac irregularities (Petrij, 1995). It is an autosomal dominant condition
arising from mutation of CBP on chromosome band 16p13.3. Murata et al
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demonstrated that several mutations within the CBP gene (found in patients with the
condition) had the ability to abolish the HAT activity of the enzyme (Murata, 2001).
Polysomy X, as the name suggests, is the inheritance of an abnormal number of X
chromosomes, which can be from either parent. The condition displays similar
physical and mental symptoms as Down’s syndrome and the greater the number of
extra X chromosomes an individual has, the greater the severity of the disease. The
extra X chromosomes are not activated and show incomplete H4 acetylation (Leal,
1998).
1.3 Archaeal Histones
Prokaryotes have less DNA to compact and do not need the same tight controls
on gene regulation. Bacterial DNA is compacted by small basic DNA binding
proteins e.g. Fis and Hu; histone-like nucleoid associated proteins. The activity of
these proteins does not seem to be regulated by posttranslational modification
(reviewed in White & Bell, 2002). Many species of archaea from the subdomain
Euryarchaeota contain histone homologues. These archaeal histones have the same
signature histone fold as eukaryotic histones but are shorter at both N and C-terminal
ends, lacking the tail domains where targeted modification takes place in the
eukaryal histones (White & Bell, 2002). Nevertheless, they do  have the ability to
form a protein core for binding and wrapping DNA in a similar way. It is possible
that gene regulation may be aided by archaeal histone dimer formations, if for
example the histone core contained various histone compositions with different DNA
binding properties (reviewed in Reeve, 2003). Transcriptional regulation in the
archaea may provide clues as to the nature of the last common ancestors with
eukaryotes and bacteria (Whitman, 1999). None of the Crenarchaeota sequenced so
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far have histones. Since Sulfolobus solfataricus belongs to the Crenarchaeota, it does
not contain histone proteins but its genome is known to encode two extremely
abundant DNA-binding proteins: Sul7 and Alba1 (White & Bell, 2002).
The evolutionary tree of life shows that archaea diverged from Eukaryotes at a
later stage than they diverged from the bacteria. This suggests that archaea are more
closely related to eukaryotes in their information processing pathways and in
particular, their core machinery involved in transcription, DNA replication and repair
(Bond et al, 2001; White & Bell, 2002). Sulfolobus solfataricus is an extreme
thermophile that lives and metabolises in temperatures between 60-89°C, pH range
2-5 (Zillig, 1980). Its proteins are easy to study because they are often
straightforward to express and are usually very stable due to the high temperature at
which they normally function. In addition to this, they can be more easily isolated
from other proteins in an E.coli expression system when the temperature factor is
exploited since all proteins from the mesophile E.coli are non-heat stable and will
form aggregates upon heating.
1.4 Sul7 enzymes
These proteins were first identified in the 1980’s by Reinhardt and colleagues
(Kimura, 1984; Grote, 1986; Choli, 1998) and found only in Sulfolobus species,
resulting in the generic family name Sul7 (White, 2002). So far, Sso7d, Sac7d and
Ssh7d have been identified and characterized (from S. solfataricus, S. acidocaldarius
and S. shibatae respectively). These sequence independent DNA binding proteins are
small, around 66 residues, and basic with a molecular weight of approximately 7 kDa
and have almost identical sequences. They constitute about 5 % of total soluble
protein in Sulfolobus cells (Baumann, 1994). The function of these proteins has not
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yet been confirmed but they are believed to be important in forming higher ordered
structures for DNA compaction and stabilization of the duplex at the high
temperatures at which Sulfolobus function, since Tm increases by as much as 33 °C
for solutions with an excess of Sac7d in thermal denaturation studies of both DNA
and DNA-protein complexes (Edmondson, 2001). The Sul7 family have been
reported to induce negative supercoiling of DNA of any topology, whether relaxed,
positively or negatively supercoiled (López-Garcia, 1998). These proteins have been
found to have cation dependent ATP-ase activity, allowing them to function as ATP-
dependent protein chaperones that disassemble and renature protein aggregates
(Guagliardi, 2000). Surprisingly, Sso7d also displays ribonuclease activity, whereas
Sac7d has none according to experimental observation (Fusi, 1993). However, the
likely scenario is that small molecular weight thermostable RNase proteins were co-
purified with Sso7d and not detected, thus giving rise to a false conclusion.
Sequence independent DNA binding proteins and their interactions with
duplex DNA were previously poorly understood because capture of the
protein–DNA complex in crystalline form was not easy and few examples existed. In
1998, Gao and colleagues managed to crystallise the Sso7d bound to DNA. From
this, it was devised that Sso7d binds the minor groove of duplex DNA without
sequence specificity and intercalates two hydrophobic side chains at positions 29
(Met) and 26 (Val). This results in an approximate 61° single step sharp kink being
introduced into the DNA, the largest of its kind known to date (Gao, 1998). Studies
carried out on Sac7d by small angle X-ray scattering  showed  that   although
binding  induced  a  large  kink  in  the  DNA,  sequential  binding  of  the protein to
long lengths of DNA at contiguous 4 bp sites leads to little change in the topology of
the DNA because the sequential bends are compensatory (Krueger, 1999). From
NMR analysis, proteins belonging to the Sul7 family have an OB fold topology
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consisting of an incomplete five stranded "-band capped by an amphipathic !-helix
bordering the "3-"4-"5 strands (Murzin 1993; Gao 1998). High-resolution crystal
structures of two different Sso7d-DNA complexes were solved and it was found that
each Sso7d monomer bound indiscriminately to a site of DNA spanning just 4 bp in
length (McAfee 1996, Gao, 1998; Reeve 2003). This binding was associated with
significant unwinding of the helix and bending of the DNA resulting in an A-DNA
type structure at the binding site (Edmondson, 2001; Gao, 1998). Although binding is
non-cooperative, the distortions induced in the DNA require cooperative interactions
between adjacent protein monomers (Edmondson, 2001). Sso7d contains a small
hydrophobic core of 11 residues. Four glycine residues at positions 10, 27, 38 and 39
are found in the loop regions and there is a greater than 45% solvent accessibility to
hydrophobic regions. Four hydrophobic amino acids located on the "3-"4-"5 sheet
of the molecule appear to be sites of contact between protein and DNA (Trp 24,
which is conserved in all Sul7 proteins (Baumann, 1995), Val 26, Met 29 and Ala
45). The fact that Sul7 members are able to bind DNA in a sequence independent
matter may be due to the bridging water molecules that occupy the cavity area
between protein and DNA, thus inhibiting any steric clash between G-C base pairs
and N2 amino groups.
1.5 Alba
This small DNA binding protein was previously known as Sso10b when it was
first identified (Grote et al, 1986) but  has been renamed  Alba  for  Acetylation
lowers binding affinity (Bell et al, 2002). Alba is a dimer, each subunit Mr of 10 kDa,
that makes up approximately 4-5 % of total soluble protein in the cell (Xue, 2000). S.
solfataricus has two copies of the Alba gene (Alba1 and Alba2), the second of which
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is expressed at a 10-20 fold lower concentration in stationary cells and has only 30-
40 % identity with Alba1 (Jelinska, 2005). Hexagonal and tetragonal crystal
structures of Alba1 have been isolated and solved by collaborating groups at St.
Andrews University and Cambridge using MAD phasing techniques to a resolution
of 2.6 Å (Wardleworth, 2002). The crystal structure of the Alba1 monomer showed
that it contained two !-helices (A and B) and four " strands (a-d). Alba proteins are
unrelated to the Sul7 family and homologues are present in many other thermophilic
and hyperthermophilic Archaea (Xue, 2000). In addition, Alba orthologues have been
found in some eukarya (Aravind, 2003). Structural studies on Alba1 have
demonstrated that it shares a common fold with DNaseI and the C-terminal end of
translation initiation factor 3 (IF3), giving rise to the conclusion that its origins arose
from an ancient nucleic acid-binding domain  (Aravind, 2003). The Alba1
homodimer contains a central body with lysine residues at positions 16 and 17,
flanked by two extended "-hairpins, which suggest three main points of contact with
the DNA (Wardleworth, 2002).
Figure 1.8: Structure of
SsoAlba1. (A) Alba1 molecule
coloured by electrostatic
potential. The groove formed
between the two loops
containing Lys16 and Lys17 is
apparent. (B) The Alba dimer
with N and C terminal ends
coloured blue and red. Lys16
(red arrow) and 17 (green
arrow) are depicted by ball and
stick notation (Wardleworth,
2002).
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Native Alba1 subunits have a mass of 10, 538 Da, 84 mass units larger (after
removal of N-terminal methionine in both cases) than recombinant Alba1 expressed
in E.coli. This 84 mass unit difference is  due to the addition of  two acetyl groups;
one at  the N-terminal serine and the other site is the $-amino group of Lysine 16 or
17. Mass spectrometry studies of Alba1 tryptic digests imply that the second
acetylation site is Lys 16 (Bell, 2002).
The hairpin loop of monomer A is ordered and responsible for making contact
with other symmetry related monomers in the crystal form. In contrast, the hairpin
loop of monomer B is disordered and does not interact with other monomers. The
dimer has a buried surface area of 690 Å2 (the interface formed between strands c/d
of monomer A and helix B of monomer B). There is an additional monomer
association between helix A and the helix B C-terminal end, with a buried surface
area of 460 Å2. The significance of this association has yet to be understood
(Wardleworth, 2002). Alba1 is highly conserved throughout both archaeal domains
(figure 1.9), suggesting a conserved function and a fundamental role.
Figure 1.9: Sequence alignment of Alba1 proteins in Archaea and Eukaryotes. Strictly conserved
residues in black and close substitutions in grey. Af-1 and Af-2, A. fulgidus (AF1956 and AF1067
respectively); Pho, Pyrococcus horikoshii (NP_143671); Mth, Methanothermobacter
thermautotrophicus str. Delta H (AAB85958); Mja, Methanococcus jannaschii (Q57665); and Sso,
Sulfolobus solfataricus (CAA67066) are included in the archaeal protein alignment (Zhao, 2003).
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Most of the non-polar residues belonging to the hydrophobic core or dimer interface
are completely  conserved (Zhao, 2003). The  loop containing Lys16 and 17 houses
the most conserved residues. Gly15, Pro18, and Tyr 22 are responsible for stabilizing
this loop. There are a number of salt bridges and ion pairs to be found stretching
across the back of the dimer, again thought to be for stability reasons (Wardleworth,
2002).
1.5.1 Alba-DNA binding and function
Alba1 binds DNA with greater affinity than Sul7d members but in common
with them, it seems to lack sequence specificity. The protein from S. shibatae has a
DNA binding site of approximately 12 bp (Xue, 2000).  From chromatin precipitation
studies, it has been demonstrated that Alba1 is distributed along the chromosome in a
ubiquitous and uniform fashion, suggesting a functional role in archaeal chromatin
architecture (Wardleworth, 2002; Marsh, 2005). DNA binding affinities of both the
native (acetylated) and recombinant  forms  of  the protein dimer measured by
electrophoretic mobility shift assays were shown to exhibit high affinity co-operative
binding by the recombinant form (dissociation constant ~30 nM) whereas the native
(acetylated) dimer bound with approximately 3 to 4 fold lower affinity (Jelinska,
2005; Guo, 2003). Mutation analysis and replacement of the lysine 16 and 17
residues with alanine and glutamate implicates them in having an important  role in
DNA binding. The ability of Alba1 to mediate transcriptional repression was also
tested. It was found that acetylated Alba1 is unable to repress transcription as are the
mutant forms of Alba1 K16A/E and K17E. It was then shown by Bell et al that
binding of archaeal Sir2 to native Alba1 results in deacetylation, thus altering and
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controlling Alba’s DNA binding affinity and ultimately giving rise to transcriptional
repression (Bell, 2002).
The Alba2 homodimer binds DNA with far weaker affinity than Alba1 but it is
able to form a tight heterodimer with Alba1 (capable of binding DNA to a similar
level as the Alba1 homodimer), which suggests that its function within the cell is
enhanced by heterodimerization with Alba1 (Jelinska, 2005). Alba can bind DNA in
two ways: (1) saturating  concentrations  of  the Alba1 homodimer bind a single
DNA duplex, giving rise to little DNA compaction (Lurz, 1986). This confirms a
previous conclusion by Reinhardt et al that it did not supercoil DNA, nor was it
involved in compaction (Dick and Reinhardt, 1986) and (2) low-intermediate
concentrations of the Alba heterodimer can bind two DNA duplexes, resulting in a
highly compacted DNA-protein complex (figure 1.10), indicating a possible role in
the control of in vivo DNA packaging (Jelinska, 2005).
Figure 1.10: Electron Micrographs of
nucleoprotein filaments formed by
Alba(1)  homodimer and Alba
heterodimer binding to duplex DNA.
DNA:protein ratios of 6bp/dimer and 12
bp/dimer are shown. The arrows in the
bottom left EM where two duplexes are
interwound, indicate stem (a) and loop (b)
structures (Jelinska, 2005). Note: ds DNA is
a  nicked circular phiX174 plasmid.
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1.5.2 A model for DNA-binding
Experiments involving the use of DAPI dye were carried out by Wardleworth
and colleagues. DAPI binds DNA in the minor groove and has fluorescent properties.
Addition of Alba1 to the DNA / DAPI complex results in loss of fluorescence from
the
DNA suggesting that Alba binds DNA in the minor groove or at least distorts this
area upon binding (figure 1.11). No evidence for increased DNA electrophoretic
mobility was found and it was therefore assumed that little or no wrapping of the
DNA by the protein occurred, this observation was also supported by EM studies
(Wardleworth, 2002).  However, interaction of DNA with  protein  will  undoubtedly
alter the net charge of the DNA resulting in an alternate rate of propagation through
the agarose gel. In addition, compacted DNA will migrate faster. Thus, it is possible
that the charge difference created by the addition of Alba to DNA (if it renders the
molecule less negative) and any potential packing / compaction, could cancel each
other out and consequently result in no change in movement through the gel, giving
rise to the wrong conclusions.
The final stoichiometry for S. solfataricus Alba binding to DNA is 5-10 bp of
double stranded DNA per Alba dimer. The first model for Alba set by Wardleworth
et al suggests that Alba binds DNA in the minor groove, like DNaseI, but it has a
longer "-hairpin that is angled in a different direction meaning that the DNA would
have to be oriented in an alternative way to that found in the DNA-DNaseI complex.
The two "-hairpin arms of the dimer are separated in length by ~40 Å, which
corresponds with the length of one complete turn of  B-form dsDNA. This means
each hairpin could potentially interact with an equivalent part of the duplex in the
minor  groove and  thus  allow interaction of  the  central  dimer body with  the major
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groove, giving three main points of contact with the DNA (figure 1.11). Small steric
clashes in the model will possibly be overcome by localized distortion of the DNA or
changes  in  the  " - hairpin loop regions. However, recent  findings by  Jelinska have
shown that the hairpin arms remain flexible upon binding and chemical shift data for
these locations remained unchanged regardless of binding status. In addition, the
residues concerned (positions 78-84) are not conserved and thus the loops are
unlikely to be involved in contacting DNA (Jelinska, unpublished results). The
model suggests that each dimer spans a region of ~15 bp duplex DNA. If additional
Alba dimers bind along the duplex in a similar fashion with a rotation of 120° around
the helix, this coincides with a stoichiometry of 5 bp in agreement with experimental
observation. Such sheathing of the DNA by Alba affords protection against nucleases
e.g. DNaseI. Therefore Alba may play a role in DNA protection (Wardleworth,
2002).
Figure 1.11: Model for Alba-DNA
binding proposed by Wardleworth
et al. Two hairpin arms interact with
the minor grooves whilst the central
body of the dimer makes contact with
the major groove (Wardleworth, 2002).
Lys16 and 17 are shown circled whilst
conserved residues Arg42 and Phe60
are labelled with red and blue arrows,
respectively
The molecular mechanism of Alba : DNA binding is not well understood but
dimer - dimer contacts have revealed a positive regulatory role in DNA binding and
it  is  thought that Alba  actually binds DNA as  a  ‘dimer of dimers’ (Zhao, 2003), in
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which binding of the  Alba complex to DNA recruits consecutive dimers to the site
and results in extended helical protein fibres  (Jelinska, unpublished results, Jelinska,
2005). In contrast to the model of Wardleworth, Zhao  and colleagues have proposed
that the central  body of the Alba  dimer binds along the minor groove rather than
the major groove. In addition to the putative roles of Alba in chromatin compaction,
protection and transcriptional repression, it is predicted that Alba may also (or in
some lineages of Archaea, exclusively) play a part in RNA metabolism since it
shares a degree of structural homology with the RNA binding versions of the IF3 – C
fold (Aravind, 2003).
1.6 The deacetyltransferase of Alba, Sir2 (discussed in section 1.2.3.3).
In Sulfolobus, a protein doublet migrating at ~27 kDa was discovered when
antisera raised against SsoSir2 (Mr ~27.6 kDa) were used to probe western blots of
whole cell extracts. After size exclusion chromatography, the doublet was found to
elute at 50-60 kDa and 27 kDa. It was reasoned that  the  increase in mass was due to
a stable protein-protein interaction forming between SsoSir2 and an unknown protein
of around 10 kDa. Addition of NAD to the extract resulted in disruption of this
interaction. After isolation of the complex, the other protein concerned was found to
be Alba. Verification of the findings were shown by an Alba-GST fusion complex,
but not GST itself,  interacting with  recombinant SsoSir2.  SsoSir2 interacts with
Lys16 of the Alba dimer, causing a deacetylation reaction to take place and thus
rendering Alba active to bind DNA with greater affinity (Bell, 2002).
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1.7 Acetyltransferases of Alba
When the work described in this thesis first commenced, the deacetylase
enzyme, SsoSir2, had already been discovered and the acetyltransferase, SsoPat
(Marsh, 2005), responsible for modifying lysine 16 was in the process of being
characterised but the N-acetyltransferase enzyme had not been identified. There are
two genes in the Sulfolobus solfataricus P2 genome, Sso0082 and Sso0209  that may
encode acetyltransferases of Alba1. The respective predicted proteins are small,
Sso0082 being 151a.a long and Sso0209 167a.a long. From multiple sequence
alignments, it appears that Sso0209 has eukaryotic N-acetyltransferase homologues
as well as archaeal N-acetyltransferase homologues. Sso0082 shows sequence
similarity to acetyltransferase enzymes from other prokaryotes (section 3.1 and
appendix I). Both Sso0082 and Sso0209 share 30% identity with each other.
Sequence alignments group Sso0209 as a putative N-acetyltransferase (NAT)
enzyme. NAT’s acetylate the !-amino group of other proteins but it has also been
documented that they are capable of internal acetylation i.e. N$- acetylation of
specific lysine residues (Polevoda and Sherman, 2003). This brings us to question
whether SsoAlba is a target substrate for Sso0209 and if so, does the enzyme
predominantly acetylate amino acids at the N! or N$ positions, or both? The closest
homologue of Sso0209 is the Ard1 protein, sharing 37 % identity and 57 % similarity
to the H. sapiens version (hArd1). This sequence conservation allows Sso0209 to be
renamed ssArd1.
hArd1 is a 26 kDa subunit belonging to a tri-subunit complex termed NatA, in
which the other two proteins are NAT1 and NAT5. The NatA complex from S.
cerevisiae has been well characterised and interesting findings from deletion mutant
strains have shown that Ard1, the proposed catalytic subunit, cannot fulfil its
Chapter 1: Introduction
37
function as an acetyltransferase in the absence of NAT1. NAT1 has no capacity to
acetylate polypeptides independently, as is the case in ard-1' mutants (Arnold,
1999). It was  first  demonstrated by Sigiura et al that mammalian NAT1 and
mammalian Ard1 combine to form a functional acetyltransferase (Sugiura, 2003).
Little is known about NAT5 apart from its homology to Ard1 and that it may be
required for complex stability with the ribosome but it is not essential for activity
(Gautschi, 2003). It has been speculated that NAT5p could be responsible for
acetylation of a small subset of proteins that are too scarce to detect (Gautschi,
2003). It appears that NAT1 in the eukaryotic cell binds the ribosome and the
emerging polypeptide chain to bring it into close proximity with Ard1 for possible
modification (figure 1.12). Not all polypeptides are modified by Ard1 because
acetylation depends largely on the N-terminal sequence as well as other factors that
are poorly understood. It is possible that other residues within the N-terminal region
may decrease or prevent acetylation (Moerschell, 1990) e.g. proline and the
positively charged residues lysine or arginine occurring at the antepenultimate
position i.e. the 3rd amino acid, after counting cleaved methionine (Polevoda &
Sherman, 2003). Equally, the absence of certain residues may be responsible for non-
modification of proteins displaying a viable target sequence (Polevoda & Norbeck,
1999).  It has been noted that acidic residues in the N-terminal vicinity enhance
acetylation in eukaryotes, but the reverse is true for archaea (Falb, 2006). NatA is
responsible for acetylating sequences beginning with serine, alanine, glycine and
threonine after removal of the initiator methionine. Acetylation of these residues by
NatA accounts for the majority of N-terminal acetylated proteins within the cell.
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Figure 1.12: A model for co-translational
N!-acetylation by NatA (taken from
Gautschi 2003). Nat1 binds to the large
ribosomal subunit (LS) to stabilise the NatA
complex and in doing so it contacts the
emerging polypeptide chain, bringing it into
close proximity with Ard1 for acetyl group
transfer. It is unknown how Nat5 connects
with the complex. NAC and Ssb1/2p
constitute other factors that bind the
ribosome and contact the polypeptide chain
in advance of NatA. Their presence or
absence seems to be of no consequence to
the binding or function of NatA.
Complex Residue Specificity Subunits Known functions
scNatA
scNatB
scNatC
scNatD
ser, ala, gly, thr
met-asp, met-glu (and
a subclass of met-asn)
met-ile, met-leu, met-
phe
histones H2A & H4
Nat1
Ard1*
Nat5
Mdm20
Nat3*
Mak10
Mak31
Mak3*
Nat4*
Influences multiple processes such as the
cell cycle, heat-shock resistance, mating,
sporulation, and telomeric silencing
Involved in mitochondrial inheritance
and actin assembly
Required for replication of dsRNA virus;
expression is glucose-repressible
?
Table 1.3: Subunits, specificities and functions of the different Saccharomyces cerevisiae NAT
complexes. *catalytic subunit of complex. All other subunits are associates essential for complex
formation.
In addition to NatA, a further two major acetyltransferase complexes, NatB and
NatC, exist in yeast (table 1.3). NatB substrates have Met-Asp- or Met-Glu- termini,
whereas NatC targets substrates containing Met-Ile-, Met-Leu- or Met-Phe- termini
(Arnold, 1999). The catalytic subunits belonging to NatB and NatC are known as
Nat3 and Mak3, respectively. Both subunits bear noticeable overall % homology to
Ard1. Another homologue, Nat4, also known as NatD, has been recently discovered
to acetylate N-terminal sequences belonging to histones H2A and H4 (Song, 2003).
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This protein does not seem to require additional subunits for acetyltransferase
activity.
The existence of a complex in higher organisms allows speculation as to
whether ssArd1 can act alone or if it absolutely requires a binding partner in order to
function. Another option is that the protein may have a binding partner to enhance its
acetyltransferase activity. Sequence analysis shows that ssArd1 is smaller in
comparison to hArd1 and scArd1 since it does not contain the extended C-terminal
region (which is often less structured) of the eukaryotic homologues. The
homologues posses a predicted coiled coil region from amino acids 194 to 224
(figure 1.13), which is thought to interact with NAT1, and supporting this theory,
early research by Park and Szostak showed very little co-immunoprecipitation of
NAT1 with a truncated version of Ard1 comprising only the first 194 amino acids of
the protein (Park & Szostak, 1992). The fact that ssArd1 lacks this potential binding
region suggests that it probably does not bind a NAT1 homologue in the crenarchaea.
In addition to this, similarity searches in Sulfolobus show absolutely no indication of
any NAT1 or NAT5 homologues. However, recent research by Arnesen and
colleagues (Arnesen, 2005) has suggested that the N-terminal amino acids 1-58 are
important for binding NAT1.
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Figure 1.13: Schematic representation of S. cerevisiae and S. solfataricus Ard1. scArd1 contains a
NAT1 binding domain at the N-terminal (1-58) region (Arnesen, 2005) OR the C terminus between
residues 194 and 224 according to early research by Park & Szostak but ssArd1 lacks this later region.
The acetyltransferase domain spans residues 45-130 (Arnesen 2005). Red arrow indicates a string of
negatively charged amino acids that may allow Ard1 to form a homodimer. Black arrow indicates a
region of Ard1 that is able to form homodimer with other Ard1 molecules (Park & Szostak, 1992).
Similarity searches using BLAST for ssArd1 homologues throughout the
archaea gives rise to a large number of hypothetical and known protein sequences
which share a high degree of sequence identity, especially in the Sulfolobales. S.
tokodaii gene ST0258 and S. acidocaldarius gene Saci_0459 are clear Ard1
homologues since they posses 77 % and 68 % identity, respectively, with ssArd1. A
distribution of Ard1 homologues in the archaea is shown in the following
dendogram (figure 1.14).
1 167
NAT1 binding domain
194  2241   238
   Acetyltransferase domain
 ? ?
 ssArd1
Eukaryal Ard1
58
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Figure 1.14: Phylogenetic tree displaying the evolutionary divergence of ssArd1 homologues
throughout the archaea (created at www.ebi.ac.uk/Tools/clustalw2/index.html).
ssArd1 (Sso0209) is boxed in red. The combined distance of horizontal lines between two subjects
indicates relative genetic similarity i.e. shorter distance equals greater similarity.
Q0W795_9EURY_RCIX281 Predicted acetyltransferase -Uncultured methanogenic archaeon RC-I,
Q12V66_METBU_Mbur_1771 SSU ribosomal protein S18P alanine acetyltransferase – M. burtonii
(strain DSM 6242), Q8PXC8_METMA_MM_1293 Acetyltransferase – M. mazei,
Q97CT7_THEVO_TV0014  ARD1 – T. volcanium, Q9HM13_THEAC_Ta0058 ard1 subunit – T.
acidophilum, Q6L124_PICTO_PT00743 Ribosomal protein s18 alanine acetyltransferase – P
torridus, Q980R9_SULSO_Sso0209 Ard  –S. solfataricus, Q976C3_SULTO_ST0258 predicted  NAT
– S. tokodaii, Q4JBG0_SULAC_Saci_0459 predicted NAT – S. acidocaldarius,
Q9YAI6_AERPE_APE1954 N-terminal acetyltransferase – A. pernix, Q8ZVJ9_PYRAE_PAE2246
N-acetyltransferase – P. aerophilum, Q2FTL4_METHJ_Mhun2553 SSU ribosomal protein S18P
alanine acetyltransferase – M. hungatei (strain JF-1 / DSM 864), Q18FN7_HALWD_rimI – H.
walsbyi (strain DSM 16790), Q3IU89_NATPD_NP0402A putative uncharacterized protein – N.
pharaonis (strain DSM 2160 / ATCC 35678), Q5V0F2_HALMA_rimI N-terminal acetyltransferase –
H. marismortui, Q9HMF0_HALSA_rimI N-terminal acetyltransferase – H. salinarium,
A0B8U4_9EURY_Mthe_1343 GNAT family acetyltransferase – M. thermophila (strain DSM 6194 /
PT), O29519_ARCFU_AF_0739 Ribosomal protein S18 alanine acetyltransferase – A. fulgidus,
Q5JHP6_PYRKO_TK2214 RimI homolog – P. kodakaraensis, Q8U428_PYRFU_PF0267 Ribosomal
protein s18 alanine acetyltransferase – P. furiosus, Q9UY34_PYRAB_16740 N-terminal
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acetyltransferase – P. abyssi, O58034_PYRHO_PH0296 hypothetical acetyltransferase – P.
horikoshii , Q8TXW0_METKA_MK0549 Acetyltransferase – M. kandleri, Q58925
Y1530_METJA_MJ1530  uncharacterised acetyltransferase – M. jannaschii,
Q6LXJ9_METMP_MMP1315 rimI NAT– M. maripaludis (genome segment 4/5),
O27080_METTH_MTH999 ARD1 – M. thermoautotrophicum, Q2NF20_METST_Msp_1202
Predicted acetyltransferase – M. stadtmanae (strain DSM 3091), Q96YV0_SULTO putative
uncharacterized protein ST2077 – S. tokodaii, Q4JCH9_SULAC_Saci_0073 Acetyltransferase – S.
acidocaldarius, P95978_SULSO_Sso0082 Orf c04040 rimI related NAT – S. solfataricus,
Q6LY09_METMP_MMP1184 N-acetyltransferase related protein – M. maripaludis,
Q8PTQ5_METMA MM_2658 Acetyltransferase – M. mazei.
1.8 Research Aims
Acetylation is a fundamental biological modification that has evolved to meet
the individual requirements of many diverse cellular processes. In this case, it
regulates the ability of Alba to bind DNA, whether directly or as a low level
molecular signal to other proteins. This thesis will primarily describe the
identification and biological characterisation of an acetyltransferase enzyme
responsible for modifying the N-terminus of the Alba1 protein. In addition, kinetic
parameters and reaction rates between Alba1 and the acetyltransferase will be
examined. Acetyltransferase activity towards several other Sulfolobus proteins will
also be tested to assess whether the enzyme is promiscuous or specific to Alba. The
active site and the substrate binding site of the putative N-acetyltransferase will be
explored using mutational analysis and crystallographic studies.
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2.1 Isolation of Sulfolobus Solfataricus genomic DNA
Genomic DNA was isolated from Sulfolobus cells (-80 °C frozen pellet) using
the animal tissue protocol from the QIAGEN DNeasy(  tissue kit (50). A 1:10
dilution of this DNA was used for Polymerase Chain Reaction (PCR).
2.2 Cloning the genes and expressing protein
2.2.1 Cloning and Vectors
The Sso0082 gene region was amplified from Sulfolobus solfataricus (P2
strain) genomic DNA by PCR using Pfu (proof reading) polymerase (Promega) and
the following specifically designed primers (Operon):
5’ primer: 5’- CGTCGGATCCCCATGGTAATTATAACTGATGCAACAG-3’
3’ primer: 3’- CCGGGGATCCGTCGACTTAATCCAGATATTTATAATATAAATTC-3’
In order to subclone the gene into the pET28c vector (Novagen) for native protein
expression, 5 µl of PCR product or plasmid was used per 20 µl reaction along with
restriction enzymes NcoI (1µl of 10U/µl) and BamHI (0.5µl of 10U/µl) and 2µl 10X
BamHI buffer (Fermentas). Samples were incubated at 37 °C for 2 hours with NcoI
and then overnight at 28 °C on addition of BamHI. Ligations were then carried out
overnight at 5 °C using 4 µl plasmid DNA, 10 µl digested product, 1 µl T4 DNA
ligase and 2 µl T4 DNA ligase buffer. The gene was also subcloned into the pLOU3
(construct prepared by Dr. Louise Major, St. Andrews University. See figure 15)
NcoI / SalI site and pGEX-5X-3 (Amersham Pharmacia Biotech) BamHI / SalI site to
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generate protein fused with maltose binding protein (MBP) and glutathione-S-
transferase (GST), respectively.
Figure 2.1: pLOU3 (or
pHIS_MalC2-Tev):
pLou3 was derived from the NEB
vector pMAL-c2X, and thus has
cytoplasmic expression of the fusion
protein. New features are N-terminal
6xHis tag before MBP and a Tev
protease cleavage site between MBP
and the (modified) polylinker.
Unique restriction sites are shown on
the map (+ NdeI which cuts twice).
The ssArd1 (Sso0209) gene was amplified from Sulfolobus solfataricus
genomic DNA using Pfu polymerase and the following primers:
5’ primer: 5’- CGTCGGATCCCCATGGAGCTCGCTGAAAAAGATAAAGG-3’
3’ primer: 5’- CCGGGGATCCGTCGACTTAGAGTGGTCTTGCCATAAGATATGC-3’
The PCR product was cloned into the NcoI/BamHI site of pET28c for native protein
expression and the NcoI/BamHI site of the pHisTev30a vector (designed by Dr.
Huanting Liu, St. Andrews University) to create a poly-histidine tag on the N-
terminal region of ssArd1.
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Figure 2.2: Vector
pHISTEV30a.
pHisTev30a designed by Dr.
Huanting Liu.
The Sir2 gene was amplified from Sulfolobus solfataricus using KOD HiFi
polymerase (Novagen) and the following primers:
5’ primer: 5’- CGTCGGATCCCCATGGTATACGAGAAAGTAGCTGAAG-3’
3’ primer: 5’- CCGGGGATCCGTCGACTTACGAAAGTATTTTCTGTCTCACG-3’
The PCR product was cloned into the NcoI/BamHI site of pET28c.
A pET30 construct containing Alba1 (Sso10b) for native expression was
obtained from Dr. Steve Bell (MRC Cancer Cell Unit, Cambridge). Three mutant
versions, K16A (purified protein only), K16EpET29 and K17EpET29 were obtained
from Dr. Ben Wardleworth (former St. Andrews lab member).
All products were cleaned up after PCR and digestion using a QIAquick
purification kit. Plasmids were then transformed into an E.coli Top10 strain
(Invitrogen) for amplification. The amplified plasmids were extracted via miniprep
kit (QIAprep( Miniprep, QIAGEN) and the constructs sent for DNA sequencing
(Dundee Sequencing service).
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2.2.2 Site Directed Mutagenesis
Mutants of Alba at the N-terminus (S2A, S2E, S2G, S2L, S2P, S2T and S2V) were
created by site directed mutagenesis using Stratagene( quickchange site directed
mutagenesis kit. Stratagene SDM involves the use of individually synthesised
primers, (each containing the mutation of interest) a high fidelity polymerase i.e. Pfu
Turbo®, DNTPs and a PCR machine. The primers anneal to the plasmid-gene
construct and Pfu Turbo® fully replicates both strands of plasmid DNA (figure 2.3).
The parent DNA is methylated and, as such, can be digested at the end of thermal
cycling using Dpn#. The construct containing the mutated gene is then transformed
into supercompetent cells.
Figure 2.3: Basis of Stratagene Site Directed Mutagenesis.
Plasmid-gene construct. Primers anneal at complimentary
DNA site on gene and replication occurs, generating high
copy construct containing mutant gene.
The following primers (Operon) were used to generate mutations in Alba1:
5’ primer: 5’-GGAGATATACATATGGCGAGCGGAACCCCAACTCC-3’       Alanine
3’ primer: 5’-GGAGTTGGGGTTCCGCTCGCCATATGTATATCTCC-3’        (MASG…)
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5’ primer: 5’-GGAGATATACATATGGAAAGCGGAACCCAACTCC-3’     Glutamic acid
3’ primer: 5’-GGAGTTGGGGTTCCGCTTTCCATATGTATATCTCC-3’         (MESG…)
5’ primer: 5’-GGAGATATACATATGGGTAGCGGAACCCCAACTCC-3’        Glycine
3’ primer: 5’-GGAGTTGGGGTTCCGCTACCCATATGTATATCTCC-3’        (MGSG…)
5’ primer: 5’-GGAGATATACATATGCTGAGCGGAACCCCAACTCC-3’        Leucine
3’ primer: 5’-GGAGTTGGGGTTCCGCTCAGCATATGTATATCTCC-3’        (MLSG…)
5’ primer: 5’-GGAGATATACATATGCCCAGCGGAACCCCAACTCC-3’         Proline
3’ primer: 5’-GGAGTTGGGGTTCCGCTGGGCATATGTATATCTCC-3’        (MPSG…)
5’ primer: 5’-GGAGATATACATATGACCAGCGGAACCCCAACTCC-3’      Threonine
3’ primer: 5’-GGAGTTGGGGTTCCGCTGGTCATATGTATATCTCC-3’        (MTSG…)
5’ primer: 5’-GGAGATATACATATGGTGAGCGGAACCCCAACTCC-3’         Valine
3’ primer: 5’-GGAGTTGGGGTTCCGCTCACCATATGTATATCTCC-3’        (MVSG…)
Point mutations were made at specific sites in ssArd1 that had been identified by
sequence alignments to be absolutely or highly conserved. The chosen residues were
D21, H88, S131_N132, D156 and E158. The following primer pairs were used:
5’ primer: 5’-CGCAAGAATGGATGCAATAGACCAAATAATAAAAATA-3’        D21A
3’ primer: 5’-TATTTTTATTATTTGGTCTATAGCATCCATTCTTGCG-3’
5’ primer: 5’-CGTTAGTCAGAAAAGGAGCTGTGGTTTCAATAGCAG-3’            H88N
3’ primer: 5’-CTGCTATTGAAACCACAGCTCCTTTTCTGACTAACG-3’
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5’ primer: 5’-TTAGAAGTAAGAGTCGCAGCATATCCCGCAATAGCCCTA-3’  S131A_
3’ primer: 5’-TAGGGCTATTGCGGGATATGCTGCGACTCTTACTTCTAA-3’  _N132A
5’ primer: 5’-GGTTATTATGCTGCTGGGGAAGACGCATATC-3’                         D156A
3’ primer: 5’-GATATGCGTCTTCCCCAGCAGCATAATAACC-3’
5’ primer: 5’-GGTTATTATGCTGATGGGGCAGACGCATATCTTATGGC-3’       E158A
3’ primer: 5’-GCCATAAGATATGCGTCTGCCCCATCAGCATAATAACC-3’
Transformation was into XL1-Gold supercompetent cells and the amplified
constructs were sent for sequencing.
2.2.3 Protein Expression
Each plasmid in turn was transformed into Rosetta BL21 cells (Novagen). Mini
cultures were set up in 5 ml L-broth containing the appropriate antibiotic (35 µg/ml
kanamycin or 100 µg/ml ampicillin) to test for best protein production. These were
induced with 0.1-0.2 mM IPTG for 3 hours. 1ml of each culture was centrifuged and
the pellet lysed in 100 µl lysis buffer (20 mM Tris-HCl, pH 8.5, 200 mM NaCl, 1
mM EDTA, 1 mM DTT) with a few granules of benzamidine. The samples were
centrifuged again to separate insoluble matter from the supernatant. The best
expressing cultures were then scaled up and the bacterial pellets were frozen until
use.
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2.3 Protein Purification
2.3.1 Purification of ssArd1
Frozen pellets were defrosted on ice by adding 30-40 ml lysis buffer (20 mM
Tris-HCl, pH 8.5, 200 mM NaCl, 1 mM EDTA, 1 mM DTT and 1 mM
benzamidine). The pellet was lysed by sonicating for 3 X 2 min on ice during which
a few granules of DNaseI were added. The soluble fraction was separated from cell
debris by centrifugation for 30 minutes at 75, 600 g and 4 °C. Supernatant was
diluted by 1/6 in buffer A (20 mM Tris-HCl, pH 8, 1 mM EDTA, 1 mM DTT) to
lower salt concentration and syringe filtered through a 2 µm Acrodisk( syringe
filter.
The protein sample was heat treated at 65 °C for 25 minutes and centrifuged
again at 4 °C, 75, 600 g for 20 minutes. This step eliminates non-heat stable E.coli
proteins. The sample was then loaded onto an anion exchange Hi Trap 5 ml HP Q-
sepharose column (Amersham Biosciences), which had been washed with buffer B
(20 mM Tris-HCl, pH 8, 1 M NaCl, 1 mM EDTA and 1 mM DTT) and equilibrated
with buffer A. Protein was eluted at 5 ml/min over a 400 ml linear gradient of 0-1000
mM NaCl. Fractions and flow through were analysed by SDS-PAGE. The 530 ml of
flow through sample contained little salt and was loaded onto a cation exchange
HiTrap 5 ml HP heparin column (Amersham Biosciences), which had been
equilibrated with buffer B. Samples were collected over a 400 ml linear gradient of
0-1000 mM NaCl and fractions were again analysed on SDS-PAGE. The
resulting630 ml of flow through that was collected was concentrated using
ammonium sulphate precipitation at 80 % saturation: proteins were pelleted by
centrifuging at 15, 900 g at 4°C for 30 minutes and resuspended in 40 ml of buffer C
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 (20 mM BisTris, pH 6, 0.3 M NaCl and 1 mM EDTA). The solution was dialysed
overnight in 3L buffer C to remove Ammonium Sulphate and persistent contaminant
proteins of less than 14 kDa and remaining proteins were separated by size on a
HiLoad( 26/60 Superdex( gel filtration column (Amersham Biosciences) that had
been equilibrated with buffer C. Fractions were checked on SDS-PAGE gel and the
band suspected as ssArd1 was cut from the gel and sent for matrix assisted laser
desorption ionisation-time of flight (MALDI-TOF) mass spectrometry for
identification.
Any protein solution still containing contaminants was then dialysed in buffer
D (20 mM MES, pH 6) and passed through a Bioscale CHT2-1 hydroxyapatite
column (Bio-Rad) or another cation exchange 30 Sp-Resource column (Amersham
Biosciences) equilibrated with buffer D.  Fractions eluted over 60 minutes with a salt
gradient of 0-1000 mM NaCl.
2.3.2 Purification of Alba1
Recombinant, K16A, K16E and K17E mutants:
Pellets were defrosted on ice and lysed in 20 mm Tris-HCl, pH 8.0, 200 mM
NaCl, 1 mM MgCl2 and 1 mM benzamidine. Samples were sonicated 3 X 2 min on
ice and DNaseI was added and allowed to incubate for 10 minutes on ice. Lysate was
then centrifuged at 75, 600 g, 4 °C, for 20 minutes. Supernatant was collected and
heated for 20 minutes at 70 °C to precipitate unwanted proteins and then cooled
down to 4 °C again during a repeat centrifugation step. Supernatant was diluted 1/5
with 20 mM Tris- HCl,  pH 8.0, 1 mM EDTA and 1 mM DTT, and loaded onto a
cation exchange heparin column that had been equilibrated with the same buffer.
Elution conditions were as follows: 5 ml/min over 40 minutes with a linear incline of
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0-100% buffer B (dilution buffer containing 1M NaCl). Fractions containing Alba
were concentrated in a 5, 000 MW vivaspin column and then loaded onto a
HiLoad( 26/60 Superdex( gel filtration column for the final purification step.
N-terminal mutants:
The procedure was the same as that outlined above but the heat step was not included
or was instead carried out after cation exchange.
2.3.3 Purification of Sir2
Pellets were defrosted and lysed in ~10 ml 20 mM Tris-HCl, pH 8.1, 200 mM
NaCl, 1 mM MgCl2 and 1 mM benzamidine. After sonicating for 3 X 2 minutes,
samples were incubated on ice for 10 minutes with DNaseI. Samples were
centrifuged as usual and checked on SDS PAGE gel. A band of ~27 kDa was excised
and sent to mass spec for identification. In the mean time, the protein solutions were
tested for heat stability at temperatures ranging from 50 °C to 70 °C for varying time
periods. Non heat-treated sample was diluted 1/6 in  buffer without salt (buffer A)
and then loaded onto a Q-sepharose column. Elution conditions were as follows;
fractions were collected at 2 ml/min intervals over a 56 minute gradient consisting of
100 % buffer A with increasing 1M salt buffer B (to 40%) over the first 20 minutes,
then increasing to 100% buffer B over 20 minutes.
2.3.4 MALDI-TOF and tryptic digest analysis
All protein samples were sent for analysis to the mass spectrometry unit at
St.  Andrews University for  identification, whole protein  mass  and  confirmation of
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mutagenesis. For impure samples, main bands were excised from SDS-PAGE gel for
ID. 20 µl of 10 µmolar pure protein samples were sent for whole protein mass
analysis and cleavage by the protease enzyme trypsin. This was done by adjusting
the pH of each sample to pH 8.0 with 1M Tris, pH 8.0. 0.5 ml (0.1mg) trypsin was
then added and the samples were incubated overnight at 37 ºC. “The resultant
peptides were diluted 1:5 into 5 % formic acid and then separated using an UltiMate
nanoLC (LC Packings, Amsterdam) equipped with a PepMap C18 trap & column
using a 3 and a half hour gradient of increasing acetonitrile concentration.  The
eluent was sprayed into a Q-Star Pulsar XL tandem mass spectrometer (Applied
Biosystems, Foster City, CA) and analysed in Information Dependent Acquisition
(IDA) mode. MS/MS data for doubly and triply charged precursor ions were
analysed using ProID software (Applied Biosytems), searching against a Sulfolobus
solfataricus protein database containing entries with and without the N-terminal
methionine.  The data was searched with tolerances of 0.2 Da for the precursor and
fragment ions, trypsin as the cleavage enzyme, one missed cleavage, and acetylation
and methionine oxidation selected as possible modifications.  Unambiguous
acetylation was assigned if the peptide match gave a confidence score of 99”
(Mackay, 2007).
2.3.5 Concentrating the samples
Concentrating of recombinant Alba and mutants was straightforward. This
was carried out in 3,000 or 5,000 MWCO vivaspin concentrators (Vivascience) in an
eppendorf centrifuge 5810 at 4000 rpm and 4 °C. For ssArd1, however, dialysis
tubing was used in the concentrating of the samples. 12-14 kDa of pre-treated
membrane was washed in buffer and filled with ~30 ml sample. This was laid flat in
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a small container, covered with large amounts of polyethylene glycol (PEG) 8K and
left at room temperature for 2-3 hours to allow the excess buffer to cross the
membrane whilst keeping the protein inside the tubing. It was necessary to achieve
high concentrations of ssArd1 to generate protein crystals for structural analysis.
Optical density A276 (ssArd1 extinction coefficient 24250 M
-1 cm-1, absorbance
1.247  (0.1% = 1g/L)) or A280 (SsoAlba1 extinction coefficient 1490 M
-1 cm-1, abs
0.141 (0.1% = 1g/L)) were taken for all concentrated samples. These initial results
were double checked by Bradford assay. 0-10 µg/µl of BSA (bovine serum albumin)
was bound to Bradford dye reagent and used to generate a standard curve showing
absorbance levels at A550. A small amount e.g. 1 µl of sample protein is then tested in
the same way and the A550 reading is compared with the standard curve, to give an
accurate reading. Alba does not bind Bradford dye in the same manner as BSA
because it contains 2X the number of arginine residues (primary reactant sites)
causing an increased number of interactions with Bradford dye molecules. Therefore,
a pure concentrated sample of Alba of known concentration (obtained from Claire
Jelinska) was used to generate a standard graph for the comparison.
2.3.6 Glutaraldehyde crosslinking
50 µg ssArd1 was incubated for 10 minutes with 50 mM NaPO4, pH 7.6 at
room temperature. Glutaraldehyde was added to a final concentration of 1% and the
solution incubated for a further 1-2 minutes. 2 M NaBH4 was used to quench the
reaction over 20 minutes. Deoxycholate and TCA were used to precipitate the
reaction before centrifuging for 20 minutes at 4 °C. The pellet was washed with cold
acetone and centrifuged again, after which, it was resuspended in 20 µl loading
buffer (NuPage) and loaded onto SDS-PAGE (4-12 %) gel.
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2.4 Identifying a possible binding partner for ssArd1
2.4.1 Affi-gel 10 column
Two columns were prepared as stated in the manufacturers protocol (BioRad).
1 ml of  6.5  mg/ml ssArd1 was diluted to 3 ml and dialysed into 20 mM MES, pH
6.5, 100 mM NaCl, 1 mM EDTA and 1 mM DTT. ssArd1 was then bound as a ligand
to one column and dH2O was added to the control column. 8 ml of Sso lysate
(prepared from approximately 2 g of cells lysed in 20 mM MES, 100 mM NaCl, 1
mM EDTA and 1 mM DTT, pH 6.5) was filtered through the columns in low salt (50
mM) buffer. Columns were washed with low salt buffer, then twice with 1 ml
volumes of 300 mM buffer, 600 mM buffer and 1 M salt buffer. 1 ml fractions were
collected from each wash and 20 µl applied to SDS-PAGE (4-12 %) gel. The gel was
sypro-ruby stained for increased clarity.
2.4.2 Western Blot analysis
A semi-dry blot was performed using a dry blot machine at 25V (400 mA) for
25 minutes. The nitrocellulose membrane was then placed in blocking buffer for 10
minutes and primary antibodies for Alba1 and Alba2 were added in 1:1000 dilution.
After incubation on a shaker machine for 1 hour (and  a further wash step) secondary
antibody (anti rabbit-host-Goat IgG-antigen) was added in a 1:5000 dilution. This
was allowed to incubate for 30 minutes. After washing, the blot was drained and
pico-detection solution (Pierce) was applied for 1 minute.
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2.5 Acetylation assays
2.5.1 Acetylating Alba with ssArd1
[Assay adapted from Takei et al, EMBO reports, 2001, Vol21, pg119-123.]
Six 25 µl reactions were set up in acetylation buffer (50 mM Tris-HCl, pH 8, 0.1
mM EDTA, 10 mM Na butyrate, 1 mM DTT and 10 % glycerol), see table 2.1.
Table 2.1: Acetylation assay sample constituents. Acetylation of native (wt)
SsoAlba1, recombinant SsoAlba1 and K16A mutant Alba1 protein by ssArd1.
These samples were incubated at 70°C for 1 hour before being flash frozen to
terminate the reaction. All samples were sent to St. Andrews University mass
spectrometry service for analysis. Assays were repeated over 2 hours and mass
spectrometry analysis was carried out:
Alba (10 µM) ssArd1 (500 nM) Acetylation
buffer
AcCoA (20µM)
Old Recombinant - + -
New Recombinant - + -
New Recombinant + + -
New Recombinant + + +
Table 2.2: Acetylation assay sample constituents. Old recombinant Alba1
sample compared to newly purified recombinant Alba1.
Alba (10 µM) ssArd1 (500 nM) Acetylation
buffer
AcCoA (20µM)
Native - + -
Recombinant - + -
K16A - + -
Recombinant + + +
Recombinant + + -
K16A + + +
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2.5.2 Radiolabelled acetylation assay on SsoAlba1 & SsoAlba2
An initial acetyltransferase assay was set up using 0.5 µM ssArd1, 10 µM Alba
and 35.7 µM 14C AcCo-A. The same 10 µl reactions were set up for Alba 2, single
stranded DNA binding protein SSB (Cubeddu, 2005), obtained from Lisa Cubeddu,
and xeroderma pigmentosum group F endonuclease XPF (Roberts et al, 2003),
obtained from Jana Rudolf. Controls (minus ssArd1) were also prepared. Each
reaction was carried out at 60°C for 30 minutes.
Focusing on Alba 1 acetylation, time points were reduced to 1, 5, 10, 15, 20
and 30 minutes. The 5 minute time point was chosen in order to determine the effects
of varying ssArd1 and Alba concentrations to establish optimal conditions. This was
carried out using 18 µM 14C AcCo-A. 250 nM ssArd1 and 10 µM recombinant Alba,
the optimal conditions selected for further experiments, were incubated with 18 µM
14C AcCoA at 55 °C over varying time points up to 5 minutes. Each time point was
repeated at least 3 times.
To investigate kinetics of the reaction, the same assay was set up over 4
minutes using 250 nM ssArd1 and up to 80 µM Alba. An excess of cold AcCoA
(9/10) was added to the radiolabelled AcCoA before adding to the samples.
2.5.3 Curcumin assay (HAT inhibitor)
9.2 mg curcumin powder was dissolved in 2.5 ml DMSO to a stock
concentration of 10 mM. Samples of 10 µM Alba, 250 nM ssArd1 and varying
curcumin concentrations (0, 50, 100, 200, 500 µM) were incubated at 55 °C for 3
minutes using 18 µM of 14C AcCoA.
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2.5.4 Radiolabelled assay on Alba1 mutants
Alba mutants were diluted to the same concentration as the recombinant
version (checked by A276 and bradford assay using pure Alba of known concentration
as a standard). All mutants at 10 µM underwent the same assay as in 2.5.2.
2.5.5 Radiolabelled acetylation assay on other substrates
Acetylation assays were carried out as described in 2.5.2 with a variety of
proteins replacing Alba (holliday junction cleavage and holliday junction
endonuclease enzymes Hjc & Hje (Kvaratskhelia and White, 2000) obtained from Jo
Parker, proliferating cell nuclear antigen subunits PCNA1 & 2 (Dionne et al, 2003)
obtained from Jen Roberts, Sso7d obtained from Biljana Petrovic-Stojanovska and
DNA repair helicase XPB1 (Richards et al, 2007) obtained from Jodi Richards), all
of which have different N-terminal sequences. Each sample was repeated 2 times for
an average result and one control was carried out for each protein.
2.5.6 Radiolabelled assay on Sulfolobus cell lysate
A scaled up version of the previous acetylation assay was carried out using 54
µM 14C acetylCoA, 2.5 µM ssArd1, 1X acetylation buffer and 10 µl of non-diluted
cell lysate. E.coli cell lysate was also used as a positive control to show how much
acetylation occurs in prokaryotes. The positive control was incubated at 37 °C, the
optimum temperature for E.coli growth as was Sso lysate for a direct comparison.
Sso lysate was also incubated at 70 °C to show acetylation extent under its ecological
growth temperature. Total soluble protein was obtained from three more cell types
(HeLa (immortal cell line derived from H. sapien), MRSA (methicillin resistant S.
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aureus) and S. cerevisiae). Bradford assay was used to determine the protein
concentration and all samples were diluted to 0.47 mg/ml. Each sample was subject
to the same acetylation assay as previously described but 36 µM 14C AcCoA and 2
µM ssArd1 were used because the excess radiolabelled AcCoA interfered with
scintillation counting. For the same reason, the frequency of acetylation was reduced
by decreasing ssArd1 concentration.
2.5.7 Radiolabelled acetylation assay using ssArd1 mutants
ssArd1 mutants were diluted to stock concentrations of 2 µM for accurate
dilution to 250 nM. Acetylation assays were carried out, as described in 2.5.2, for
each mutant and again with the recombinant wt version.
2.6 Stability of acetylated Alba1
 2.6.1 Acetylation of Alba N-terminus for Differential Scanning Calorimetry
We used 2 mg/ml Alba (i.e. 96 µM) in a total of 6 ml. 177.6 µM acetyl CoA,
and 2.4 µM ssArd1 were used (a direct scale up from 20 µl sample) and the sample
was incubated at 55 °C for 11/2-2 hours. Gel filtration was carried out to separate
ssArd1 and acetyl CoA from acetylated Alba. The acetylated Alba was concentrated
in a viva spin column to ~1 ml, giving a protein concentration of ~2 mg/ml. The
sample was checked on SDS-PAGE gel to confirm purity and concentration before
being sent to Glasgow University for differential scanning calorimetry using a
Microcal-MCS system (carried out by Margaret Nutley). 1 mg/ml protein sample was
degassed and heated (20-100 ºC at a scan rate of 60 ºC/hour) in a calorimeter cell at a
constant rate along side an identical reference cell containing the same solution
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buffer as the sample. Differences in heat capacity between the contents of the two
cells yields thermodynamic data on the sample of interest (Cooper, 2000). Scans
were repeated to ascertain refolding ability of protein and experimental
reproducibility.
2.6.2 Circular Dichroism (CD) spectroscopy of Alba
Recombinant and acetylated Alba were each dialysed in buffer appropriate for
CD spectroscopy (10 mM Bis-Tris, 200 mM NaF, 0.5 mM EDTA) and further
diluted to a 1 mg/ml concentration, the required concentration for near UV analysis.
The aforementioned buffer was used as a blank. Protein solution was inserted into a
cuvette with a 0.5 cm pathlength and spectra were recorded between 450 nm and 260
nm at a scan rate of 20 nm/min in a JASCO J-810 spectalpolarimeter using Spectra
Manager Software. Far UV spectra were recorded between 260 nm and 180 nm at a
scan rate of 50 nm/min using a protein concentration of 0.5 mg/ml in a circular
cuvette with a 0.02 cm pathlength. Each sample was scanned three times for average
values and the blank was subtracted. The data were submitted to the Dichroweb
(Lobley,  2002;  Whitmore,  2004)  server  for  analysis  (http://www.cryst.bbk.ac.uk/
cdweb/html/home.html).
2.7 Crystallisation
2.7.1 Crystallisation of ssArd1
ssArd1 was concentrated to a maximum of ~9 mg/ml (in 20 mM Tris-HCl, pH
8.5,  200 mM  NaCl, 0.5 mM  EDTA, 0.5 mM  DTT buffer) and  snap  frozen  before
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storing at - 80 °C to prevent precipitation. A pre-crystallisation test was performed to
test the optimal concentration of ssArd1 to use in subsequent trials. 96 well sitting
drop plates were used for crystal trials, where drops were set up in a total volume of
4 µl (2 µl protein : 2 µl reservoir solution) so that the drops did not dry out quickly
and allowed time for vapour diffusion. The reservoir volume was usually set to ~180
µl. Trials were set up with Hampton research: crystal screens I and II, Pegion,
PEG/LiCl grid screen, cryo, Natrix, Lite, Ammonium sulphate grid screen, Index and
Salt-RX. Additional screens used were Emerald biosciences: screens I and II, Wizard
screens I and II (decode genetics), and jMAC (developed in-house kit). Screens were
set up at 4 °C and 19 °C under conditions that allowed minimum variation in
temperature and movement. All screens were repeated with a mix of Acetyl-CoA to
ssArd1 in a ratio of 1:1 and also 2:1 as there may be as many as two molecules
required per protein dimer to stabilise it due to predicted structural comparisons from
the 3D PSSM program.
Initial crystals were obtained with Hampton Pegion  solution 39 (0.2 M
NaH2PO4, 20 % (w/v) PEG3350, final pH 4.5), and a fine grid screen was set up to
optimise crystal growth (see table 6.1 in chapter 6 for details of specific solution
constituents). Each optimised solution was set at pH of 4.25, as well as 4.7 and 5.2.
All conditions were set up (1:1) using 1.5 µl of ssArd1 protein solution at 5.4 mg/ml,
6.9 mg/ml and 7.17 mg/ml ssArd1 with (2X and 1X) and without acetyl coenzyme A.
Further plates were set up using these solutions with Hampton Research additive
screens I, II and III. Oil ( a mix of 50:50 paraffin oil with al’s oil) was also dispersed
as a layer over the top of the reservoir’s to allow slower vapour diffusion, to produce
more robust crystals. Trials that gave rise to crystals were repeated with addition of
2.5-5 % ethanol, 2.5 % (v/v) PEG 400/1500 or 1 mM pentaglycine, additives that
increase crystal size and also aid the growth of 2D crystals in the 3rd dimension. All
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other solutions that yielded crystals with potential (i.e. size and morphology) for X-
ray diffraction were optimised in the same way.
2.7.2 Diffraction and data analysis
Potential protein crystals that were plentiful in number were stained with izit
dye to distinguish them from common salt crystals. Protein crystals were cryo-
protected in their reservoir solution with addition of 20 % glycerol, MPD, or PEG400
for a period of 2 minutes. These crystals were then mounted on the X-ray machine
(MSC/Rigaku MicroMax-007 rotating anode X-ray generator with Osmic optics, set
up to serve two image plate detectors, a HTC detector with X-Stream cryohead on
the right port, and an R-Axis IV++ with X-Stream cryohead on the left) and placed in
the beam path. Capillary mounting of the crystal was also performed to exclude the
cryo-protecting step. Initial data was collected at 0° and 90° to ensure the crystal
diffracted at all angles. Data was then collected with a crystal to detector distance of
200 mm and a 1° rotation of the crystal for each image. The diffraction pattern was
analysed by crystallographic software MOSFLM (Leslie, 1992). Crystals were also
taken to the ESRF synchrotron (beamline 14.1) to achieve better resolution.
2.7.3 CD spectrometry on ssArd1
ssArd1 was diluted 1/10 to a final concentration of ~1.3 mg/ml in 10 mM Na-
phosphate buffer, pH 7, 200 mM Na-fluoride, 0.5 mM EDTA. The sample was then
dialysed into the same buffer to remove excess Tris-HCl and NaCl. The
aforementioned buffer was used as a blank. Protein solution was inserted into a
cuvette with a 0.5 cm pathlength and spectra were recorded between 450 nm and 260
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 nm at a scan rate of 20 nm/min in a JASCO J-810 spectalpolarimeter using Spectra
Manager Software. Far UV spectra were recorded between 260 nm and 180 nm at a
scan rate of 50 nm/min using a protein concentration of 0.5 mg/ml in a circular
cuvette with a 0.02 cm pathlength. Each sample was scanned three times for average
values and the blank was subtracted. The data were submitted to the Dichroweb
(Lobley, 2002, Whitmore, 2004) server for analysis (http://www.cryst.bbk.ac.uk/cd
web/html/home.html).
2.7.4 Seleno-methionine incorporation
3 ml of ssArd1 overnight culture was gently centrifuged and resuspended in 3
ml of warmed M9 media.
M9 media preparation: 1L of autoclaved dH2O containing 15 mM NH4Cl, 20 mM
KH2PO4, 20 mM Na2HPO4.7H2O. pH was adjusted to 7.4 with 5 M NaOH. 100 ml of
filtered (non-autoclaved) solution containing 20 % glucose, 0.3 %MgSO4 , 10 mg Fe2
(SO4)3  and 10 mg thiamine was added to this. Finally, 35 µg/ml kanamycin and 50
mg L-Se-Met was added.
This was aliquoted into 4X 250 ml volumes of M9 in 1L flasks to allow for
plentiful aeration and cultures were allowed to grow at 37 °C until A595 reached 0.3.
Amino acids were then added to induce SeMet-ssArd1 protein production. Cells
were lysed by usual method (section 2.3). Lysate was analysed by SDS-PAGE and
the ssArd1 band was excised for mass spectrometry analysis for confirmation of
seleno-methionine incorporation.
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2.7.5 ssArd1 and Alba in complex
Using a ratio of 4.3 µM: 2.14 µM: 1µM, a mix of ssArd1:AcCoA:Alba was
produced and sent to St. Andrews University SPoRT laboratory, where 100 nL drops
of protein mix and crystal screen were dispensed by robotic arm and incubated at 19
°C. These samples were digitally photographed periodically for signs of nucleation
and/or crystal growth.
2.7.6 Molecular replacement
The 3DPSSM/Phyre programme (Kelley, 2000) uses threading to predict
homologous structures based on the protein sequence input. For ssArd1, this
programme recommended several acetyltransferase proteins that were overlaid using
SSM (Krissinel, 2004) as implemented in the MSD fold website at EBI. The overlaid
structures suggested a common structural core to the acetylase that was used as a
search model in molecular replacement with the program PHASER (McCoy, 2007).
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3.1 Introduction
In the first instance, the Sulfolobus Solfataricus genome was scanned to
identify possible acetyltransferase encoding genes (section 1.7). Sequence analysis
placed the focus of attention onto two specific genes, Sso0082 and Sso0209. From
multiple sequence alignments, it appears that Sso0082 has sequence similarity to
bacterial acetyltransferase enzymes e.g. RimI. Sso0209 has eukaryotic N-
acetyltransferase homologues as well as archaeal acetyltransferase and N-
acetyltransferase homologues and most notably its closest match with a protein of
known function in the human proteome is (h)Ard1. Therefore, we have renamed
Sso0209 as ssArd1 (as discussed in section 1.7). This chapter describes the cloning of
these two genes, and also SsoSir2, the deacetylase, and the subsequent expression
and purification of proteins from the successful clones. The gene products were then
investigated through a series of assays to establish their capacity (if at all) to
acetylate Alba and to characterise them further. In addition to the putative
acetyltransferase enzymes, assays with the known deacetylase (SsoSir2) were also
desirable to affirm whether it reversed the acetylation process carried out by these
particular enzymes. SsoSir2 deacetylates the K16 residue of the Alba protein (Bell
2002), allowing it to bind DNA with an approximate three to four fold higher affinity
than the acetylated version in vitro (Jelinska, 2005).
3.2 Sso0082
The complete Sso0082 gene region was amplified successfully by gradient
PCR (figure 3.1) using the following primers:
5’ primer: 5’- CGTCGGATCCCCATGGTAATTATAACTGATGCAACAG-3’
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3’ primer: 3’-CCGGGGATCCGTCGACTTAATCCAGATATTTATAATATAAATTC-3’
Figure 3.1: Gradient PCR on Sso0082 at different
annealing temperatures.
Lane 1 = size markers, 2 = 50 °C, 3 = 57 °C and 4 =
65 °C.
An annealing temperature of 50 °C produced the highest yield of specific Sso0082
product. Restriction digests allowed the fragment to be inserted into the BamHI/NcoI
site of pET28c, the NcoI/SalI site of pLOU3, the BamHI/SalI site of pGEX-5X-3 and
the NcoI/BamHI site of pHisTev30a. Competent E.coli Top 10 cells were
transformed with each of the above constructs and colonies were recovered for all
constructs except pHisTev30a. Repetition of digests, ligation and transformation
yielded a small number of colonies for the pHisTev30a construct from which 3 were
chosen for colony PCR. PCR on all samples including controls failed each time and
hence, the plasmid was purified and checked by restriction digests. A plasmid of the
expected size (plasmid + insert) was indeed observed on the agarose gel for some
transformants, whilst PCR on the Sso0082 constructs showed a band of ~ 453 bp for
Sso0082 from 2 of the samples (results not shown). The E.coli strain Rosetta BL21
was transformed with the correct construct and colonies for all constructs were
recovered for expression studies.
        1           2            3           4
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3.3 ssArd1
The ssArd1 gene (501bp) was amplified successfully by gradient PCR (figure
3.2) using the following primers:
5’ primer: 5’- CGTCGGATCCCCATGGAGCTCGCTGAAAAAGATAAAGG-3’
3’ primer: 5’- CCGGGGATCCGTCGACTTAGAGTGGTCTTGCCATAAGATATGC-3’
Figure 3.2: PCR on ssArd1 at different annealing
temperatures.
Lane 1 = size markers, 2= 62 °C and 3 = 65 °C
An annealing temperature of 65 °C produced the highest yield of specific ssArd1.
The amplified product was cloned into the NcoI/BamHI sites of pET28c and the
NcoI/BamHI sites of the pHisTev30a vector. In addition, ssArd1 was inserted into the
pGEX –5X-3 vector to give a Glutathione-S-transferase (GST) tagged version of the
protein for purification via GST pull-down assay. Each construct was transformed
into Top10 and Rosetta cells. After plasmid purification from Top10 colonies, PCR
on pure pGEX-5X-3/ssArd1 and pET28c/ssArd1 constructs confirmed that gene
insertion was successful (figure 3.3a). However, the very low signal intensity of the
PCR results obtained from the pGEX construct may be due to cross contamination
during the reaction and therefore, does not confirm the existence of the gene.
Restriction enzyme digests to verify these findings only returned a positive result for
the insertion in pET28c and not for pGEX-5X-3 (figure 3.3b).  Mini inductions of
Rosetta cultures were carried out before sequencing in order to identify positive
colonies that produced a protein band of the expected size on SDS-PAGE gel.
   1           2            3
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Figure 3.3a: PCR of pGEX-5X-3/ssArd1 and pET28c/ssArd1. 1 = size markers, 2 and 3 = pGEX-
5X-3 PCR (duplicate) and lanes 4 and 5 = pET28c PCR (duplicate).
Figure 3.3b: Digests on pGEX-5X-3/ssArd1 and pET28c/ssArd1. 1 = size markers, 2 = restriction
digest of pGEX-5X-3, 3 = restriction digest of pET28c construct.
3.4 SsoSir2
The SsoSir2 gene was amplified by gradient PCR (figure 3.4) using the
following primers:
5’ primer: 5’- CGTCGGATCCCCATGGTATACGAGAAAGTAGCTGAAG-3’
3’ primer: 5’- CCGGGGATCCGTCGACTTACGAAAGTATTTTCTGTCTCACG-3’
Figure 3.4: PCR on SsoSir2  at different
temperatures.
1 = size markers, 2 = 50 °C, 3 = 55 °C and 4 = 60
°C
An annealing temperature of 60 °C produced the highest yield of specific SsoSir2
product. The PCR fragment was cloned into the NcoI/BamHI sites of pET28c and the
resulting construct was used to transform E.coli Top10 cells for plasmid production.
However, sequencing results for vector/insert showed that the gene cloned was not
1.5kbp
1kbp
750bp
  1            2            3            4
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SsoSir2 but in fact SsoPCNA1. The procedure was repeated twice with many controls
but the same results were obtained. The primer sequences were analysed against
those required for SsoPCNA1 amplification and no resemblance was found.
SsoPCNA1 was under study in our laboratory at the same time and, thus, the likely
explanation is that the competent cell stock was contaminated with a construct
containing this gene insertion. This highlights the importance of maintaining
stringent aseptic techniques in the laboratory environment at all times. Further
attempts to clone SsoSir2 were put on hold.
3.5 Purification of Sso0082
The vector, pHisTev30a, contains a poly histidine tag of 6 consecutive residues
at the insert site that enable expression of a given protein attached to a (6X) his-tag at
the N-terminus. This tag allows one-step purification of the protein to take place on a
nickel nitrilotriacetic acid (Ni-NTA) resin. The tag can then be cleaved off and
separated from the desired protein. Mini inductions of 3 ml cultures containing
pHisTev30a/Sso0082 gave insoluble protein, which was initially suspected due to
larger pellet size and proven to be the case after SDS-PAGE analysis of supernatants
(not shown) and pellets (figure 3.5a). After many efforts to solubilise the protein e.g.
alteration of buffer constituents to include either glycerol, triton or 2 % (v/v) ethanol
and/or greater salt concentration, changing IPTG concentration and/or the OD at
which induction was instigated, growing the culture at 25 °C or using heat
shock/cold shock on the cells, the protein was still insoluble.
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Figure 3.5a: Expression of Sso0082 from pHisTev30a. Lane 1 = size markers, 2 = pellet from
uninduced control, 3 = pellet from induced control showing insoluble proteins.
Figure 3.5b: Expression of MBP-Sso0082 fusion and Sso0082-GST fusion proteins. Lane 1 = size
markers, 2 = pLOU3 control, 4 = induced pLOU3, 3 = pGEX-5X-3 control, 4 = induced pGEX5X-3.
Mini expression of MBP-Sso0082-fusion protein from pLOU3 (figure 3.5b)
yielded a small amount of soluble protein at approximately 60 kDa but scaling up of
the culture to 1L resulted in insoluble protein. All efforts to maintain it in the soluble
fraction failed. Despite DNA sequencing proving that the gene was present in the
pGEX-5X-3 vector, no soluble fusion of ~ 43.6 kDa was found. A faint band can be
observed at ~26 kDa, which may be GST expressing on its own (figure 3.5b). Since
Sso0082 has solubility problems when expressed on its own in vitro, there is a high
probability that it exists in complex with a binding partner (a possible homologue of
the Nat type proteins found in the eukaryotes) in vivo or alternatively it may be
membrane associated. At this point, it was decided to terminate the work with
Sso0082.
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3.6 Purification of ssArd1
Mini induction of Rosetta cultures from colonies containing the
pET28c/ssArd1 construct (this vector contains a histidine tag but it is not utilised in
this instance) indicated reasonable solubility for recombinant ssArd1 (figure 3.6).
Figure 3.6: Expression of native ssArd1
from pET28c.
Lane 1 = size markers, 2 = uninduced control,
3 = supernatant from induced culture.
A 6 L scale up culture was successful in producing a similar level of soluble protein.
Heat treatment at 65 °C for 20 minutes eliminated the majority of E.coli proteins
(figure 3.7a). Ion exchange chromatography was then utilized as a second
purification step, on the basis that buffering the protein to an appropriate pH to give
it an overall positive or negative charge will allow it to bind to a resin of opposite
charge. ssArd1 has a theoretical isoelectric point (pI) of ~7.6 calculated from the pK
values of  its amino acid content (http://www.expasy.org/tools/protparam.html). This
calculation is based on the analysis of polypeptide migration in an immobilised gel
environment between pH 4.5 and pH 7.3 (Bjellqvist et al, 1993; Bjellqvist et al,
1994). Based on the pI value, the protein was buffered to pH 8.5 to induce an overall
negative charge on the molecule but it did not bind to the anion exchange resin
(figure 3.7a). Buffering the protein to pH 9 made no difference to the lack of binding.
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Likewise, cation exchange on the heparin column at pH 6.0 did not cause ssArd1 to
bind either and the majority eluted again in the flow through (figure 3.7b). Further
buffer alterations did not make any difference to the binding affinity for either resin.
The discrepancy between predicted behaviour and actual behaviour of the protein on
the columns could be due to several factors including weak buffer capacity since
ssArd1 is a fairly small molecule, post-translational modification or blockage of the
N-terminus, and the protein morphology i.e. existence as monomer and/or dimer, all
of which would heavily influence the isolelectric point.
Figure 3.7a: Anion exchange on ssArd1 using a 5 ml Q-sepharose Hi-Trap column at pH 8.5.
Lane 1 = marker, 2 = sample after heat, 3 = column flow through, 4-8 = column fractions
representing each peak.
Figure 3.7b: Cation exchange on ssArd1 using a 5 ml heparin Hi-Trap column at pH 6. Lane 1 =
marker, 2 = sample after Q-sepharose, 3 = flow through, 4-8 = column fractions representing each
peak.
Ammonium sulphate (80 % w/v) precipitation was used to reduce the volume
of the flow through (unbound protein solution) from the heparin column. The volume
was  decreased  from  660 ml  to  approximately  45 ml,  therefore  concentrating  the
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sample as well as purifying it further (figure 3.8a). Overnight dialysis into 20 mM
BisTris, pH 6, 300 mM NaCl and 1 mM EDTA was followed by gel filtration
chromatography (HiLoad( 26/60 Superdex( column), separating proteins on the
basis of their size. The column was first calibrated with protein standards of known
molecular weight. The ssArd1 absorbance trace showed two main peaks at 280 nm
(figure 3.8b). The first peak eluted at a volume of 208 ml, which corresponds to a
molecular weight of ~40 kDa. ssArd1 is present here as a dimer but the majority of
the protein elutes at 236 ml in monomeric form (~19.5 kDa) along with some
persistent minor contaminants (figure 3.8c). To separate ssArd1 from the
contaminants, SP-resource and hydroxyapatite (ion exchange) resins were used but
yet again ssArd1 did not bind to either column although most of the contaminants
did. The protein was now pure enough to be used for biochemical and structural
analysis.
Figure 3.8a: Ammonium sulphate precipitation (80 %
w/v) of ssArd1 supernatant.
Lane 1 = size markers, 2 = dilute flow through from 5 ml
heparin column (i.e. before procedure), 3 & 4 = resuspended
precipitate from two different protein samples, 5 =
supernatant containing left over proteins that did not
precipitate.
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Figure 3.8b: Typical gel
filtration (HiLoad(  26/60
Superdex( column) trace for
ssArd1.
Peaks correspond to dimeric and
monomeric forms of the protein.
Peak 1 is ~ 40 kDa and peak 2 is
~ 20 kDa.
Figure 3.8c: SDS-PAGE gel
showing ssArd1 gel filtration
fractions.
Fractions are from peaks 1 & 2 of
figure 3.8b; 1 = size markers, 2 =
fractions covering peak 1 and 3 =
fractions covering peak 2.
In order to ease the purification, attempts were made to create a tagged version
of the protein as discussed in section 3.3.  The three new constructs provided
potential fusion proteins: (6X) His-ssArd1, ssArd1-GST and MBP-ssArd1. Mini
expression trials yielded a band of ~ 22 kDa for (6X) His-ssArd1. This was identified
by mass spectrometry as ssArd1 and scaled up for greater protein production.  The
tagged protein was subsequently purified on a 5 ml IMAC column (figure 3.9a) and
incubated with TEV protease to cleave off the His-tag. Sample was compared on a
gel before (it seems that the tag has degraded slightly as a small amount of untagged
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ssArd1 appears here) and after cleavage but although a fainter band appeared at
about 22 kDa showing that the protease had worked, no increase in the amount of
untagged protein at around 19.5 kDa was observed (figure 3.9b). After
centrifugation, it was clear that protein had precipitated. Sequencing results for the
His-ssArd1 construct suggested that His-ssArd1 was not present in the construct.
Figure 3.9a: Expression of His-
ssArd1 and purification on a 5ml
IMAC column. Lanes: 1 = size
markers. 2 = crude sample after
heating, 3 = column flow through, 4 =
1st small peak, 5 to 9 = ssArd1 peak.
Figure 3.9b: Before and after
treatment with TEV protease. Lanes:
1 = size markers, 2 = pre cut his-
ssArd1, 3 = post cut his-ssArd1
His-tagged ssArd1 isolated from the final column (gel filtration) was prepared
for analysis by mass spectrometry, however, the protein precipitated prior to analysis.
Further attempts to create a (6X) His tagged version failed. Despite sequence results
confirming the presence of the gene in the pGEX-5X-3 vector, GST was found to
express on its own with no trace of ssArd1. The pLOU3 vector did yield a high
amount of fusion protein (results not shown) but the enzyme responsible for cleaving
the tag off was prohibitively expensive and since native expression in pET28c did
give a reasonable amount of ssArd1 expression, it was resolved to continue working
with this construct and optimise the purification conditions. This involved increasing
the heat treatment to 25 minutes, then slowly pumping small volumes of the filtered
supernatant through Q-sepharose and heparin columns using buffers of varying pH.
Buffer containing 20 mM Tris, pH 8.5, 50 mM NaCl, 1 mM EDTA and 1 mM DTT
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worked well for both columns. The flow through was collected and the columns were
washed with 1 M salt buffer. Almost all ssArd1 eluted in the flow through and most
of the contaminating proteins were excluded. The protein was concentrated by
ammonium sulphate precipitation as before and the final purification step on the gel
filtration column yielded pure protein (figure 3.10).
Figure 3.10:  SDS-PAGE gel of pure
s s Ard1 from gel  f i l tration
chromatography (HiLoad(  26/60
Superdex( column). Pure ssA r d 1
eluted from gel filtration over one peak.
1 = size marker, 2 = fractions collected
for monomeric peak of pure ssArd1
eluted at 225-250 ml volume from size
exclusion chromatography.
3.7 Concentrating pure ssArd1
Almost all ssArd1 in any given sample was lost due to sticking to the
membrane of the low protein binding vivaspin concentrator. A method was therefore
devised where the sample was placed in dialysis tubing and saturation of the tubing
with high MW PEG enabled slow diffusion of buffer out of the tubing.
Concentrations of between 5-13 mg/ml were achieved by this method but the protein
tended to precipitate. The concentrated sample was immediately frozen in liquid
nitrogen and storage at –80 °C until required.
Research into hArd1 shows that the pure protein forms protofilaments (which
can resolubilise) with a large "-sheet content under physiological pH and
temperature and that this process is accelerated by thermal denaturation as well as
high protein concentration (Sanchez-Puig, 2006). This could be largely due to the
flexible  unstructured  C-terminal tail  of  hArd1. ssArd1 does  not  contain  a  similar
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flexible C-terminal region. Obviously, ssArd1 is not thermally denatured and the
physiological conditions are very different to those of hArd1 but it seems that high
protein concentration causes ssArd1 to form aggregates as well, which do not go
back into the soluble state even on gentle heating.
 3.8    Circular Dichroism
Circular Dichroism (CD) spectroscopy is a measure of the differential
absorption (usually in UV range) of right- and left- circularly polarised light. The far
UV spectra (between 180 and 220 nm) is dominated by electronic transmissions of
the protein backbone and typical signals are listed in table 3.1.
!-Helix Negative signal at 222 nm
Negative and positive signals at 208 and 190 nm
respectively
"-Sheet Negative signal at ~215 nm
Positive signal at ~198 nm
Table 3.1: Secondary structure signals relating to !)helix and ")sheet conformation of
ssArd1.
The CDSSTR program from CDPro (http://lamar.colostate.edu/~sreeram/CD
Pro/main.html) was used to generate the spectrum (figure 3.11) showing the
absorbance of polarised light by ssArd1 and to then calculate the secondary structure
(table 3.2) of the protein based on this signal  information.  CDSSTR  has  estimated
that  ssArd1  contains  44 % (56 % including distorted helix) !-helical structure and 9
% (15 % including distorted sheet) "-sheet structure.
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Figure 3.11: Far UV CD spectra of ssArd1. NRMSD: 0.006. Helix segments per 100 residues:
2.981, Strand segments per 100 residues: 3.347. Average helix length per segment: 18.694, Ave strand
length per segment: 4.816.n4.98 helix = (4.98 * 18.694) 93.1 residues (55.75 %), 5.59 sheet= (5.59 *
4.816) 26.9 residues (16 %).
Table 3.2: Proportion of protein (multiply by 100 for %) estimated to have a certain structure.
Helix1 is standard !-helix, Helix2 is distorted !-helix, Strand1 is standard "-sheet and strand2 is
distorted "-sheet (as determined in Sreerama, 1999).
According to the CD data reported for hArd, it contains a random coil content
of 44 % (Sanchez-Puig, 2006), which is similar to the ~37 % predicted (by PHYRE)
random coil content of ssArd1. However, CD spectra only identifies ~15 % of the
ssArd1 structure as unordered but if the turns are included, in a manner similar to
PHYRE predictions, the value rises to a more agreeable ~28 %. The hArd1-'C
(residues 1-178) version reportedly shows a random coil content of 40 % (CD signals
for hArd1 and hArd1-'C are shown for comparison in figure 3.12), which seems
rather high considering the removal of more than 80 residues, 82 % of which are
estimated to exist as unordered by the JNET server (Cuff & Barton, 1999).
Helix1 Helix2 Strand1 Strand2 Turns Unordered Total
0.44 0.12 0.09 0.07 0.13 0.15 1
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Regardless, this truncated version is a better comparison to ssArd1 because it does
not contain a flexible C-terminal region. The spectra of hArd1-C and ssArd1 show a
high !-helical content and they superimpose with only slight variation between them
(after unit conversion) thus giving evidence of a very similar globular structure.
Figure 3.12: Far UV CD spectra for hArd1 and hArd1-!C. (adapted from Sanchez-Puig, 2006).
Note: conversion of these units to Delta Epsilon (De), the units used in figure 3.11, is achieved by the
following formula: De = * / 3298.
3.9     Does ssArd1 have a binding partner in vivo?
The existence of a complex in higher organisms allows speculation as to
whether ssArd1 can act alone or if it absolutely requires a binding partner in order to
function. Another option is that the protein may have a binding partner to enhance its
acetyltransferase activity. Sequence analysis shows that ssArd1 is smaller in
comparison to hArd1 and scArd1 since it does not contain the extended C-terminal
region (which is often less structured) of the eukaryotic homologues. It was not
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possible to make a knock out  of  ssArd1 in S. solfataricus. This would have been the
best way to evaluate the enzyme’s target substrate(s). A GST-pulldown assay was
not feasible either since the enzyme could not be expressed with the N-terminal tag
(see section 3.5), therefore ssArd1 was bound to an affi-gel column matrix and S.
solfataricus cell lysate was applied to the column. Unbound proteins were washed
off and bound proteins were eluted via a number of high molarity salt washes.
Fractions were tested on SDS-PAGE gel and sypro-ruby stained for increased
visualisation. Any bound protein (either binding partner or substrate) may be
identified. Although ssArd1 exhibits acetyltransferase activity on it’s own, it is
indeed possible that ssArd1 may have a specific binding partner e.g. a Nat1
homologue, which could enhance it’s catalytic efficiency.
A large number of Sulfolobus proteins were eluted in the wash stage of the
purification, however, many of these non-specifically bound proteins were still
present in the higher salt washes (figure 3.13a). It is unlikely that ssArd1 interacts
with all of these and it could be the case that this method is just not efficient i.e.
native ssArd1 would have been present in the cell lysate and any binding partners
would likely be already interacting with this free form of the enzyme, leaving fewer
molecules available to bind the column, thus making detection difficult. In addition,
any likely substrates of ssArd1 have already been modified in the Sulfolobus cell
because we could not knock the gene out. There were no suspect bands to indicate
that ssArd1 is part of a complex in the archaea as it is in eukaryotes and similarity
searches for a Nat1 homologue in the S. solfataricus P2 genome failed to identify a
protein with significant homology over the 854 residue sequence, although a
hypothetical S. solfataricus protein (gi|15899426|ref|NP_344031.1 Sso2710) with 22
% identity was found corresponding to a 245 amino acid segment of scNat1.
Western blot analysis using antibodies against Alba1 and Alba2 showed possible
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binding of both proteins (figure 3.13b). A control experiment using an affigel column
in the absence of ssArd1 did not produce a similar response. In the presence of an
active ssArd1, the majority of Alba1 and/or Alba2 is probably already acetylated.
Figure 3.13a: Sypro-Ruby Stained
SDS-PAGE gel of affigel 10 cell lysate
fractions.
M = size marker, 1 = Sso lysate before
addition to column.
All even numbers show fractions
obtained from specific salt washes (50
mM, 350 mM, 650 mM and 1M) of the
control column. All remaining odd
numbers show fractions obtained from
the specific salt washes of the ssArd1
column.
Figure 3.13b: Western blot (of SDS-PAGE gel
from figure 3.13a) with antisera raised against
Alba1 and Alba 2.
C = control column lysate, + = ssArd1 column lysate,
1 = 50 mM salt wash, 2 = 300 mM salt wash, 3 = 600
mM salt wash, 4 = 1M salt wash. Alba1 and Alba2
are indicated by arrows.
3.10   Summary and conclusions
Despite trying a variety of conditions, Sso0082 could not be rendered soluble
and  work on  this protein was terminated. This may be  because it  exists in complex
M    1   2   3   4    5    6    7    8   9   10  11  12 13 14  15
 50mM     350mM       650mM     1M wash
wwash         wash           wash
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with another protein in vivo. Cloning of a (6X) histidine tagged version of ssArd1 for
simplified purification failed and the only viable route was to purify the recombinant
protein. Purification was not simple because the protein failed to bind ion exchange
resins under favourable conditions and eluted with the flow through. Therefore a
five-step purification procedure was necessary. In brief, this involved heating the
protein sample at 65 °C for 25 minutes, pumping lysate through a cation exchange
column and then an anion exchange column, precipitating the protein by ammonium
sulphate addition and finally subjecting it to size exclusion chromatography. There
were difficulties with concentrating purified ssArd1 as this aggregated readily,
similar to the properties of hArd1. Circular dichroism studies suggested that ssArd1
contains a majority secondary structure of !-helices, accounting for 44 – 56 %, in
agreement with hArd1-'C. "-sheet content seems to be much lower at only 9-15 %.
This value is rather low in comparison to the predicted ~ 30 % "-sheet content by the
PHYRE programme (section 1.5). And finally, the investigation into the existence of
a putative binding partner for ssArd1 offered little revelation, probably because there
isn’t one but it would be naïve to completely rule it out. It may be worth
investigating the small Sso2710 hypothetical protein in future.
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4.1 Introduction
Native SsoAlba1 is 84 daltons larger than recombinant Alba1. This is due to
the acetylation of two residues, serine 2 and lysine 16 (Bell, 2002). It has already
been demonstrated that ssPat is the acetylase responsible for modifying K16 but the
N-terminal acetylase enzyme is still unknown. It has also been documented that
NAT’s are in some cases capable of internal acetylation as well i.e. N$- acetylation of
specific lysine residues (Polevoda and Sherman, 2003). This brings us to question
whether SsoAlba1 is a target substrate of ssArd1 and if so, does the enzyme
predominantly acetylate amino acids at the N! or N$ positions, or both? As a
homologue of the yeast NatA subunit scArd1, we predict that ssArd1 will also be an
N-terminal acetylase which will acetylate sequences beginning with serine, alanine,
glycine and threonine after removal of the initiator methionine. With an N-terminal
sequence of SSGT, SsoAlba1 may be a target for ssArd1. Acetylation largely
depends on the N-terminal sequence (Polevoda and Sherman, 2003), several factors
may affect the addition of the acetyl group. It is possible that other residues within
the N-terminal region may decrease or prevent acetylation (Moerschell, 1990).
Equally, the absence of certain residues may be responsible for non-modification of
proteins displaying a viable target sequence (Polevoda & Norbeck, 1999).
4.2 Acetylation of SsoAlba1 by ssArd1 and non-labelled AcCoA
Matrix Assisted Laser Desorption Ionisation – Time-of-Flight (MALDI-ToF)
mass spectrometry analysis of recombinant wt SsoAlba expressed in E.coli showed
that the protein was not modified, with exception to the N-terminal methionine,
which was cleaved off during the expression phase. Recombinant Alba1 has an intact
Chapter 4: Acetylation of Alba1 by ssArd1
86
mass of 10454 Da. Incubation of recombinant Alba with ssArd1 in the absence of
acetyl-CoA served as a negative control, also showing the same intact mass of 10454
Da. In the presence of a small amount of substrate, acetyl CoA, an increase in mass
of approximately 42 Da larger was observed. This could be explained as the addition
of aceto-nitrile adducts from the mass spectrometry process unless a small amount of
acetyl-CoA had been co-purified with one of the proteins but this seems unlikely due
to the rigorous purification steps. In hindsight, it would have been appropriate at this
point to do a negative control with alba and acetyl-CoA to test for non-enzymatic
acetylation. Non-enzymatic acetylation is a common occurrence in proteins with
cysteine residues, the only amino acid that can act as an acetyl acceptor under
conditions that lack the addition of an acetylase enzyme (Dormeyer, 2005), however,
SsoAlba1 does not contain any cysteine residues. After addition of the ssArd1, a 42
Da increase representing one acetyl group was evident for approximately 80 % of the
substrate (see figure 4.1).
Figure 4.1a: MALDI-ToF
Intact mass on SsoAlba1.
a] 20 µM recombinant wt
Alba + acetylation buffer,
b] 20 µM rec wt Alba +
acetylation buffer + 500
nM ssArd1, c] 20 µM
recombinant wt Alba +
acetylation buffer +500 nM
ssArd1 + acetyl CoA. Each
Sample was incubated at
70 °C for 2 hours.
(A) rec Alba1
(B) rec Alba1 +
      ssArd1
(C) rec Alba1 +
ssArd1 + AcCoA
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Although this procedure confirms the likely acetylation of Alba by ssArd1 and
gives an estimate of the amount of Alba modified, the peak height is not necessarily
quantitative because the ionisation process is competitive and protein solutions from
different purification batches will likely contain a small number of contaminants.
The size and chemistry of these components will result in different extents of
ionization. Incubations at higher temperatures or over longer time periods showed
evidence of up to four acetyl group additions to the substrate. Tryptic digests (figure
4.2) showed a mixture of acetylated sites including the N-terminal serine, N-terminal
serine and lysine 16, lysine 48 and lysine 64 or 68. Peptides where K64 and K68
appeared separately and unacetylated were evident but unfortunately the mass for
peptides containing either acetylated residue were too small or too large to be seen.
However, it appears that these residues may have been modified due to saturation of
the initial site and in any case K48, K64 and K67. Native Alba is only acetylated on
S2 and K16, therefore, acetylation of K48, K64 and K67 may only occur under assay
conditions in which non-specific acetylation is promoted.
Table 4.1: Peptides produced by tryptic digestion of SsoAlba1. The theoretical mass (i.e. from
unmodified protein) and actual mass (i.e. after acetylation) are shown for each peptide. Potentially
modified residues in each peptide are shown in red.
Peptides seen Theoretical mass Actual Mass
  2-16(-)SSGTPTPSNVVLIGK(K) 1456.8 1498.8
  2-17(-)SSGTPTPSNVVLIGKK(P) 1584.9 1668.9
  45- 57 (R)AISKAVDTVEIVR(N) 1400.81 1442.8
 60-71  (R)FLPDKIEIKEIR(V) 1500.88 1542.9
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Fragment 2-17 seems an unlikely occurrence because proline in position P1´ (i.e.
residue following Lys), being a bulky residue, usually exerts a strong negative effect
on peptide cleavage. Under certain circumstances it would be possible for trypsin to
cleave at K17 e.g. when a lysine residue is present in the P2 position, as
demonstrated by Keil, 1992 (figure 4.1b). This explains the occurrence of peptide 2-
17 from samples where K16 is acetylated.
Figure 4.1b: Negative influence of residues in
position P2 and P1´ on the cleavage of lysine
at position P1 by trypsin. P2 shown on
vertical scale, P1´ on horizontal scale. The area
of the black square represent the percentage of
inhibition in the corresponding cross-section for
each tripeptide sequence P2-Lys-P1´ (according
to Keil, 1992).
Analysis of fragments from a K16E mutated versions of Alba1 treated with ssArd1
showed that the double acetylated fragment 2-17 did not occur. Only a single
acetylated fragment was detected, presumably modified at S2.
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Figure 4.2: MALDI-TOF spectra of tryptic digests. Samples A-F (see section 2.5.1) were incubated
for 1 hour at 70 °C.   A = 10 µM native Alba, B = 10 µM rec Alba, C = 10 µM K16A mutant, D = 10
µM rec Alba + 0.5 µM ssArd1 + 20 µM AcCoA, E = 10 µM rec Alba + 0.5 µM ssArd1, F = 10 µM
K16A + 0.5 µM ssArd1 + 20 µM AcCoA. 1 = N-term acetyl group, 2 = N-term + K16 acetyl groups,
3 = K48 acetyl group, 4 = K64/68 acetyl group.
Further analysis of sample D (10 µM recombinant Alba1, 0.5 µM ssArd1 and
20 µM AcCoA) (figure 4.3) showed that a mixed population of acetylated sample
was present. This demonstrates the acetyltransferase ability of ssArd1 and shows that
recombinant Alba1 contains several possible sites for modification. The substrate
also appears to be oxidised. The enzyme’s order of preference for the above sites
were probed by using a range of incubation times from 15 minutes to several hours at
a lower temperature of 55 °C. The results (not shown) suggested that S2, rather than
K16 was the first site to be targeted. Radiolabelled assays validated these findings
and allowed better quantification  (section 4.4).
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Figure 4.3: MALDI-TOF analysis of sample D. (1) 1 acetyl group (10495.77), (2) 2 acetyl groups
(10538.78), (3) 3 acetyl groups (10581.23), (4) 4 acetyl groups (10618.48).
4.3 Optimum temperature
Since more control over the reaction rate can be gained by lowering the
temperature of incubation it was necessary to explore the effect of temperature on
enzyme activity. An SDS-PAGE gel on samples labelled with 14C AcCoA over a
temperature gradient from 25-75 °C showed a general increase in acetylated substrate
with increasing temperature (figure 4.4a). A plot of acetylation vs temperature
(figure 4.4b) reveals a slightly higher amount of substrate was acetylated at 55 °C
than at 75 °C (the physiological temperature at which the organism exists). Whether
this difference is real or down to error, the graph shows that 55 °C is the optimum
temperature at which further experiments should proceed. It is likely that some
evaporation of the 10 µl samples may have occurred at the highest temperatures
1
 2   3
4
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because it is not possible to overlay such small volumes with oil and this could in
fact account for the lower amount of acetylated product.
Figure 4.4a Phosphorimage of SDS-PAGE analysis of radiolabelled acetylated Alba1. Each
sample was incubated at different temperatures for 10 minutes and contained 20 µM Alba1, 250 nM
ssArd1 and 18 µM 14C acetyl-CoA. Each positive sample is followed by a control.
Figure 4.4b: Quantification of acetylated Alba1. Data was calculated to show pmoles of Alba1
acetylated.
4.4 Determination and quantification of preferred acetylation site.
As previously stated, it appears that ssArd1 preferentially targets S2 for
acetylation. To confirm this finding, a radiolabelled assay was carried out in
triplicate for a variety of Alba1 samples. These included wt recombinant Alba1 as
well as K16E and S2P mutated versions. The K16E mutated protein was acetylated
to almost the same level as the wt version, which suggests that K16 is not a major
target for modification by ssArd1. In contrast the S2P mutated version showed very
little acetylation, thus verifying the hypothesis that ssArd1 does function as an N!-
acetyltransferase of SsoAlba.
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Figure 4.5: Acetylation of recombinant Alba1, K16E mutant Alba1 and S2P mutant Alba1 by
ssArd1 at 55 °C over time. (A) 20 µM recombinant Alba, 250 nM ssArd1 and 18 µM 14C Acetyl-
CoA. 1 = 0, 2 = 20, 3 = 40, 4 = 60, 5 = 90, 6 =120, 7 = 180, 8 = 240, 9 = 300 10 = 90 control, 11 = 300
control (Time in seconds). (B) 20 µM K16E, 250 nM ssArd1 and 18 µM 14C Acetyl-CoA. Numbered
same as in (A). (C) 20 µM S2P, 250 nM ssArd1 and 18 µM 14C Acetyl-CoA. 1 = 0, 2 = 20, 3 = 40, 4 =
60, 5 = 90, 6 = 120, 7 = 180, 8 = 300 (Time in seconds).  Control samples are not shown. (D) Graph
comparison of wt recombinant Alba acetylation with K16E and S2P mutated versions. Band intensities
were calculated by imagegauge software and converted to pmoles of Alba acetylated.
4.5 Kinetics of reaction
Reactions were carried out in triplicate using a constant concentration of
ssArd1 (250 nM) and increasing concentrations of recombinant Alba up to 80 µM.
All samples were incubated for 4 minutes at 55 °C, a timescale which allows
accurate detection and quantification of acetylated Alba. 9/10 cold acetyl-CoA and
1/10 14C acetyl-CoA was used to ensure that the isotope was not a limiting factor in
the reaction. Radioactivity was counted by scintillation from dried SDS page gels on
which the samples had been run (figure 4.6A) and results were quantified as nmoles
of alba acetylated per minute per mg of ssArd1, the standard units for easy
comparison of Km and Vmax values with other acetylases, and represented on a graph
(figure 4.6B). The data were fitted to the Michaelis-Menten equation (below) by
wt Alba 1 k= 12min-1
K16E k= 9.7min-1
S2P k= 0.11min-1
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using a non-linear least squares approach (Kaleidagraph+-Macintosh computer
program) to ‘minimize the square of the error between the original data and the
values predicted by the curve equation’ (Kaleidagraph manual version 3.6).
Figure 4.6a: Phosphorimage of SDS-PAGE gel showing increasing acetylation with increasing
Alba1 concentration. Incubation was carried out at 55 °C over 4 minutes using 250 nM ssArd1 and
180 µM acetyl-CoA, 1/10 of which was 14C labelled. Lanes: 1= 0, 2= 4, 3= 8, 4= 16, 5= 24, 6= 36, 7=
48, 8=60, 9= 70 and 10= 80 (µM Alba1).
Figure 4.6b: Michaelis-Menten curve.
Band intensities were calculated by image
gauge software to show µmol/min Alba1
acetylated during the reaction. Vmax  =
2062 ±  100 nmoles/min/mg enzyme.
Arrhenius and Van’t Hoff have shown that:
Temperature quotient (Q10) = Velocity of reaction at T
n+10  = ~2
          Velocity of reaction at Tn
i.e.  an  increase  in  10 °C  will  approximately double (depending on  the  activation
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energy) the velocity (v0) of reaction (van’t Hoff, 1884; Arrhenius, 1889), thus Vmax
must be multiplied by 4 to achieve a result corresponding to the real physiological
conditions (~75 °C) of the organism. Hence Vmax is estimated to be 8250 nmoles/
min/mg.
kcat = Vmax / [E]  
        = 8250 / 51
        = 160 min-1 (3 sec-1)
kcat  represents the number of substrate molecules that each molecule of enzyme
converts to product per minute and from the above calculation it is evident that
multiple turnover is achieved by ssArd1. This calculation is based on the monomeric
unit but if ssArd1 is a dimer, which is likely, the value of [E] would be halved, giving
rise to a higher kcat value of 320 min
-1 (3 sec-1). Each sample was incubated for 4
minutes and in hindsight it would have been better to do the assay over lesser time
such as 1 minute. But even if we calculate the amount of acetylated Alba after 1
minute based on the above data, this is unlikely to be a true value since substrate in
the initial samples at 4 minutes were almost saturated. We find that almost half of the
substrate is used in the early samples e.g. the y-axis value for sample 2, containing 4
µM  (0.004 nmoles total) Alba1 and 0.0025 nmoles ssArd1, reads 398
nmoles/min/mg acetylated Alba, thus 398/51 x 0.0025 = 0.0195 nmoles Alba1 were
acetylated in a sample containing only 0.04 nmoles. And for sample 3, containing 8
µM Alba1, the y-axis reads 801 nmoles/min/mg acetylated Alba, thus 801/51 x
0.0025 = 0.0393 nmoles Alba1 were acetylated in a sample containing 0.08 nmoles.
It is clear from this data that substrate was a limiting factor early on in the assay,
making it difficult to determine the rate of the reaction. The accuracy of the software
for the measurement of band intensities also comes into question in this case due to
NOTE: [E] is expressed here as nmoles enzyme
(ssArd1) in 1mg.
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the need for excessive isotope in order to achieve a reasonable acetylation signal in
the early samples. The problem is that the unincorporated label (lower band) appears
to be so intense that it is reasonable to suspect that the software has a limit to the
intensity that it can measure and therefore the % incorporation of acetyl by Alba1
may actually be much lower than that calculated. On the other hand, a signal showing
~133 nmoles/min/mg acetylation could be detected in the zero sample where no
Alba1 was present. So, it is quite clear that the measurements for the reaction are not
ideal and it would be better to develop another means of assaying acetylation
kinetics. In addition, it would be very difficult to achieve a realistic Km using the
radiolabelled assay above no matter how many parameters we change because there
are intrinsic limitations of the assay. We can be confident however, that the Vmax is a
realistic measure of the reaction because the later samples include excess Alba1.
kcat/Km (M-1.min-1) is the apparent second rate constant and a measure of catalytic
efficiency. We cannot calculate this value since we do not have an accurate Km but
we can be certain that the Km is below 11 µM and based on this we can speculate that
the catalytic efficiency of ssArd1 for the acetylation of Alba1 will be very high and
therefore Alba1 is a good substrate for the enzyme. [Note: Substrates having a
kcat/Km ratio in the range 10.5-10.6 M-1.sec-1 are considered to be very good
substrates i.e good affinity and rapid turn over.]
A paper published in 2000 describes the development of a non-radioactive
assay as a means of testing acetylation. Kim et al monitored the amount of free
CoASH generated during their histone acetylation reaction by adding !-ketoglutarate
dehydrogenase or pyruvate dehydrogenase and ! -ketoglutarate or pyruvate,
respectively, as a target substrate for oxidation by CoASH (Kim, 2000). This reaction
is coupled by the reduction of NAD to NADH, which was measured by
spectrophotometric analysis at 340 nm (Kim, 2000). The kinetic parameters
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calculated from each of the enzyme coupled reactions were largely in agreement with
each other and strongly contradicted the values obtained from a radiolabelled filter
binding assay (using [3H]acetyl-CoA and histone H3 as a substrate) that was carried
out simultaneously. The results showed that the radiolabelled assay gave 1.5 to 4 fold
lower kcat and 1.5 to 5 fold higher Km values. The discrepancy was shown to be due
to technical difficulty in washing product off the membrane and variable scintillation
counting efficiency. Although filter binding was not employed in the 14C-AcCoA
assays, scintillation counting was not entirely accurate and more reliable results may
have been produced by using an enzyme coupled assay of the kind described in Kim
et al, 2000.
Several other NAT’s have been evaluated for kinetic data (Table 4.1) but few
of them bear any sequence or substrate similarity to ssArd1 and, as such, cannot be
used as a good comparison. NAT1 Vmax/Km= 418 and NAT2 Vmax/Km= 0.101
values can be obtained from a publication by Dupret et al, 1994. NAT1 is far more
efficient than Nat2 but it is not uncommon for acetyltransferase Vmax/Km values to
be in the range of NAT2 (Vatsis, 1999). Human serotonin AANAT has a value of
Vmax/Km = 0.0269 µl/min/mg (Ferry, 2000).
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Table 4.2: Comparison of Vmax and kcat with other acetylase enzymes. 
1PAZ, p-aminosalicylic
acid, 2 SMZ, sulfamethazine.
4.6 Specificity of ssArd1 for N-terminal sequence
In addition to Alba mutants K16E and S2P, another seven mutations were
created by site directed mutagenesis where the N-terminal serine (after the cleavable
methionine) was substituted with alanine, glutamine, glutamic acid, leucine, proline,
threonine or valine. Each  mutated  plasmid  was  used to transform  E.coli Top10
cells. The  mutated sequences were confirmed by sequence analysis.  Positive
samples  were  selected for  transformation into  Rosetta BL21 cells  and  several
colonies were picked for mini-expression trials. Alba mutants were purified in the
same way as the wt recombinant version as described in (Wardleworth, 2002).
Purified mutant proteins were analysed by mass spectrometry for an intact mass to
N-acetyltransferase Substrate Km µM kcat (min-1) Vmax
nmol/min/mg
GST*- Human
Serotonin N-
acetyltransferase
(Ferry et al,2000)
Serotonin
Tryptamine
1350 ± 115
880 ± 75
N/D
N/D
132 ± 12
302 ± 25
Human Arylamine N-
acetyltransferase 1
Human Arylamine N-
acetyltransferase 2
   (Dupret et al, 1994)
SMZ1
PAS2
SMZ1
PAS2
4850 ± 550
8 ± 1
114 ± 27
7100 ± 470
“Vmax provides
rough estimates
of kcat”
610 ± 50
3340 ± 190
11.5 ± 1.0
3.6 ± 0.1
Klebsiella pneumoniae
AANAT
(Chung et al, 1997)
2-aminofluorene 1080±50 N/D 9.17 ± 0.11
M.tuberculosis
AAC(2,)-Ic
(Hegde et al, 2001)
KanamycinA
KanamycinB
Sisomycin
320 ± 29
1.4 ± 0.05
3.4 ± 0.3
15.2 ± 0.4
32 ± 0.3
258 ± 6.3
?
?
?
ssArd1 (S.sol) Sso10b <11.4 160 ± 1.8
(monomer)
8250 ± 412
yGCN5 (kim, 2000) H3 frag (aketo)
H3 frag (pyruv)
   130.2 ± 52.9
113.7 ± 24.4
27 ± 4.2
25.8 ± 1.8
?
?
S.typhimurium RimL
(Vetting, 2005)
Ribosomal protein
L12
1.0 ± 0.2 21 ± 1 min-1 ?
E.coli RimL
(Miao, 2007)
L12 0.55 25.71 min-1 ?
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allow us to determine which, if any, did not have the N-terminal methionine cleaved
off (table 4.3). Recombinant wt alba, S2A and S2G do not have this residue. S2E and
S2L still maintain the methionine, whilst the others appear to exist in both forms.
Table 4.3: wt Alba Vs
mutants. Table displays intact
mass for each protein and
presence or lack of N-terminal
methionine.
Purified mutant proteins were concentrated and diluted to approximately 50
µM. Each sample dilution was subject to Bradford assay using a known
concentration of pure wt Alba as a standard for  the  dye reagent to bind. 10 µl of
each 50 µM sample is  shown on SDS-PAGE gel (figure 4.7A). These samples were
assayed in the same way as the wild-type recombinant Alba and acetylation levels
were quantified from phosphorimage of SDS-PAGE gels by imagegauge software.
The results (figure 4.7B) show that alanine is the next preferred residue for N-
terminal acetylation after serine. Surprisingly the glutamic acid and leucine
substitutions, both of which maintain the initial  methionine,  exhibit a similar  level
of modification. Although the residue acetylated in both cases is methionine, it is
important  to  note  that  the  subsequent residue  will  usually  impact sequence
recognition by the enzyme. Leucine and glutamic acid have very different properties
so it would perhaps be expected that the acetylation levels would differ somewhat.
The valine substitution also displays a moderate amount of acetylation, whereas
threonine and glycine are the least acetylated residues.
Molecular
Weight Da
N-term Met
Rec Alba 10454 X
S2A 10438 X
S2E 10627 -
S2G 10424 X
S2L 10611 -
S2T 10468/10599 X/-
S2V 10466/10597 X/-
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Figure 4.7a: SDS-PAGE gel on
Alba1 variants. 50 µ M wt
recombinant Alba in comparison with
pure N-terminal mutant Alba proteins
to show purity of samples and similar
concentration. % activity of each
mutated version of Alba is shown.
Figure 4.7b: Acetylation levels of wt Alba1 and mutated Alba1 compared.  Graph shows  pmole
acetylation levels of 20 µM Alba and N-terminal mutant proteins over 5 minutes at 55 °C, using 250
nM ssArd1 and 18 µM 14C acetyl-CoA. Each result is an average of triplicate samples. Imagegauge
software was used to calculate % acetylation from band intensities on SDS-PAGE gels.
In addition to ssArd1 displaying a high degree of homology with yeast and
human Ard1 (the catalytic subunit of NatA), it also exhibits a preference to acetylate
N-terminal serine and alanine residues in that order, in a manner similar to NatA.
Threonine, glycine and valine are also substrates for NatA, whereas met-glu is a
substrate of NatB and met-leu is a substrate of NatC (table 4.4). This evidence, taken
together implies that ssArd1 may be an ancestral Nat protein with relaxed sequence
specificity from which three distinct eukaryal Nat’s have evolved.
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Table 4.4: Nat substrate specificity in S. cerevisiae. Values outlined in blue show % acetylation in
mammals. Adapted from Polevoda and Sherman, 2003.
4.7 Differential Scanning Calorimetry
Solution Differential Scanning Calorimetry (DSC) is a procedure designed to
measure the uptake of energy generated by gradually increasing the temperature of a
protein sample, causing it to unfold. This is compared with a reference sample (the
buffer minus protein), which is used to create a baseline. Accurate sample
concentrations are essential for fully quantitative analysis and several scans per
sample are typical. Heat energy uptake is labelled as Cp endotherm and measured in
calories per degree Celsius.
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Data: unacetylated Alba
Model: MN2State
Chi^2 = 292027
Tm = 95.52 ± 0.02212
!H = 2.01E5 ± 1.22 E3
!HV = 1.35E5 ± 1.03 E3
Data: Acetylated Alba
Model: MN2State
Chi^2 = 2.82566 E6
Tm = 96.06 ± 0.0618
!H = 2.34E5 ± 3.87 E3
!HV = 1.32E5 ± 2.73 E3
Figure 4.8: Thermogram showing DSC data for non-acetylated and acetylated Alba1.
Temperature stability (excess heat capacity, Cp,  as a function of temperature) of native recombinant
Alba is represented by a black line, whilst acetylated Alba is represented by a blue line. Inset is an
example of how the raw data appears before deduction of the baseline. Scan rate 60 ºC per hour.
!Hcal (kJ/mol) is the calorimetric enthalphy representative of the total heat energy uptake by the
sample under transition and is equal to the total area below the thermogram peak. !HVH is the van’t
Hoff enthalpy, an independent estimate of the enthalpy of transition based on an assumed 2-state
model for the process. It is the area under the peak at any given temperature, divided by the total area
under the peak and measures the extent of unfolding that has occurred at that specific temperature.
Tm is the transition temperature at which approximately 50 % of protein
molecules are either unfolded or in an ‘ideal dynamic reversible two-state
equilibrium’ where any molecule spends half its time folded and the other half
unfolded. Raw data is normalised by deducting the baseline and streamlining the
sample concentrations. N-terminally acetylated Alba did not appear to be any more
or less sensitive to temperature denaturation as there is only a small difference of
0.54 ºC between the two samples (figure 4.8). The negative portion at the start of the
curves is due to the high heat capacity of water in the buffer, which is reflected only
at temperatures well below the onset of thermal unfolding. Theoretically, !Hcal and
!HVH should be equal. Variation between the two values may be caused by error in
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sample concentration and the level of purity. However, they can also be compared so
as to give information on the apparent mechanism of unfolding and the reversibility
of  the process. If the unfolding transition is not two-state (i.e. it consists of one or
more intermediate steps) !Hcal will be larger than !HVH. This may be the case with
both samples here but it could also be down to error in the concentration
(underestimation) since Bradford reagent was used to determine the protein
concentration. Both samples were carefully purified and exhibit similar calorimetric
enthalpies, thus suggesting that the unfolding mechanism is perhaps not two-state.
But it would be naïve to read too much into these values. Le Chatelier’s principle
shows that binding of any small molecule to the native form of the protein will
stabilise the folded state, which is what seems to happen in the case of acetylated
Alba, albeit in minute quantity. The ability of the acetylated sample to absorb more
heat energy implies several possibilities: this sample is more concentrate, it is more
stable and/or the presence of the ligand cofactor itself is responsible for the increase
in !Hcal. Rescanning the samples (not shown) proved that the thermal process was
reversible given that approximately 75% of the protein in both samples was able to
refold correctly. The melting temperatures of other thermostable proteins within the
Sulfolobus genera vary, as do their refolding ability. DSC studies on Sso7d have
given a Tm of 98 ºC (Knapp, 1996), whilst the Tm of Sac7d is reported to be 90.7 ºC
(McCrary, 1996). Data on the thermostability of other acetylated proteins is not
available but in terms of general stability, in vivo acetylation of the site-specific
DNA-binding transcription factor E2F1 prolongs the half-life of the enzyme
(Martínez-Balbás, 2000). Another example is the increased stability of the
microtubule against depolymerizing reagents  upon acetylation of !-tubulin
(Takemura, 1992).
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4.8 Summary and Conclusions
ssArd1 displays acetyltransferase activity optimally at 55 °C in vitro and is
responsible for acetylating the N-terminal serine of SsoAlba. It also seems to be able
to acetylate several lysine sites upon long incubation periods but its primary target is
Ser2. Kinetic parameters were not easily obtained in the radioactive assay due to the
reaction speed and the need for excess acetyl-CoA. Some areas of the procedure may
be prone to additional error (out with the expected error of sample handling etc) such
as the image reading software’s capacity to determine accurate amounts at highly
saturated scintillation levels (e.g. for unused acetyl-CoA). We can confidently
assume that Vmax parameters are correct since the substrate is plentiful in later
samples but Km is undetermined, suffice to say that it is lower than 11 µM. The kcat
value shows multiple turnover and catalytic efficiency (kcat/Km) is estimated to be
>1600 M-1.sec-1. It may also have been useful to employ Electrospray ionisation (EI)
mass spectrometry as a means quantitative analysis for comparison with this assay.
Mutational analysis determines that the preferred N-terminal residues of ssArd1 are
serine > alanine > met-glu > met-leu > valine > threonine > glycine > proline. The
only discrepancy here between ssArd1 and NatA preference is valine. This could be
due to error or in fact be a real property belonging to ssArd1. The fact that
methionine is also acetylated by this enzyme shows that it displays functional
similarity to NatB and NatC in addition to NatA, and this supports the theory that
ssArd1 is an ancestral Nat from which the three distinct eukaryal forms have
evolved.
DSC analysis of the both acetylated and unacetylated Alba shows that both
forms of the protein have a melting temperature (Tm) in the region of 95-96 ºC but
gives little other information on the apparent benefit of existing in one form or the
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other. It was certainly expected that native Alba from a hyperthermophilic organism
would not denature at temperatures below 80 ºC and in this case it does not appear
that acetylation affords any extra protection from thermal denaturation or vice versa.
It is likely then that the acetylation of Alba serves as an intracellular signal in several
ways; (1) to initiate the binding of other proteins/complexes to itself, (2) to
increase/decrease the half life of the protein, and (3) to integrally lower its affinity
for binding DNA, the later of which has already been proven. Binding of other
proteins to Alba may be investigated by raising antisera against SsoAlba1 from
Sulfolobus cell lysate or by binding the purified protein to gel beads in the same way
as the affi-gel assay was carried out for ssArd1. Protein half life could possibly be
assessed using an epitope (e.g. TAP) tagged system and western blot analysis.
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5.1 Introduction
Ard1 is a member of the gcn5-like N-acetyltransferase superfamily
(GNAT’s). It shares a reasonable amount of sequence homology (up to 37%
identity) with a large number of hypothetical proteins and several known GNAT’s,
which is evident from sequence alignments (Appendix 1). Although many bases
may have mutated over time within different species, significant domain homology
between the proteins is a common feature. On comparison of ssArd1 with yeast
Gcn5 HAT, we can predict that the core HAT fold has been maintained in ssArd1
by aligning the two proteins with each other. Domains A, B and D are clearly
evident but domain C is far less conserved and is not found in these two cases.
Domains A and B contain residues that are known to form contacts through side
chains, the main chain peptide backbone and via hydrogen bonding through water
molecules to acetyl CoA. Only a few HAT structures have been solved with acetyl
CoA and substrate. The acetyl CoA binding seems to be very similar throughout the
GNAT family but residues responsible for substrate binding are not conserved
because, as previously discussed, GNAT’s have a wide range of substrates, from
histones and proteins to short peptides and antibiotic compounds. Little is known
about how these enzymes distinguish between substrates because identification of
amino acids responsible for substrate recognition and binding is difficult since these
residues are not conserved between different GNAT subsets belonging to the
superfamily. Neither is it simple to pinpoint residues involved in the catalysis of
acetyl group cleavage and addition to the substrate. In many HAT’s, there is a
cysteine residue close enough to the active site that can thus act as a strong general
base for the catalysis of the reaction. ssArd1 does not contain any cysteine residues
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that could be implicated as part of the catalytic site, therefore a sequence alignment
must be used to detect highly conserved residues.
5.2 Identification of highly conserved residues
ssArd1 was aligned with known Ard1 homologues from several species
including S. cerevisiae, H. sapiens and C. elegans. The alignment also included two
other homologous sequences, scNAT3 and scMAK3, the catalytic subunits of NatB
and NatC respectively (Figure 5.1). Identical residues are shown highlighted in
black and several were chosen for mutational analysis (based on  their physical
properties).
Figure 5.1: Sequence alignment of known Ard1 proteins and homologues. Motifs responsible for
Acetyl-CoA binding are underlined. Motif A (in blue) spans S.cerevisiae residues 112-146 and motif
B (in red) spans residues 152 to ~170 (Song, 2003).
     !    !
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Each of these residues: D21, S131-N132, D156 and E158 were mutated to alanine,
whilst H88 was mutated to asparagine (sustaining the polar characteristic of
histidine but without the charged side chain). D156 was chosen because although it
is not conserved completely in the alignment, it is found in all four Ard1
homologues and therefore may be involved in substrate recognition. Primer design
for each mutation can be found in chapter 2 and purification of the mutated proteins
proceeded in the same manner as that used for recombinant ssArd1 in chapter 3.
Each mutant protein was diluted to a 2 µM concentration and analysed by SDS-
PAGE (figure 5.2a). The wild type and mutated proteins were incubated as
described in section 4.4, with 20 µM ssAlba1 and 18 µM acetyl-CoA at 55 °C.
Samples were monitored in triplicate over ten time points (0, 1, 2, 3, 4, 5, 10, 15, 20,
25) and the results were plotted (figure 5.2b). The initial rates of reaction are
difficult to determine since the data provides a curved rather than a straight line.
Hence, the first three time points were plotted separately (not shown) to give the
initial linear rate and the gradient of each line after deduction of the control value
was used to calculate the % activity of each mutated ssArd1 enzyme as compared to
the wild type. Individual % activities are specified at the bottom of figure 5.2a.
Figure 5.2a: SDS-PAGE gel on
ssArd1. Gel shows pure wt ssArd1
versus pure mutants of ssArd1;
D21A, H88N, S131A-N132A,
D156A and E158A. Each protein
is at the same concentration of 2
µM. % acetyltransferase activity
that each mutated protein
possesses is shown underneath the
gel.
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Figure 5.2b: Wild type ssArd1 activity Vs activity of ssArd1 mutants.
Graph showing 1-5 minute acetylation levels for wt ssArd1 versus mutated ssArd1 proteins. Later
time points were excluded because they are not important for calculating the initial rate of reaction.
Non-enzymatic (background rate) acetylation is shown in yellow and denoted as ‘controls’. Linear
plot from initial data points depicted on the right hand side allows calculation of % activity for each
mutant Alba protein for comparison with wild type recombinant Alba protein.
Note: Y-axis is % acetyl incorporated into ssAlba1 rather than pmoles as only a percentage
comparison is required for this particular assay.
Surprisingly, all ssArd1 mutated proteins retained some level of acetylase
activity but two of the mutations, H88N and S131A-N132A, exhibited very low
levels of acetyltransferase activity (less than 1/5 of the wild type). It may be that
these particular residues are involved in catalysis or substrate recognition. S131-
N132 correspond to D214 in yGcn5, which occurs on the loop between "5 and !4.
This loop is reoriented upon acetylCoA binding allowing D214 to be moved slightly
out of the active sight so that substrate (H3) can bind. Hydrogen bonding between
D214 and residues 215-217 grants additional stability to the complex (Langer,
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2001). D156A also showed a substantial decrease in activity and could play a role in
substrate recognition/binding. To understand more about the effect of the mutations,
it is necessary to examine yeast (y)Gcn5 since it is one of the best studied members
of the GNAT family and it aligns well with ssArd1 (figure 5.3).
Figure 5.3: Alignment of ssArd1 with S. cerevisiae Gcn5 HAT domain.
Key: Identical residues (!), highly similar residues (:), similar residues (.). Underlined are motifs D,
A and B in that order. Italic residues are point mutations that reduce yGcn5 activity. Bold residues
make contact with AcCoA.(Duntall, 1998b). Highlighted ssArd1 sequence shows the structure
predicted by the 3D-PSSM program. Blue and red highlights show known "-sheet and !-helix
secondary structure, respectively, as determined by crystallographic data for yGcn5 (Trievel, 1999).
Further analysis of sixteen Ard1 homologues (appendix II) identified several residues (highlighted in
yellow) that are absolutely conserved and that do not bind AcCoA. These residues are not found in
yGcn5.
3D-PSSM/Phyre programme (see sections 2.7.6 and 6.7) was used to predict
secondary structural features based on the primary sequence of ssArd1 and compare
these to previously solved structures of similar enzymes. Looking at figure 5.3, it is
obvious that the predicted secondary structure of ssArd1 compares favourably with
the structure of yGcn5. "1, !1, !2, "2 and "3 correspond well to those of Gcn5,
with only a little variation in the positions of the sheets and helices due to slightly
longer or shorter loops connecting them. Of course, the prediction tool is not 100%
accurate so there may be some error in the precise locations of the predicted
conformations. "4 containing the putative catalytic base-H88 (discussed later) aligns
perfectly. Prediction of a very short helix in ssArd1 after this sheet may not be
accurate and its presence would only have a small impact on the overall structure.
ssArd1 MELAEKDKGRDFTLRNARMDDIDQIIKINRLTLPENYPYYFFVEHLKEYGLAFFVAIVDN60
yGcn5HAT--VVEENEGK-IEFRVVNNDNTKENMMV--LTGLKNIFQKQLPKMPKEYIARLVYDRSHL146
.:.*:::*:.: :* .. *: .: : :. ** :* : : *** :. .
ssArd1 SVVGYIMPRIEWGFSNIKQLPSLVRKGHVVSIAVLEEYRRKGIATTLLEASMKSMKNDYN120
yGcn5HATSMAVIRKPLTVVGGITYRPFDKRE-FAEIVFCAISSTEQVRGYGAHLMNHLKDYVR---N202
*:. * * . : : . ..:* *: . : :* .: *:: . ::.. *
ssArd1 AEEIYLEVRVSNYPAIALYEKLNFKKVKVLK-----GYYADGEDAYLMARPL--------167
yGcn5HATTSNIKYFLTYADNYAIGYFKKQGFTKEITLDKSIWMGYIKDYEGGTLMQCSMLPRIRYLD262
:.:* : :: **. ::* .*.* .*. ** * *.. ** .:
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!4, "5 and !5 match well, showing the presence of a structurally conserved central
region for acetyl-CoA binding. The end of the sequences differ in that ssArd1 shows
the presence of a sixth beta sheet ("6) before the final alpha helix (!5). Therefore,
this last part of the structure may play a role in substrate selectivity.
Trievel et al (1999) expressed yGcn5 with a large number of block mutations,
spanning three or four residues (Trievel, 1999). Of these mutant versions, several
were found to affect the activity of the enzyme and these are listed below:
KQL 126-128, PKM 129-131, YIA 135-137, FAE 171-173, RGY 186-188, GAHL
189-192, KDY 197-199, DNVA 214-217, IGY 218-220 and FKK 221-223.
From the information they gathered, they selected several residues within the blocks
for point mutation and those that affected enzyme activity but did not contact acetyl-
CoA are detailed in table 5.1.
Point mutations
of yGcn5
Corresponding
a.a’s of ssArd1
Similar
properties
Putative role
H145 D59 - Substrate binding and catalysis
E173 H88 - catalysis
MN 193-194 LE 108-109 "" ?
Y220 L138 x Substrate binding
KK 222-223 EK 140-141 "" ?
GF 225-226 NF 143-144 -" ?
G 239 G152 " Substrate binding
I 241 Y 154 x Substrate binding
YE 244-245 GE 157-158 x" Substrate binding
TL 248-249 YL 161-162 x" Substrate binding
Table 5.1: Point mutations that affect yGcn5 activity through mechanisms other than cofactor
binding. Sequence alignment reveals the corresponding residues of ssArd1 (column 2). These amino
acids are marked in terms of their resemblance to one another. All residues are located within the
binding pocket of the enzyme except MN193-194 which is located on !2 and depending on rotation,
may be close enough for substrate contact, KK222-223 which is located on !3 and GF225-226 on
the solvent exposed loop between !4-!5.
Key: (-) somewhat similar, (") very similar or identical, (x) no similarity.
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Omitting the similar residues ("), we are left with D59 ((Gcn5) H145 counterpart), a
position  which  has  retained  its’ polar  properties  because it  is  on a solvent
exposed loop, yet it is different enough to implicate it in substrate binding. In
addition to this, a string of other Ard1 conserved amino acids (i.e. not found in
Gcn5) appear before and after D59 i.e. V55, A56, G64, Y65, M67, R69 and I70,
further strengthening the importance of this region. L138 on "5 is possibly
associated with substrate binding but N143 is situated right next to the AcCoA
binding site and as such is probably not involved. Y154 and G157 occur in an outer
(structural details contained in Ch6) loop and are probable candidates, as is the
nearby Y161. A more detailed alignment (appendix II) of sixteen Ard1 proteins and
predicted homologues (not used for figure 5.1 because they are only putative/not
confirmed) implicates further conserved and highly similar residues that, according
to the previous research on other GNATs, are assumed not to bind AcCoA and
neither do they appear conserved in Gcn5. These are N29, L33, P34, Y37, A56
(already flagged), GY 64-65, S91, L126, L138 (already flagged), Y154, G157 and
Y161. All of these residues could potentially be future mutagenesis targets for
disrupting substrate recognition and/or binding.
Method of catalysis:
The catalytic mechanism of (y)Gcn5 could potentially proceed in two ways:
1) Via a ping-pong mechanism where the acetyl group is momentarily transferred
to a cysteine residue in the vicinity of the active site, giving rise to an
acetylated enzyme intermediate which is covalently bound, before catalysis of
acetyl group transfer to the substrate (e.g. in Dupret, 1992, Watanabe, 1992)
(figure 5.4).
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2) Direct acetyl transfer via nucleophilic attack on the acylcarbon of the cofactor
by the substrates primary amine, leading to transfer of the acetyl group from
the co-factor to the substrate (figure 5.4) (Dyda, 2000).
Figure 5.4: Catalytic mechanism of HATs. Ping-pong and ternary complex catalytic mechanisms
as proposed for the MYST HATs and Gcn5/PCAF, respectively, are illustrated. (Hodawadekar and
Marmorstein, 2007).
However, (y)Gcn5 does not contain a cysteine residue close enough to the
active site to accept the acetyl group, which means that the reaction is likely to
proceed via direct nucleophilic attack on the cofactor. E173 has been postulated to
act as a general base for catalysis of the reaction (Langer, 2001), causing
deprotonation of substrates at the N-terminal amine group. Many biochemical and
kinetic experiments carried out by various groups (De Angelis, 1998; Duntall, 1998;
Tanner, 1999) as well as the existence of ternary complexes found by
crystallography (Hickmann, 1999; Rojas, 1999) support the theory that the catalytic
mechanism for the gcn5 family involves the initial formation of a ternary complex,
in which E173 (or similar) catalyses the deprotonation of the $-amine (!-amine in
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the case of Ard1) leaving it ready to engage in a nucleophilic attack on the bound
cofactor carbonyl carbon. The acetyl group is then transferred to the appropriate site
on the acceptor substrate, be it lysine or serine (Tanner and Trievel, 1999). ssArd1
does not possess any cysteine residues but it does contains a histidine residue at
position 88 corresponding to E173 in the alignment. Histidine can also act as a
general base and it is reasonable to assume that this residue is important, although
perhaps not essential,  for catalysis within the Sulfolobus cell where the cytosolic pH
of ~6.0 (She, 2001) means that the R-group belonging to this residue has a 50 %
chance of existing in a protonated state. It remains to be proven whether H88 acts as
a general base under the in vitro conditions (pH 8.5) utilised during this project.
Mutagenesis studies show that acetylation levels fall when this residue is substituted
by alanine. It must therefore play a substantial role.
5.3 Promiscuity of ssArd1 for other substrates
In order to determine whether ssArd1 acetylation is dependent only on N-
terminal sequence, a variety of other recombinant proteins, Hje, Hjc, PCNA1&2,
SSB, Sso7d, XPB1 and XPF were incubated as described in section 4.4 (Sso7d was
purified from S. solfataricus).  20 µM of each sample was tested on SDS-PAGE gel
(figure 5.5a) for purity and approximate concentration. 20 µM concentrations of
each protein were used for assaying (Note: this is the monomer concentration
because it is the acetylation of the accessible N-terminal tails that is being analysed).
Some of these proteins had an alanine residue substituted at their N-terminus (table
5.1) but vary in terms of structure.
Chapter 5: ssArd1 active site and promiscuity for other substrates
115
Figure 5.5a: SDS-PAGE gel of
several Sulfolobus proteins.
20 µM of S. solfataricus
recombinant* proteins (in
monomeric form). Each sample
was diluted to match ssAlba1
concentration. *S s o 7d was
purified as the native form.
Figure 5.5b: Phosphorimage of SDS-page gels displaying acetylation levels of various
Sulfolobus proteins. Gels show the intensity of radioactive signal from acetyl incorporated into
different Sulfolobus proteins by ssArd1 over a 5 minute time period. Protein samples include
SsoAlba1, Hjc, Hje, PCNA1, PCNA2, SSB, Sso7d, XPB1 and XPF. C = control sample for the
previous protein trio. Note: the control for Sso7d is not shown in this figure.
The average intensities were converted to % acetyl incorporated into each sample
and are compared in the following bar chart (figure 5.6). For a complete
comparison, S2A has also been included.
Figure 4.9B: Acetylation of S.solfataricus proteins by 250nM ssArd1 at 55°C over 5 minutes using
18µM 14C AcCoA.Wt Alba c    Hjc    c      Hje     c      PCNA1 c   PCNA2 c   SSB    c       Sso7d        XPB1   c    XPF    c
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Figure 5.6: Bar Chart showing acetylation of various S. solfataricus proteins. Each sample (20
µM monomer concentration) was evaluated in triplicate to display the respective error for acetylation
levels by 250 nM ssArd1 at 55 °C over 5 minutes using 18 µM 14C AcCoA.
Hjc and Hje (holliday junction resolving enzymes) were acetylated to a
reasonable level by ssArd1. This is not surprising since they have the preferred
alanine residue available for modification. There is little difference between the
amount of acetylation occurring in these samples, presumably because they have
similar structures and functions. The data also suggests that the change in the
subsequent amino acid from a small hydrophobic alanine to a larger, positive
arginine (table 5.2) does not make much difference to the action of ssArd1. The
residues following this position also have quite different properties e.g. a
hydrophobic residue in place of a hydrophilic residue when aligned but on the
whole, the N-termini contain the same ratios of such residues. Only a little variation
can be seen, which   may  be   partly  due   to   error  in  the  determined  sample
concentrations.
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SSB (single stranded binding protein) was also acetylated to a similar degree. The
N-terminal sequence of SSB is MEEK… (table 5.2) which is not a eukaryal Ard1
substrate but is instead a Nat3 substrate. This data provides evidence to support the
theory that ssArd1 is a promiscuous ancestral NAT from which the three eukaryal
NAT’s have evolved. Native Sso7d (which is not acetylated in vivo) is not an in
vitro substrate for ssArd1 despite harbouring an alanine residue. The subsequent
threonine is small like alanine (in Hjc) but also polar like arginine (in Hje) and,
hence, would not have a significant affect on the acetylation level. This suggests that
ssArd1 recognises protein structure as well as N-terminal sequence.
Table 5.2: Sul fo lobus  protein N-terminal
sequences.
The first few amino acids partly determine the ability
of the protein to become a substrate for acetylation.
The % acetylation value (activity) is shown for those
proteins that are indeed acetylated by ssArd1 in Vitro
and compares them to Alba1.
XPF displays only limited modification which is at a level similar to the control.
Overall, Alba1 is the preferred substrate of ssArd1.
5.4       Acetylation of cell lysates
Since a knock out of ssArd1 was not possible, an alternative approach was
to inhibit the acetyltransferase action in the cell so that the enzyme could be added
to cell lysate at a later stage to monitor the effects. This would give a better
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indication of the number of potential targets of ssArd1. A search for inhibitors of
NAT’s was carried out but there are very few commercially available and any that
were available are quite specific for certain enzymes. The only inhibitor accessible
was Curcumin. Increasing concentrations were added during the normal assay but
no inhibition was shown, therefore it was only possible to assay lysates that had
been subject to modification within the cell. However, proteins that are targets for
acetylation will not be 100% modified within the cell due to the action of
deacetyltransferases.
A variety of cell lysates from prokaryotic and eukaryotic origin were
incubated with ssArd1 for 1 hour at 37 °C. Sso lysate was also incubated at 70 °C.
Each sample was analysed on SDS-PAGE gel (figure 5.7) and a number of bands
can be seen representing proteins acetylated by ssArd1.
Figure 5.7: Acetylation of cell lysates from E.coli, H. sapiens, MRSA, S. solfataricus and S.
cerevisiae. Each lysate concentration is approximately 0.47 mg/ml. Positive samples contain 36 µM
14C AcCoA and 2 µM ssArd1. Negative samples contain 36 µM 14C AcCoA without ssArd1. Each
sample was incubated at 37 °C over 1 hour.
Pigment caused by SDS-loading
buffer.
Chapter 5: ssArd1 active site and promiscuity for other substrates
119
In figure 5.7, Sso lysate does not appear to show bands indicative of acetylated
protein but close up analysis reveals a few acetylation occurrences (one being just
above the darker pigment caused by the SDS-loading buffer, which makes it
difficult to see), some of which will be natural substrate. The assay was repeated at
70°C to give an indication of the amount of acetylation that occurs at the organisms
biological temperature and more bands were visible than at 37 °C (results not
shown). The majority of bands appear in the yeast and MRSA extracts, showing that
ssArd1 is capable of acetylating a number of prokaryotic and eukaryotic proteins.
The E.coli extract also shows a number of modified proteins. Unfortunately though,
there was no easy way to identify the proteins that were modified but it does provide
an idea of the extent of acetylation possible in the different organisms. Several other
HATs are known to show a degree of promiscuity regarding the substrates they
acetylate, especially those with dual function as transcriptional co-activatiors such
as p300/CBP, which acetylates H2A, H2B, H3 and H4 as well as HMG proteins,
p53, GATA-1, HIV Tat etc.  PCAF targets H3, HMG proteins, p53, MyoD, E2F etc
(Sterner & Berger, 2000).
5.5 Summary and Conclusions
A sequence alignment of Ard1 homologues highlighted several regions of
conservation within the sequences. Five specific points were chosen for mutational
analysis to pinpoint particular residues that could potentially be involved in catalysis
and/or substrate binding. It is surprising that none of the five mutations (D21A,
H88N, S131A-N132A, D156A and E158A) were sufficient to completely abolish
the acetyltransferase activity of ssArd1. However, H88N and S131A-N132A did
reduce the enzyme activity by more than 80 %. On comparison with yGCN5, it is
Chapter 5: ssArd1 active site and promiscuity for other substrates
120
highly likely that H88 acts as the catalytic base and that the reaction proceeds not
via a ping pong mechanism but through nucleophilic attack on the acylcarbon
leading to the formation of a ternary complex before the CoA is finally transferred to
the N-terminal residue of the substrate. S131A-N132A are close to the acetylCoA
binding domain so may be involved in substrate binding, but N132 is very similar to
the AcCoA binding residue at the corresponding position in yGCN5, therefore it is
likely that the decrease in activity could be attributed to an affect on cofactor
binding. S131 as far as we know does not bind CoA but it is next door to N132 and
is again highly similar to it’s counterpart in yGCN5. Mutation of D156 also gave
rise to a large decrease in activity and was thus postulated to engage in substrate
recognition or catalysis. To determine between the roles of binding and catalysis,
kinetic experiments would need to be carried out to define the catalytic efficiency,
Vmax/km values for the mutants.
ssAlba1 is not the only substrate of ssArd1, though perhaps the main one.
Evidence shows that the enzyme is capable of modifying Hjc, Hje and SSB.  It is
especially interesting to note that the N-terminal sequence of SSB would not be
targeted by eukaryal Ard1 (in the NatA complex) because this sequence is preferred
by Nat3 (of the NatC complex). This supports the theory that ssArd1 may be an
ancestral NAT from which the three modern day eukaryal NAT complexes have
evolved. In addition to these findings, ssArd1 not only targets specific N-terminal
sequences but seems to recognise the structure of potential substrates. As for
enzyme promiscuity, a number of proteins from prokaryotic and eukaryotic cell
lysate were successfully modified by ssArd1 in vitro. Further studies will be
required to identify individual targets.
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6.1 Introduction
The Ard1 protein family has yet to be structurally characterized. One can
predict from sequence alignments that they contain the common features of the
GNAT superfamily i.e. domains A-D, the specific order of the domains and the
common acetyl-CoA binding motif. The structure of these domains is fairly similar
throughout the GNAT family but each enzyme differs in its mechanism of substrate
binding, which is of course not only due to its structural conformation but also the
amino acid sequence it possesses. So far, the structural information received for
many members of the GNAT family centre around the ability of certain residues such
as cysteine or glutamine to act as a catalytic base for the procession of the acetylation
reaction but in the case or ssArd1, no cysteine residues exist and a glutamine residue
cannot be found in the proposed catalytic site, but sequence analysis highlights a
histidine residue which could be used to achieve the same end means (see chapter 5).
Structural information, obtained by crystallising the pure protein will test this
hypothesis. It is also desirable to crystallise ssArd1 in complex with a cofactor and
substrate to give a full representation of the interaction occurring at the molecular
level, thus identifying residues responsible for contact with the substrate and to give
insight into how the enzyme performs catalysis of the acetylation reaction. This will
provide essential information in regards to substrate binding, conformational change
and the reason behind different enzymes having differing substrate preferences. It
will also give an indication as to whether the catalytic mechanism is generally the
same throughout the superfamily.
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6.2 Introduction to Crystallography
Protein crystallography is an essential technique for the determination of
molecular structures and is often used to analyse and understand the interaction
between enzymes and substrates, which among other things, gives scope for
therapeutic drug intervention. The procedure utilises electro-magnetic radiation (X-
rays) to view atomic detail at a wavelength of approximately 1 Å (0.1 nm) but the
nature of the technique means it is not possible to physically focus the X-ray
diffraction pattern using a normal type lens (e.g. in the case of light microscopy) or a
magnet (e.g. in the case of electron microscopy), so it must be done via mathematical
equations using specialised software programmes. The diffraction pattern produced
is recorded on a detector (an image plate or charge coupled device (CCD)) and then
analysed by the software.
In order to achieve a strong enough diffraction pattern with good signal to
noise ratio, an array of molecules must be used rather than just one. The molecules
need to be in the same three-dimentional orientation (order) and hence the reason for
converting solution protein into a more solid structure; a 3D array of molecules
bonded non-covalently to form a protein crystal (Rhodes, 1993). The internal order
of the crystal determines the angles of diffraction and the resolution achieved. As the
X-rays hit the atom, the electron cloud surrounding it is disturbed and this results in
diffraction of the X-rays at the same frequency of which they were emitted (Rayleigh
scattering). Scattered waves in the same phase will combine to heighten the signal,
resulting in a detailed 3D map showing the electron distribution throughout the
protein. Both constructive (in phase) and destructive (out of phase) interference
effects arise from the electron. In-phase rays give rise to the appearance of discreet
reflections (spots) on the detector but out-of-phase rays will cancel each other out.
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Since electrons are quite close to the nuclei of the atoms they belong to, it often
results in a good interpretation of the location of specific atoms within the molecule.
Each reflection contains information on all the atoms in the structure and
conversely each atom also contributes to the intensity of each reflection. The
amplitude and phase of the X-ray waves relating to each individual reflection are
important in reassembling the image of the molecule but phase information cannot be
recorded experimentally and only the amplitude is known. This is known as ‘the
phase problem’ and as such, must be solved before an interpretable electron density
map can be calculated. Constructive interference (conditions that produce
diffraction) occurs when the phase shift is proportional to 2., and is expressed by
Braggs law, which takes into account the relationship between the scattering angle
and the interplanar space (explained in figure 6.1).
Bragg’s law: where d = interplanar spacing between atomic lattice, hkl = set of
parallel planes (index of hkl-Miller indices), / = wavelength, * = angle of incidence,
n = integer.
2dhklsin* = n/
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Figure 6.1: Example of the diffraction of two parallel X-rays after coming into contact with the
atoms of a crystal lattice. dhkl represents the interplanar spacing between two rows of atoms, 0 is
the angle of diffraction relative to the plane of atoms and dsin0 is the value between A and B.
Previous to 1934, dried protein crystals were used for diffraction but the results
were unreliable (Tulinsky, 1999). Bernal and Crowfoot-Hodgkin then discovered that
crystals suspended in their mother liquor yielded better diffraction patterns (Bernal
and Hodgkin, 1934). To enable protein crystals to form, the aqueous protein solution
must be placed in an environment with the correct stimuli and a limited supply of
oxygen to allow diffusion of the chosen buffer into the protein solution, causing slow
precipitation of the protein whilst also preventing it from drying out. Protein purity is
very important for the success of crystal growth, the solution must be at least 97 %
homogeneous. The concentration of the protein solution is also important but can
vary largely from protein to protein. Approximately 10 mg/ml is the recommended
starting point but a quick test can be done to identify the approximate concentration
at which reasonable precipitation occurs. The incubation temperature is also crucial
as some proteins prefer to precipitate at room temperature (~19 °C) whereas others
form better crystals at 4 °C (and this may also lead to better crystal packing if
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precipitation happens too rapidly at room temperature). In addition to these factors,
pH and precipitant type is crucial. Variation in pH can lead to different packing
orientations of the molecules. Hence, it is obvious that the process of crystallography
is not at all straightforward, especially when it concerns a  protein that has never
been crystallised before. Once crystals are produced, they are extremely fragile
because the irregular surfaces of the molecules mean that large solvent containing
channels are formed throughout the crystal and the non-covalent linkages are thus
weakened (Rhodes, 1993). A typical protein crystal will contain approximately 50%
solvent. Although the resulting fragility can be a problem, there is also a huge
advantage to these solvent channels in that they are capable of soaking up certain
metal ions that enable the solving of the phase problem. Likewise, they can be useful
for the binding of substrates and inhibitors. Salt crystals are common and it is
difficult to identify a salt crystal from a protein crystal by eye. Salt crystals are more
tightly packed because they lack the solvent channels and will not take up Izit™ blue
dye as opposed to protein crystals. This is fine for crystals that are not of suitable
quality for x-ray diffraction but those that do look suitable should be tested by other
means e.g. under a polarised lens because protein crystals commonly refract light.
Alternatively they can be handled by a nylon loop to check for fragility (salt is robust
due to the many strong ionic interactions) and finally they can be placed in the beam
line of the x-ray generator for diffraction analysis. The resulting pattern will confirm
the presence of salt or protein (salt crystals yield a only few dispersed, very high
density reflections).
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6.3 Methods for crystallising protein
There are several techniques that have been developed and applied for crystal
growth but what works for one protein doesn’t always work for another. One must
weigh up the properties of the prepared solution first e.g. air and temperature
sensitivity. Listed below are some of the more common methods (in bold) used:
Application of a high pressure environment is a method that was found useful for
growing glucose isomerase crystals (Visuri, 1990). Slow evaporation can be useful
for samples that are not air sensitive, where a large volume of sample is plated out
and left exposed to an air supply by loosely covering with tinfoil for example.
Solvent diffusion (also known as the layering technique) involves using a syringe to
dribble a chosen (less dense) solvent into the protein solution. It should sit on top of
the first solution to form a discreet layer. A common solvent combination to try here
is C H2Cl2/Et2O (if your compound is insoluble in ether). Sublimation requires
sealing of the sample inside a glass tube under a vacuum and placing it at relatively
high temperatures in an oven or likewise. Vapour Diffusion is probably the most
common technique utilized today from which two methods have evolved: the sitting
drop (figure 6.2a) and the hanging drop (figure 6.2b). The latter is the simplest setup
but the sitting drop allows for a greater volume to be used if required. Both methods
rely on the extraction of water from the drop into the reservoir solution, which
increases the protein and precipitant concentration in the drop. At the same time, the
elements of the reservoir diffuse into the drop until an equilibrium is reached.
Reservoir solution will typically contain a buffer to maintain the pH e.g. Tris-HCl
(Branden & Tooze, 1999), an ionic precipitant such as sodium chloride and an
organic precipitant such as a high molecular weight polyethylene glycol (PEG). All
of these compounds will be at a higher concentration in than in the original drop
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(which usually contains similar constituents). The equilibrium hopefully creates
optimum conditions that will remain until the crystallisation process is complete
(McRee, 1993; Rhodes, 1993).
Figure 6.2: Vapour Diffusion. (A) Sitting drop method of vapour diffusion.  (B) Hanging drop
method of vapour diffusion. The very same labels apply (not shown) as in 6.1a. Both are closed
systems to prevent the drop and the reservoir from drying out. Typically, solute is mixed in a 1:1 µl
ratio with mother liquor (reservoir solution) and reservoir solution may be between 100-200 µl.
6.4 Protein crystals of ssArd1
Concentrating ssArd1 was difficult because it readily precipitated. Initially the
highest possible concentration achieved was 3.15mg/ml. Crystal screens from
Hampton and Wizard were utilised for preliminary testing. Hampton I, II and
Peg/Ion solvents were used along with Wizard I and II solvents. An aesthetically
pleasing crystal was obtained from Wizard I condition 44 but diffraction analysis
showed it to be salt. Plenty of non-crystalline precipitate was observed and several
conditions produced tiny needles but after several weeks of incubation no other
crystals had formed. Many of the drops looked clear under the microscope and it
seemed likely therefore, that the protein concentration was not high enough. Further
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expression and purification of ssArd1 at the higher pH of 8.5 (where the pH is not
close to the pI of ~7.6) resulted in more concentrated protein yields.
Three separate batches of purified ssArd1 protein solution were concentrated in
dialysis tubing from approximately 100 ml to about 2 ml each and analysed on SDS-
PAGE gel for purity (figure 6.3). Each of the samples showed good purity, although
lane 2 shows up three very slight bands below the main one. These could be
contaminants but it is likely that they are breakdown products of ssArd1. Bradford
assay determined the relative concentrations to be 8.1 mg/ml, 9.8 mg/ml and 6.4
mg/ml.
Figure 6.3: SDS-PAGE gel on pooled and
concentration fractions from all 3 samples. M =
mark 12 protein marker, lane 1 = 8.1 mg/ml (415
µM), lane 2 =  9.8 mg/ml  (502 µM) and lane 3 = 6.4
mg/ml (329 µM).
Acetyl Co-enzyme A was added to half of the ssArd1 samples (0.5 µl of 12.4 µM per
1 µl of enzyme) in the hope that it would stabilise the enzyme and make it more
likely to crystallize. Many more crystal screens were set up manually using the
different protein concentrations and the samples with added AcCoA in ratios of 1:1,
2:1 and 3:1 enzyme : reservoir solution. In addition to the previously used screens
(Hampton Crystal Screen I and II, Hampton PegIon, Wizard Crystal screen I and II);
Hampton Index, Peg/LiCl, Ammonium sulphate, Salt Rx, Natrix, Crystal Screen
     M  1     2      3
kDa
36.5
31.0
21.5
14.4
6.0
3.5
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Cryo,  Crystal Screen Lite and Emerald Bioscience Crystal Screen I and II were used
this time. After 2-3 weeks, the following crystals appeared (figure 6.4).
Figure 6.4: Crystals of ssArd1 under polarizing light. (A) Needles obtained from 5.9 mg/ml ssArd1
in Hampton Crystal screen I condition 12 (30 %  (v/v) isopropanol, 0.1 M Na Hepes pH 7.5, 0.2 M
MgCl2). (B) Starbursts obtained from 8.1 mg/ml ssArd1 + AcCo-A in Emerald Wizard I condition 35
(20 % (v/v) 1,4-butanediol, 0.1 M acetate pH 4.5). (C) & (D) Same plates shown under different light.
Obtained from 8.1 mg/ml ssArd1 + AcCo-A in Hampton Crystal screen I condition 6 (30 % (v/v) PEG
4000, 0.1 M Tris-HCl pH 8.5, 0.2 M MgCl2).
The needle-type crystals stained dark blue with Izit dye and when micro seeded
they did reproduce. Thus, the specific condition was chosen and a grid of solutions
was made where each component of the crystal screen was varied very slightly one at
a time. These were incubated at 4 °C and 19 °C but crystal morphology did not
improve sufficiently. The starbursts easily broke apart when tapped gently and they
were also floating near the top of the drop as opposed to being heavy and rigid like
salt, verifying protein crystals but macro seeding in mother liquor was not  a success.
A few days later the crystals dissolved completely. Attempts to reproduce these
crystals by optimising the condition (at 4 °C and 19 °C) failed. The plates had nice
sharp edges but also contained irregular regions and refracted light well, which is a
positive indication. But they did not grow suitably in the third dimension and were
too thin to be used in the X-ray beam line. They did not appear again when the
condition was reproduced and neither did they stain with Izit dye, both negative
A B C D
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signals signifying probable salt crystals. After several repetitions of the screens, a
few crystals of decent size (figure 6.5) grew from 8.1 mg/ml ssArd1 + AcCoA in
Hampton Peg/Ion 39 (0.2 M sodium dihydrogen phosphate (monobasic, initial pH
~4.25), 20 % PEG 3350 (final pH ~4.5) after three weeks of incubation at 19 °C.
Figure 6.5:  ssArd1 Crystals formed in Hampton
Pegion, solution 39. Approximate dimensions: Width
~ 0.15 mm, Height ~ 1.2 mm, Depth is difficult to
measure but may be about 0.02 mm.
Producing a suitable cryoprotectant for the crystal was difficult. Crystals
seemed to split in 10 %, 20 % or 25 % glycerol even when soaked slowly with
increasing concentration. They dissolved quickly in MPD. Synchrotron diffraction
pattern results were similar to that which was gathered in-house. Diffraction of the
25 % glycerol protected crystal occurred (figure 6.5) to a reasonable resolution of ~ 3
Å but this did not provide enough detail at the molecular level. The smeared double
dots in figure 6.5 confirmed that the crystal had split (or was already twinned with
another crystal although it looked like a single formation).
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Figure 6.6: Diffraction pattern from an ssArd1 crystal. Detector distance = 200mm, 45 second
exposure per 1° angle rotation through 180°, Resolution to 2.9 Å. Other figures can be found in table
6.1.
Table 6.1 shows slight variations of Pegion 39 that were made in the attempt to
optimize crystal growth. All solutions were at the initial pH values of 4.25, 4.7 and
5.2. All conditions were set up in a 1:1 ratio using 1.5µl of ssArd1 protein solution at
concentrations of 5.4 mg/ml, 6.9 mg/ml and 7.17 mg/ml each with the addition of 2X
and 1X (molecules Acetyl-CoA per molecule ssArd1) and without acetyl coenzyme
A.
Table 6.1: Optimised Hampton Pegion 39 conditions. E.g. 0.3M sodium dihydrogen
phosphate and 30 % PEG 3350. Each made at pH 4.25, 4.7 and 5.2.
0.3M/30% 0.25M/30% 0.2M/30% 0.15M/30% 0.1M/30%
0.3M/25% 0.25M/25% 0.2M/25% 0.15M/25% 0.1M/25%
0.3M/20% 0.25M/20% 0.2M/20% 0.15M/20% 0.1M/20%
0.3M/15% 0.25M/15% 0.2M/15% 0.15M/15% 0.1M/15%
0.3M/10% 0.25M/10% 0.2M/10% 0.15M/10% 0.1M/10%
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Little was observed in the original condition but all 30 % PEG3350 concentrations
(pH4.7) gave very small needles for the higher protein concentrations when used in a
ratio of 1:2 enzyme to AcCoA. 0.1 M Na dihydrogen phosphate and 20 % PEG3350
at pH5.2 gave larger needles but unfortunately, all efforts to reproduce further
worthy crystals with this solution failed.
The protein samples (ssArd1 and ssArd1 + AcCoA) were later sent to the St.
Andrews SPoRT laboratory to be plated out in 100 nM droplets by robotic arm.
Several screens, some similar to those above, were added in a 1:1, 2:1 and 1:2 ratio.
These individual droplets were automatically photographed routinely to highlight any
crystal growth or nucleation. A single crystal rod appeared from the JMAc screen
(produced by colleagues at St. Andrews University) condition 52 (20 % PEG 8000,
0.2 M MgCl2 and 0.1 M MOPS pH 6.5). Although very small, it gave diffraction at
two angles (0° and 90°) confirming that it was protein. After many optimisations, the
best crystals (fig 6.7) grew in (1:1 µl ratio) solution of 20 % PEG 8000, 0.2 M
MgCl2, 0.1 M Tris-HCl pH 8.5 with addition of 0.5 µl Hampton Additive screen II
condition 6 (30 % (w/v) D(+) glucose monohydrate). Several other additives worked
well also.
Figure 6.7: ssArd1 crystals. Formed in 20 % (v/v) PEG
8K, 0.2 M MgCl2, 0.1 M Tris-HCl, pH 8.5 with addition
of 30 % (w/v) D(+) glucose monohydrate.
ssArd1 crystals were now being produced in their hundreds over a period of
just three days but none of them diffracted to the same or better quality than those
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obtained from peg 39. They were simply too thin in the 3rd dimension to obtain data
for a full 180° rotation. Further optimisations failed, as did trying increase their size
by slowing their growth via incubation at 4 °C. A layer of  oil was also dispensed on
top of the room temperature drops to slow the vapour diffusion rates. Many star burst
crystals formed by this method but, as such, were useless. Therefore, the best data
achieved was to 2.8 Å from the Hampton pegion 39 solution.
Data was collected at ESRF synchrotron (ID 14.1) for 120 images, each
representing a 1° rotation of the crystal. The data were then interpreted using
MOSFLM (Leslie, 1992) and scaled using SCALA in the CCP4 software package
(Collaborative Computational Project, Number 4, 1994). The scaled statistics from
SCALA are given below (figure 6.8). The processed data gives a unit cell with
dimensions a = 42.3 Å, b = 69.4 Å and c = 58.0 Å, and angles  ! = & = 90°,  " =
97.8°. The predicted space group is P21 with a mosaicity of 1.1°
Figure 6.8: SCALA generated data.
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From the above (figure 6.8) the data are reasonable to 2.8 Å resolution where the
Rmerge is 0.296 and Mn(I) / %(I) is 3.0. The data are ~88 % complete to the resolution
with a redundancy of ~2.5.
A monoclinic P21 space group has molecules related by a 180º (i.e. two-fold)
screw axis with a translation of half of the lattice vector (figure 6.9a and b). The
equation for a certain point in the lattice is x, y, z. The equivalent point where the
reflection appears is -x, y + 1/2, -z, thus positioning it in a neighbouring unit cell.
Figure 6.9a: A typical P21 monoclinic unit
cell. Important features are a, b and c  cell
lengths. There are no constraints in this model
i.e. sides can be different lengths. Angles ! and
& = 90°, " varies.
Figure 6.9b: Example of primitive
monoclinic unit cell with a 2-fold screw
axis. The arbitrarily chosen unit cell
lengths are: a, b, c = 6, 10, 6. An object
occuring at coordinate x, y, z  (1, 2, 1) is
shown in red and its reflection appears at
–x, y+1/2, -z (-1, 7, -1), shown in lilac. The
object has rotated 180° around the y-axis
giving rise to two-fold symmetry, which is
perpendicular to both the x and z axes. In
addition, it has been translated by half a
unit cell (b/2).
Mosaicity is a measure of the degree of long-range order of the unit cells
within the crystal and of the order in the molecule itself. Lower mosaicity (<1°)
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indicates better ordered crystals and hence better diffraction. This is estimated at 1.1°
for the ssArd1 crystal, showing that it is not so well ordered. The rate of the flash
cooling step involved in cryogenic data collection can disrupt the dimensions of the
unit cell and cause an increase in crystal mosaicity (Teng and Moffat, 1998). This
may have contributed to the observed disorder factor, especially considering the
nature of the cryoprotectant used (i.e. that it was not ideal for protection and likely
caused the crystal to split).
Rsym is the error between reflection intensity measurements of symmetry
related reflections, which should theoretically be identical (Rhodes, 2000). Rmerge is a
similar calculation but includes “all the measurements of symmetry related partners”
over different data frames (Blow, 2002). Many authors use Rsym and R merge
interchangeably because there is little difference between the values. One hopes to
attain a small Rmerge value but it is highly dependent on how many times the
reflections are measured i.e. the data redundancy (= number of reflections measured /
number of unique reflections). The value will therefore increase with the number of
measurements taken. Hence, a new calculation has been devised, Rmeas, which is
more accurate (Diederichs and Karplus, 1997) but many researchers still use Rmerge.
The ssArd1 data display an Rmerge of ~8 % at low resolution (>3.5 Å) and ~30 % at
the high resolution shell (3.0-2.8Å), which is typical for protein crystals. But the data
quality turns out to be quite reasonable given the overall value of ~8 %.
The Matthews coefficient, Vm is the volume of cell occupied per Dalton of
protein and is on average ~2.4 Å3 per Dalton, although it has been known for certain
protein structures to vary from 1.9 to 4.2 Å3/ Da (Blow, 2002). Given the MW of
19.5 kDa for ssArd1, a single monomer in the asymmetric unit would give a Vm =
4.32 Å3/ Da with a 72 % solvent content, whereas with two molecules in the
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asymmetric unit the Vm = 2.16 Å3 / Da with a 43 % solvent content. The asymmetric
unit therefore most likely contains a dimer.
The atomic B-factor (also known as Debye-Waller factor) is a measure of the
atomic  disorder and is made up from the actual atomic motion of an atom and its
statistical disorder throughout the crystal. A typical B-factor for a well ordered
molecule may be about 20 Å2 (Blow, 2002), allowing reasonably detailed resolution
in the region of 2 Å. The Wilson B-factor is derived from a statistical analysis of the
diffraction intensities and gives an idea of the overall atomic B-factor of the
molecule. For the ssArd1 dataset, the Wilson B-factor is ~60 Å2. This means the
crystal is very disordered (a combination of static disorder and that which is caused
by thermal vibration), in agreement with the mosaicity value.
6.5 Co-crystallization of ssArd1 with ssAlba1
Several hundred samples containing ssArd1, ssAlba1 and acetyl-CoA, with the
addition of many different precipitant solutions, were set up manually and by robotic
assistance in order to grow crystals that would result in better diffraction and higher
resolution data. Not only was it thought that this complex may provide a more
structurally stable lattice, but it would also be interesting to identify the site of
interaction between ssArd1 and ssAlba1 at the molecular level to clarify and add to
the observations made in Chapter 5.
Many nucleation sites occurred and about 50 % of the conditions produced
needles. Attempts (as above in section 6.4) to change the morphology of the needles
into more substantial rods failed. Some small blocks and rods did eventually appear
but they remained very small. The crystals below (fig 6.10) were taken to the
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Daresbury synchrotron for X-ray diffraction because they were far too small to be
tested in-house.
Figure 6.10: ssArd1: SosAlba1 co-crystals(?). 100 nL drop containing ssArd1 (331.1 µM monomer
= 7.3 mg/ml), ssAlba1 (152.2 µM monomer = 1.82 mg/ml) and acetyl-CoA (708 µM) in a precipitant
solution of  0.05 M Cadmium sulphate, 0.1 M HEPES pH 7.5, 0.5 M Sodium acetate from (Qiagen)
NeXtal Classics Lite.
However, no diffraction pattern was obtained to confirm the crystal identity to that of
either salt or protein.
6.6 Solving the phase problem - are you MAD?
Seleno-methionine is often substituted in place of methionine when
producing protein for crystallography. This is done because Selenium is chemically
similar to Sulphur, but contains 34 electrons to sulphur’s 16. This allows the use of
anomalous scattering to identify the various locations of the Selenium atoms. Seleno-
methionine has roughly the same properties as normal methionine and does not affect
the protein structure in any way. This procedure is called MAD (multiple wavelength
anomalous dispersion) phasing.
ssArd1 was expressed in a methionine auxotroph in medium containing seleno-
methionine and other amino acids. The protein was shown to express well (fig 6.11).
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Figure 6.11: SDS-PAGE gel showing expression
of ssArd1 from a methionine auxotroph. ssArd1
highlighted in red at molecular weight of ~19.5 kDa.
M = Mark 12 molecular weight marker, C =
uninduced control, I = Induced  protein expression.
The 19.5 kDa band was excised and sent to the St. Andrews university mass
spectrometry unit for analysis. No seleno-methionine residues were found to be
incorporated into the enzyme. The whole procedure was repeated two more times but
continued to fail. This experiment was not taken further.
6.7 Molecular Replacement
This technique relies upon the previously deposited data for proteins of similar
function, which presumably share sequence homology and/or structural homology.
One can use sequence alignments to come up with similar sequences that are already
known. The PHYRE program attempts to fold the sequence of the target protein onto
all of the unique protein structures in the protein database. It will then alert the user
to a list of the most likely structural homologues within the protein data bank (PDB).
These structural models can then be used in a program called PHASER (McCoy,
2007) to carry out molecular replacement against the diffraction data from ssArd1.
Molecular replacement uses a model structure to calculate “diffraction data” which is
then compared to the actual diffraction data from ssArd1. The process is divided into
two stages: rotation and translation. PHASER produces a list of possible orientations
 M       C      I
kDa
31.0
21.5
14.4
6.0
3.5
ssArd1
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for the model in the ssArd1 unit cell, and then attempts to find the position of each of
these within the unit cell. PHASER orders its solutions by their Z-scores i.e. the
number of standard deviations above the mean score. Each solution has a rotation
function score (RFZ) and a translation function score (TFZ). PHASER then
determines if the solutions pack in the unit cell i.e. whether there are any clashes
between symmetry related molecules. In the case of ssArd1, PHASER was asked to
find two molecules in the asymmetric unit. The PHASER documentation suggests
that if the Z-score is <5, the structure is not solved. If Z is 5-6 it is unlikely. If Z is 6-
7 it is possible, whilst 7-8 is probable. A Z-score of  >8 means the structure is
definitely solved.
Six proteins were highlighted by PHYRE as having structural homology with
ssArd1. The PDB codes for these structures are: 1mk4 (probable acetyltransferase
from B. subtilis), 1u6m (GNAT acetyltransferase from E. faecalis), 1ghe (Tabtoxin
resistance protein, GNAT related from P. syringae), 1s3z, 1wk4 and 1z4e. Each of
the above individual search models were used, as well as a combined model where
PHASER is supplied with several models that have been superimposed. This has the
effect of reinforcing the search model where there is similarity and reducing the
weight of parts of the model that deviate. Running these ensembles in PHASER
gives a translation function (TF) Z-score and a rotation function (RF) Z-score. TFZ is
the first one to observe and if the value is above 5-6, the RF score is examined next.
Table 6.2 lists the TF-Z scores for each model.
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Table 6.2: PDB file numbers for
structures with homology to ssArd1.
MSDfold SSM (Krissinel, 2004) was used
to align the monomers for % sequence
identity with ssArd1. A TF Z-score <5 =
structure not solved. 5-6 = unlikely.
None of the above models provided a suitable solution but it was possible to create a
common core structure (figure 6.12) by trimming the superimposed models so that
elements that deviated between the models were removed, resulting in a small
increase in the TF-Z score. At only 5.3, it is unlikely (but not impossible) that we
have a solved structure and it is likely that the basic core of ssArd1 resembles that
which is shown in figure 6.12.
Figure 6.12: Superimposed core domain of GNAT
related enzymes. Based on structural homology
alignment of ssArd1 and seven other acetyltransferase
enzymes (some with known function, some putative)
by the Phyre programme, the core domain of the
ssArd1 monomer will look very similar to what is
shown on the left. 3 !-helical regions and 5 "-strands
that are common in all the structures and very closely
positioned when superimposed can be identified.
In late 2006 another acetylase was deposited in the protein databank, 2ob0,
described as a human MAK3 homolog that shares 28 % sequence identity with
ssArd1. This structure was used as a search model in PHASER. When used as a
complete  structure  there  was  no  significant solution, with  the  highest  TFZ  score
PDB file
number
%
identity
TFZ-
score
1mk4 18 4.6
1u6m 19 4.0
1ghe 15 4.6
1s3z 15 4.0
1wk4 18 5.0
1z4e 19 5.0
With all cores 5.3
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being 5.0. However, a pruned search model was created using the program
CHAINSAW which included complete side chains where there was identity with
ssArd1, and truncated side chains (to C" or C&) where there was non-identity. Running
PHASER with this model and including data between 15.0 and 4.0 Å gave a single
solution for two monomers in the asymmetric unit with a TFZ score of 7.1 (figure
6.13). The two molecules pack well in the cell, but it was not possible to refine the
solution, which may be due to the relatively poor quality of the diffraction data.
Figure 6.13: Crystal structure of ssArd1 obtained from molecular replacement.
Search model PDB code: 2ob0. The packing of the two monomers in the unit cell
are shown (green and cyan) with symmetry-related molecules shown in grey.
6.8 Summary and Conclusion
ssArd1 seems to crystallise better in the presence of acetyl-CoA, indicating that
this cofactor may help to stabilise the protein. Crystallisation proved to be very
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difficult and the only viable data obtained was from a diffraction pattern with some
slightly skewed reflections due to the combined nature of the disordered crystal,
possible twinning and the fact that the cryo solution was not 100 % suitable for
preventing damage to the lattice during the freezing process. The data suggests a P21
monoclinic unit cell with a volume suitable for containing two protein molecules per
asymmetric unit. Data is complete to ~88 % and resolution was achieved to 2.8 Å.
Attempts to gain phase information by incorporation of the heavy element selenium
failed. Molecular replacement provided a plausible solution using a pruned model of
a human acetylase, but unfortunately the model did not refine or progress any further,
so the search is on for better quality crystals.
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7.1 Conclusions
Attempts to express soluble Sso0082 were terminated after several months. It is
possible that this enzyme exists in vivo as a subunit of a protein complex. ssArd1
expressed well but purification was initially problematic. A five step purification
program was finally developed for this protein. Upon concentration of the protein
solution, much precipitation occurred. For this reason, Circular Dichroism was
carried out to ensure that aggregation was not a consequence of misfolded protein.
These studies confirmed the presence of a folded globular protein wherein
approximately half of its structural conformation was designated !-helical in nature.
"-sheet content was estimated to be  only 9-15 %, which is quite low compared to the
predicted structure on the basis of sequence properties (PHYRE, section 1.5)  and
homology with a variety of proteins with solved structures e.g. yGcn5 (see Ch 4 &
5).
Since eukaryal Ard1 is the catalytic subunit belonging to a protein complex,
NatA, it was fitting to acknowledge that the crenarchaeal enzyme may also have a
binding partner(s). However, ssArd1 exhibited acetyltransferase activity in the
absence of other proteins. Further to this, no protein other than SsoAlba1, (and to a
lesser degree SsoAlba2) interacted with column-bound ssArd1. The majority of N-
terminal acetylation in the eukarya is generally carried out by the three main NAT
complexes NatA, B and C. Other known NAT complexes include AANAT/14-3-3,
HAT1/HAT2 and PCAF, discussed in chapter 1. But there are also a variety of NATs
and HATs that act alone e.g. Hpa2 and AAC.
ssArd1 primarily modifies the N-terminal serine belonging to ssAlba1 and
acetyltransferase activity is optimal at 55 °C in vitro. Longer incubation periods
resulted in additional acetylation at several lysine sites. Secondary to a preference for
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N-terminal serine; the enzyme is capable of modifying N-terminal alanine. ssArd1
residues preferences are serine > alanine > methionine (-glu) and methionine (-leu) >
valine > threonine > glycine > proline. Thus, not only does ssArd1 possess an
affinity towards NatA substrates, it also modifies NatB and NatC substrates,
suggesting that it represents a common ancestor from which these complexes have
evolved.
Kinetic experiments to attain values relative to enzyme activity made it possible
to establish Vmax as ~8250 nmoles/min per mg of enzyme but it was not feasible to
calculate an accurate value for Km because the velocity of reaction was so high that
Alba1 was almost if not completely depleted in the earliest samples. Km is 1 11.425
µM. kcat shows multiple turnover and the calculated catalytic efficiency of ssArd1 is
estimated to be greater than 1600 M-1.sec-1.
Differential scanning calorimetry on acetylated Alba1 and non-acetylated
Alba1 did not give any major insight into whether the protein was more stable in its
acetylated form. Both samples had the same melting temperature, give or take 0.5 °C.
The reason for in vivo acetylation of Alba1 probably lies within the realms of cell
signalling and it is likely that acetylation affects the half life of the protein in addition
to the more obvious consequences of lowering its binding affinity for DNA.
Point mutations of ssArd1 resulted in the identification of the putative catalytic
base histidine at position 88. The sequence homology with yGCN5 strongly suggests a
similar catalytic mechanism. This would consist of deprotonation of the substrate
primary amine by H88, which in turn causes the primary amine to carry out a direct
nucleophilic attack on the acylcarbon of acetyl Co-enzyme A. This creates a
tetrahedral intermediate between substrate, acetyl-CoA and enzyme before the acetyl
group is ultimately transferred to the substrate.
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S131-N132 lie close to the acetylCoA binding domain so may be involved in
substrate binding, but it is likely that the decrease in activity in the S131A-N132A
mutant could be attributed to poor cofactor binding. Mutation of D156 also results in
a decrease in activity and has thus been postulated to engage in substrate
recognition/binding. It is conserved in yGCN5 where it is situated on a loop with no
co-factor contact. This loop (prior to "6) makes numerous contacts with substrate as
does the loop between !1 and !2 (Wang, 1998). In accordance with the sequence
alignment then, residues between 32 to 48 and 52 to 61 in ssArd1 will be may be
involved in substrate recognition.
ssArd1 is a promiscuous N-terminal acetyltransferase that recognises protein
structure as well as N-terminal sequence. It represents an ancestral form of NAT
from which the three main acetyltransferase complexes NatA, NatB and NatC have
derived their specific functions. Of the proteins it has been shown to modify thus far,
ssAlba1 remains to be the preferred substrate. In addition, the enzyme is capable of
acetylating many different proteins from eukaryotic and prokaryotic cell lysates but
none of these could be identified during the course of this work.
Crystallisation of ssArd1 was an arduous process, from which very few
diffraction quality crystals developed. The data achieved was just under 3 Å
resolution but disruption to the order of the crystal created problems during the data
analysis steps. The calculated model implies a P21 space group with two monomers
per asymmetric unit. Molecular replacement largely failed but did permit insight into
the core structure of ssArd1, presenting an arrangement of three !-helices and five "-
strands.
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7.2 Future work
Based on the comparison between ssArd1 and yGCN5 sequences, further
mutational studies would be useful in identifying regions specific for substrate
recognition, expressly concentrating on residues located within the two loop sections
that were mentioned previously in this chapter. As well as this, there are a string of
other residues that need to be examined for their role in substrate binding i.e. N29,
G64, Y65, M67, R69 and I70, S91, L126, L138 Y154, G157 and Y161.
It would be beneficial to carry out a non-radioactive kinetic experiment,
perhaps using a coupled assay, to achieve better kinetic data and overcome the
problems with substrate depletion. It was not possible to create a knockout of ssArd1
in Sulfolobus but this can now be achieved due to recent scientific advances (Albers,
2007). This would enable changes in protein acetylation to be examined in a more
convenient and reliable way, whilst also providing insight into the effect of 'Ard1 on
cell viability.
And in terms of solving the crystal structure of the enzyme, it may be worth
creating a truncated version of the protein because this has been tried and tested for
many problematic samples in the past, often resulting in a solved structure. Among
many examples of successfully crystallized truncated structures are the N-terminally
truncated form of the DegS protein (a stress sensor of the bacterial periplasm) where
crystals  of  the  full  length  protein  were  not  attainable  (Grininger, 2004) and AcP
(acylphosphatase) from S. solfataricus (Zuccotti, 2005).
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Appendix 1
Sso0209 blast search. Black shaded residues indicate absolute identity, grey shaded residues indicate
similarity.
Sso0209.      1 ----------MELAEKDKGRDFTLRNARMDDIDQIIKINRLTLPENYPYYFFVEHLKEYG
STO           1 ----------MEFAEAKKGKEYRIRNARLTDVDQIIKINRLALPENYPYYFFVEHLKEYE
Pab           1 MTLEIRIDGPQRLLGKDGKTEFIIREATLKDLNDIISINRKVLPENYPNWFFVEHLEQFP
Trypan        1 ---------------------MQVRRATMEDMYQMQHCNLRCLPENYNLRYYLYHILSWP
ARD1          1 -------------------MPINIRRATINDIICMQNANLHNLPENYMMKYYMYHILSWP
Ape           1 ----------MNREAQGSQEGVRIRKARAQDIPIVMEINLESLPENYWYGFYKYILDNWG
HsapQ9BSU3    1 ---------------------MNIRNAQPDDLMNMQHCNLLCLPENYQMKYYLYHGLSWP
Mouse.        1 ---------------------MNIRNARPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWP
Sso0209.     51 LAFFVAI------------VD-N--------------------------SVVGYIMPRIE
STO          51 AAFFVAE------------VD-G--------------------------EVVGYIMPRIE
Pab          61 KAFIVAE------------IE-G--------------------------KVVGYVMSRVE
Trypan       40 QLLYVQE------------DNNG--------------------------NVVGYVLAKME
ARD1         42 EASFVATTTTLDCEDSDEQDENDKLELTLDGTNDGRTIKLDPTYLAPGEKLVGYVLVKMN
Ape          51 EAFLVAE-------------VGG--------------------------EIVGYAMSRVE
HsapQ9BSU3   40 QLSYIAE------------DEDG--------------------------KIVGYVLAKME
Mouse.       40 QLSYIAE------------DENG--------------------------KIVGYVLAKME
Sso0209.     72 WGFSNI-----------------------KQLPSLVRKGHVVSIAVLEEYRRKGIATTLL
STO          72 WGFSNL-----------------------KQLPTLVKKGHVVSIAVLEQYRRLGIGTALL
Pab          82 YGWSNI-----------------------HR-GKAVRKGHIVSVGVLPEARRLGIATAMM
Trypan       62 EEEHA-----------------------------EKVFGHITSIAVLRTHRRLGIASRVM
ARD1        102 DDPDQQ-----------------------N----EPPNGHITSLSVMRTYRRMGIAENLM
Ape          72 QTSDPVLLGMKDELEGDKSVIDKILDAIRNQLSEERPVGHLVSIAVRPGFRGRGIGSKLL
HsapQ9BSU3   62 EEPD------------------------------DVPHGHITSLAVKRSHRRLGLAQKLM
Mouse.       62 EDPD------------------------------DVPHGHITSLAVKRSHRRLGLAQKLM
Sso0209.    109 EASMKSMKNDYNAEEIYLEVRVSNYPAIALYEK-LNFKKVKVLKGYYADGEDAYLMARPL
STO         109 QASMKAMKEVYNAEEVYLEVRVSNSPAINLYKK-LGFKEVKVLRHYYADGEDAYLMAAPL
Pab         118 LRAMKAMKVYYGASEVYLEVRVSNTPAISLYEK-LGYKVVGRIPRYYSDGEDAFLMACPL
Trypan       93 NAALHEMEHEYDANFCSLHVRKTNDAALHLYQNTLNFRCANVESKYYVDEEDAYHMKRFF
ARD1        135 RQALFALREVHQAEYVSLHVRQSNRAALHLYRDTLAFEVLSIEKSYYQDGEDAYAMKKVL
Ape         132 SATVRVMKNVYRVDAIFLEVRVSNMPAIRLYEK-FGFRKVRRIKGYYRDGEDAFVMVKRL
HsapQ9BSU3   92 DQASRAMIENFNAKYVSLHVRKSNRPALHLYSNTLNFQISEVEPKYYADGEDAYAMKRDL
Mouse.       92 DQASRAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYADGEDAYAMKRDL
Sso0209.    168 ------------------------------------------------------------
STO         168 ------------------------------------------------------------
Pab         177 ------------------------------------------------------------
Trypan      153 KGSNPGFYVTESRQLVRQPNTGAGAAAGSAAEASGQRPDKKNSVDKQKEQLELAAELLEE
ARD1        195 KLEELQISNFTHRRL---------------------------KENEEKLEDDLESDLLED
Ape         191 ------------L-----------------------------------------------
HsapQ9BSU3  152 ------------SQMADELRRQMDLKKGGYVVLGSRENQETQGSTLSDSEEACQQKNPAT
Mouse.      152 ------------TQMADEPASGPGSSCLLSGDLGPVSFHPLPSGLLAAAEAAPGAEGKGQ
174
Sso0209.        -------------------------------
STO             -------------------------------
Pab             -------------------------------
Trypan      213 DLKSSGKGRRQPHQQHQKGGKHGKGKK----
ARD1        228 IIKQGVNDIIV--------------------
Ape             -------------------------------
HsapQ9BSU3  200 EESGSDSKE-PKESVESTNVQDSSESSDSTS
Mouse.      200 AHGSGGLGE-QSGEQRQRAFELRRGLS----
Sso0209: Sulfolobus solfataricus ssArd1 N-acetyltransferase, STO: Sulfolobus tokodaii 167aa long
hypothetical N-terminal acetyltransferase, Pab: Pyrobaculum aerophilum str. IM2 176aa N-
acyltransferase, Trypan: Trypanosoma brucei putative N-acetyltransferase subunit Ard1, Ard1:
Saccharomyces cerivisiae N-terminal acetyltransferase complex, Ape: Aeropyrum pernix (strain K1)
N-terminal acetyltransferase complex subunit APE1954, HsapQ9BSU3: Homo sapiens MGC10646
protein, Mouse: Mus musculus Ard1 protein.
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Appendix II
ssArd1 alignment with other Ard1 homologues.
CLUSTAL W (1.83) multiple sequence alignment
ssArd1                              --------------------------------MELAEKDKGRD-FTLRNA 17
gi|15920446|ref|NP_376115.1|        --------------------------------MEFAEAKKGKE-YRIRNA 17
gi|70606292|ref|YP_255162.1|        --------------------------------MEITEDSKRKINYQIRLA 18
gi|14601741|ref|NP_148282.1|        --------------------------------MN-REAQGSQEGVRIRKA 17
gi|67466743|ref|XP_649513.1|        -------------------------------------------MFTIRKA 7
gi|51593357|gb|AAH80651.1|          PSTRFSPVVLAPWTRFLRQTVPLKVGDSLFWVHCSPTGSLPSAIMNIRNA 50
gi|149701444|ref|XP_001492559.      --------------------------------------------MNIRNA 6
gi|20071196|gb|AAH27219.1|          --------------------------------------------MNIRNA 6
gi|10835057|ref|NP_003482.1|        --------------------------------------------MNIRNA 6
gi|149029890|gb|EDL85002.1|         --------------------------------------------MNIRNA 6
gi|47086985|ref|NP_998499.1|        --------------------------------------------MNIRNA 6
gi|58267770|ref|XP_571041.1|        --------------------------------------------MDIRQA 6
gi|71657918|ref|XP_817467.1|        --------------------------------------------MQIRRA 6
gi|15240705|ref|NP_196882.1|        -------------------------------------------MVCIRRA 7
gi|7649677|emb|CAB89123.1|          --------------------------------------------MQVRRA 6
gi|94468972|gb|ABF18335.1|          --------------------------------------------MNIRCA 6
gi|126276259|ref|XP_001386974.      ------------------------------------------MGITIRQA 8
                                                                                  :* *
ssArd1                              RMDDIDQIIKINRLTLPENYPYYFFVEHLKEYGLAFFVAI---------- 57
gi|15920446|ref|NP_376115.1|        RLTDVDQIIKINRLALPENYPYYFFVEHLKEYEAAFFVAE---------- 57
gi|70606292|ref|YP_255162.1|        TLSDIDQIIRINRSALPENYPYYFFVEHLKEYGQAFYVAD---------- 58
gi|14601741|ref|NP_148282.1|        RAQDIPIVMEINLESLPENYWYGFYKYILDNWGEAFLVAE---------- 57
gi|67466743|ref|XP_649513.1|        TPADLPAIQNVNLTNLPENYNLQLYYYHLILYP-TSFVAV---------- 46
gi|51593357|gb|AAH80651.1|          QPDDLMNMQHCNLLCLPENYQMKYYLYHGLSWPQLSYIAE---------- 90
gi|149701444|ref|XP_001492559.      RPDDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE---------- 46
gi|20071196|gb|AAH27219.1|          RPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE---------- 46
gi|10835057|ref|NP_003482.1|        RPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE---------- 46
gi|149029890|gb|EDL85002.1|         RPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE---------- 46
gi|47086985|ref|NP_998499.1|        RPEDLMNMQHCNLLCLPENYQMKYYFYHGLSWPQLSYIAE---------- 46
gi|58267770|ref|XP_571041.1|        TIDDLLGMQNANLLNLPENYTFKYYLYHALTWPELSYVAV---------- 46
gi|71657918|ref|XP_817467.1|        TMEDMYQMQHCNLRCLPENYNLRYYFYHILSWPQLLYVQE---------- 46
gi|15240705|ref|NP_196882.1|        TVDDLLAMQACNLMCLPENYQMKYYLYHILSWPQLLYVAE---------- 47
gi|7649677|emb|CAB89123.1|          TMEDMYQMQHCNLRCLPENYNLRYYLYHILSWPQLLYVQE---------- 46
gi|94468972|gb|ABF18335.1|          KPEDLMNMQHCNLLCLPENYQMKYYFYHGLTWPQLSYVAE---------- 46
gi|126276259|ref|XP_001386974.      TINDIQAMQNANLHNLPENYQLKYYMYHILSWPQASFVATTYEDIVESND 58
                                       *:  :   *   *****    :      :     :
ssArd1                              -------------VDN---------SVVGYIMPRIEWG------------ 73
gi|15920446|ref|NP_376115.1|        -------------VDG---------EVVGYIMPRIEWG------------ 73
gi|70606292|ref|YP_255162.1|        -------------LEG---------EVVGYVMPRIEWG------------ 74
gi|14601741|ref|NP_148282.1|        -------------VGG---------EIVGYAMSRVEQTSDPVLLGMKDEL 85
gi|67466743|ref|XP_649513.1|        ------------TPDN---------KVVGYCLTKIEDDDP---------- 65
gi|51593357|gb|AAH80651.1|          ------------DEDG---------KIVGYVLAKMEE-EP---------- 108
gi|149701444|ref|XP_001492559.      ------------DEDG---------KIVGYVLAKMEE-DP---------- 64
gi|20071196|gb|AAH27219.1|          ------------DENG---------KIVGYVLAKMEE-DP---------- 64
gi|10835057|ref|NP_003482.1|        ------------DENG---------KIVGYVLAKMEE-DP---------- 64
gi|149029890|gb|EDL85002.1|         ------------DENG---------KIVGYVLAKMEE-DP---------- 64
gi|47086985|ref|NP_998499.1|        ------------DENG---------KIVGYVLAKMEE-DP---------- 64
gi|58267770|ref|XP_571041.1|        ------------DPKG---------RIVGYILAKMEEEP----------- 64
gi|71657918|ref|XP_817467.1|        ------------DYNR---------NIVGYVLAKMED-EEK--------- 65
gi|15240705|ref|NP_196882.1|        ------------DYNG---------RIVGYVLAKMEE-ES---------- 65
gi|7649677|emb|CAB89123.1|          ------------DNNG---------NVVGYVLAKMEE-EEH--------- 65
gi|94468972|gb|ABF18335.1|          ------------DDKG---------NIVGYVLAKMEEPEPG--------- 66
gi|126276259|ref|XP_001386974.      TEAGEEFGGEKEDPKGDSAYINRGEKIVGYVLGKMEDDPEAE-------- 100
                                                              :*** : ::*
176
ssArd1                              ---FSNIKQLPSLVR--------KGHVVSIAVLEEYRRKGIATTLLEASM 112
gi|15920446|ref|NP_376115.1|        ---FSNLKQLPTLVK--------KGHVVSIAVLEQYRRLGIGTALLQASM 112
gi|70606292|ref|YP_255162.1|        ---FSNLKHIPSLVR--------KGHIVSIAVLEPFRKIGVGTSLLQNSL 113
gi|14601741|ref|NP_148282.1|        EGDKSVIDKILDAIRNQLSEERPVGHLVSIAVRPGFRGRGIGSKLLSATV 135
gi|67466743|ref|XP_649513.1|        -------------------HPVVTGQVTSISVLRTYRRLGIATKLIRAAE 96
gi|51593357|gb|AAH80651.1|          -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 139
gi|149701444|ref|XP_001492559.      -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 95
gi|20071196|gb|AAH27219.1|          -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 95
gi|10835057|ref|NP_003482.1|        -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 95
gi|149029890|gb|EDL85002.1|         -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 95
gi|47086985|ref|NP_998499.1|        -------------------DDVPHGHITSLAVKRSHRRLGLAQKLMDQAS 95
gi|58267770|ref|XP_571041.1|        -------------------SDAPSGHVTSISVLRPYRRLGLANKLMKQSQ 95
gi|71657918|ref|XP_817467.1|        -------------------PANIHGHITSIAVLRTHRRLGIASRVMRASM 96
gi|15240705|ref|NP_196882.1|        --------------------NECHGHITSLAVLRTHRKLGLATKLMTAAQ 95
gi|7649677|emb|CAB89123.1|          -------------------AEKVFGHITSIAVLRTHRRLGIASRVMNAAL 96
gi|94468972|gb|ABF18335.1|          -------------------EESTHGHITSLAVKRSYRRLGLAQKLMNQAS 97
gi|126276259|ref|XP_001386974.      -------------------DKTPHGHITSLSVMRTYRRMGIAEKLMRQSL 131
                                                            *::.*::*   .*  *:.  ::  :
ssArd1                              KSMKNDYNAEEIYLEVRVSNYPAIALYEK-LNFKKVKVLKGYYADGEDAY 161
gi|15920446|ref|NP_376115.1|        KAMKEVYNAEEVYLEVRVSNSPAINLYKK-LGFKEVKVLRHYYADGEDAY 161
gi|70606292|ref|YP_255162.1|        KAMKDTYNAEEVYLEVRVTNYPAISLYKK-FNFREVKLLKHYYADGEDAY 162
gi|14601741|ref|NP_148282.1|        RVMKNVYRVDAIFLEVRVSNMPAIRLYEK-FGFRKVRRIKGYYRDGEDAF 184
gi|67466743|ref|XP_649513.1|        NSMIEVFGARAMMLQVRVSNQPALHLYEKTIGFTVTKVSKHYYLDGEDAL 146
gi|51593357|gb|AAH80651.1|          RAMIENFNAKYVSLHVRKSNRPALHLYSNTLNFQISEVEPKYYADGEDAY 189
gi|149701444|ref|XP_001492559.      RAMIENFSAQYVSLHVRKSNRAALHLYSNTLNFQVSEVEPKYYADGEDAY 145
gi|20071196|gb|AAH27219.1|          RAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYADGEDAY 145
gi|10835057|ref|NP_003482.1|        RAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYADGEDAY 145
gi|149029890|gb|EDL85002.1|         RAMIENFNAKYVSLHVRKSNRAALHLYSNTLNFQISEVEPKYYADGEDAY 145
gi|47086985|ref|NP_998499.1|        RAMIENFNAKYVSLHVRKSNRAALHLYSNTLKFQISEVEPKYYADGEDAY 145
gi|58267770|ref|XP_571041.1|        EAMVAHYDAHHITLHVRKSNRAAISLYRDTLGFEVHGMEKSYYADGEDAY 145
gi|71657918|ref|XP_817467.1|        KEMEKEYDANYCSLHVRKTNDAALHLYQETLGFRCANVEKGYYVDEEDAF 146
gi|15240705|ref|NP_196882.1|        AAMEQVYEAEYVSLHVRRSNRAAFNLYTETLGYKINDVEAKYYADGEDAY 145
gi|7649677|emb|CAB89123.1|          HEMEHEYDANFCSLHVRKTNDAALHLYQNTLNFRCANVESKYYVDEEDAY 146
gi|94468972|gb|ABF18335.1|          HAMVECFNAQYVSLHVRKSNRAALNLYTNSLGFRILEIEPKYYADGEDAY 147
gi|126276259|ref|XP_001386974.      YAMCESFDAQYVSLHVRKSNRAALHLYRDSLNFEVTSIEKSYYQDGEDAY 181
                                      *   : .    *.** :* .*: ** . : :        ** * ***
ssArd1                              LMARPL-------------------------------------------- 167
gi|15920446|ref|NP_376115.1|        LMAAPL-------------------------------------------- 167
gi|70606292|ref|YP_255162.1|        LMAAPL-------------------------------------------- 168
gi|14601741|ref|NP_148282.1|        VMVKRLL------------------------------------------- 191
gi|67466743|ref|XP_649513.1|        ILTHNFTLDTLIN------------------------------------- 159
gi|51593357|gb|AAH80651.1|          AMKRDLSQMADELRRQMD-LKKGGYVVLGSRENQETQG------------ 226
gi|149701444|ref|XP_001492559.      AMKRDLAQMADELRRQLE-QRKGGYVV-GSRENQETQG------------ 181
gi|20071196|gb|AAH27219.1|          AMKRDLTQMADEPAS----GPGSSCLLSGDLGPVSFHPL----------- 180
gi|10835057|ref|NP_003482.1|        AMKRDLTQMADELRRHLELKEKGRHVVLGAIENKVESKG----------- 184
gi|149029890|gb|EDL85002.1|         AMKRDLTQ------------------------PQGLAPL----------- 160
gi|47086985|ref|NP_998499.1|        AMKRNLTQMADELQ-------KPGVRLWGSEAPPSQDTS----------- 177
gi|58267770|ref|XP_571041.1|        GMRYVFKKPE---------------------------------------- 155
gi|71657918|ref|XP_817467.1|        HMKKFFKGPNPGLYVAAN----RQLVRQQNSAAAAVTGMAALQRNGGTAP 192
gi|15240705|ref|NP_196882.1|        DMRKNLKGKQN--------------------------------------- 156
gi|7649677|emb|CAB89123.1|          HMKRFFKGSNPGFYVTES----RQLVRQPNTGAGAAAG------------ 180
gi|94468972|gb|ABF18335.1|          SMRRDLAELAELYG------------------------------------ 161
gi|126276259|ref|XP_001386974.      AMRLTLELDEL--------------------------------------- 192
                                     :   :
ssArd1                              --------------------------------------------------
gi|15920446|ref|NP_376115.1|        --------------------------------------------------
gi|70606292|ref|YP_255162.1|        --------------------------------------------------
gi|14601741|ref|NP_148282.1|        --------------------------------------------------
gi|67466743|ref|XP_649513.1|        -------KDCSSVVVDEWKRVMQEQENKQKE------------------- 183
gi|51593357|gb|AAH80651.1|          ---STLSDSEEACQ-QKNPATEESGSDSKEPKE---SVESTNVQDSSESS 269
gi|149701444|ref|XP_001492559.      ---STHPGSEGACQEQKISAADDSGSDSKEPSE---SPESTDVQDSSEDS 225
gi|20071196|gb|AAH27219.1|          ---PSGLLAAAEAAPG-AEGKGQAHG-SGGLGEQSGEQRQRAFELRRGLS 225
gi|10835057|ref|NP_003482.1|        ---NSPPSSGEACREEKGLAAEDSGGDSKDLSEVSETTESTDVKDSSEAS 231
gi|149029890|gb|EDL85002.1|         ---VSCLET----------------------------------------- 166
gi|47086985|ref|NP_998499.1|        ---VTGLVEKLTVQDGEKEGDGDSGGESKEMSEVSEATESTDVKDSS--S 222
gi|58267770|ref|XP_571041.1|        -----------ESLKE---------------------------------- 160
gi|71657918|ref|XP_817467.1|        PPPPPSSSSAGGQR-GENDTADLEKEQLKLVAELLEESNKESGKGRQQKQ 241
gi|15240705|ref|NP_196882.1|        --------HHHAHGHHHHHGGGCCSGDAKVVET----AQAVDGKAVSK-- 192
gi|7649677|emb|CAB89123.1|          -----SAAEASGQRPDKKNSVDKQKEQLELAAELLEEDLKSSGKGRRQPH 225
gi|94468972|gb|ABF18335.1|          -----AGREHSDAVISNHTGGSHAGHDGHCC------------------- 187
gi|126276259|ref|XP_001386974.      ----------LPSLAQKGERDDLSKDLLESL------------------- 213
177
ssArd1                              -----------------
gi|15920446|ref|NP_376115.1|        -----------------
gi|70606292|ref|YP_255162.1|        -----------------
gi|14601741|ref|NP_148282.1|        -----------------
gi|67466743|ref|XP_649513.1|        -----------------
gi|51593357|gb|AAH80651.1|          DSTS------------- 273
gi|149701444|ref|XP_001492559.      DSAS------------- 229
gi|20071196|gb|AAH27219.1|          -----------------
gi|10835057|ref|NP_003482.1|        DSAS------------- 235
gi|149029890|gb|EDL85002.1|         -----------------
gi|47086985|ref|NP_998499.1|        DS--------------- 224
gi|58267770|ref|XP_571041.1|        -----------------
gi|71657918|ref|XP_817467.1|        KQQQQSKGGNKRGKTKK 258
gi|15240705|ref|NP_196882.1|        -----------------
gi|7649677|emb|CAB89123.1|          QQHQ--KGG-KHGKGKK 239
gi|94468972|gb|ABF18335.1|          -----------------
gi|126276259|ref|XP_001386974.      -----------------
Identities of proteins [and their host organisms] from alignment (in order of occurrance):
hypothetical N-terminal acetyltransferase [Sulfolobus tokodaii str. 7]
gi|15920446|ref|NP_376115.1|[15920446]
N-acetyltransferase [Sulfolobus acidocaldarius DSM 639]
gi|70606292|ref|YP_255162.1|[70606292]
N-terminal acetyltransferase [Aeropyrum pernix K1]
gi|14601741|ref|NP_148282.1|[14601741]
N-terminal acetyltransferase [Entamoeba histolytica HM-1:IMSS]
gi|67466743|ref|XP_649513.1|[67466743]
ARD1B protein [Homo sapiens]
gi|51593357|gb|AAH80651.1|[51593357]
PREDICTED: similar to ARD1 homolog B protein [Equus caballus]
gi|149701444|ref|XP_001492559.1|[149701444]
Ard1 protein [Mus musculus]
gi|20071196|gb|AAH27219.1|[20071196]
N-acetyltransferase, homolog of S. cerevisiae ARD1 [Homo sapiens]
gi|10835057|ref|NP_003482.1|[10835057]
N-acetyltransferase ARD1 homolog (S. cerevisiae) (predicted), isoform CRA_b [Rattus norvegicus]
gi|149029890|gb|EDL85002.1|[149029890]
ARD1 homolog a, N-acetyltransferase [Danio rerio]
gi|47086985|ref|NP_998499.1|[47086985]
ard1 family protein [Cryptococcus neoformans var. neoformans JEC21]
gi|58267770|ref|XP_571041.1|[58267770]
N-acetyltransferase complex ARD1 subunit [Trypanosoma cruzi strain CL Brener]
gi|71657918|ref|XP_817467.1|[71657918]
GCN5-related N-acetyltransferase, putative [Arabidopsis thaliana]
gi|15240705|ref|NP_196882.1|[15240705]
putative N-acetyltransferase subunit ARD1 [Trypanosoma brucei]
gi|7649677|emb|CAB89123.1|[7649677]
major N alpha-acetyltransferase subunit [Aedes aegypti]
gi|94468972|gb|ABF18335.1|[94468972]
N-terminal acetyltransferase complex ARD1 subunit (Arrest-defective protein 1) [Pichia stipitis CBS
6054]
gi|126276259|ref|XP_001386974.1|[126276259]
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